Novel sulfoneurea compounds

ABSTRACT

The present invention relates to compounds of formula (I): wherein A, B, L, X, Y, R1, R2 and R4 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

FIELD OF THE INVENTION

The present invention relates to compounds of formula (I), and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

BACKGROUND OF THE INVENTION

The NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activity is pathogenic in inherited disorders such as cryopyrin-associated periodic syndromes (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis.

NLRP3 is an intracellular signalling molecule that senses many pathogen-derived, environmental and host-derived factors. Upon activation, NLRP3 binds to apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC). ASC then polymerises to form a large aggregate known as an ASC speck. Polymerised ASC in turn interacts with the cysteine protease caspase-1 to form a complex termed the inflammasome. This results in the activation of caspase-1, which cleaves the precursor forms of the proinflammatory cytokines IL-1β and IL-18 (termed pro-IL-1β and pro-IL-18 respectively) to thereby activate these cytokines. Caspase-1 also mediates a type of inflammatory cell death known as pyroptosis. The ASC speck can also recruit and activate caspase-8, which can process pro-IL-1β and pro-IL-18 and trigger apoptotic cell death.

Caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms, which are secreted from the cell. Active caspase-1 also cleaves gasdermin-D to trigger pyroptosis. Through its control of the pyroptotic cell death pathway, caspase-1 also mediates the release of alarmin molecules such as IL-33 and high mobility group box 1 protein (HMGB1). Caspase-1 also cleaves intracellular IL-1R2 resulting in its degradation and allowing the release of IL-1α. In human cells caspase-1 may also control the processing and secretion of IL-37. A number of other caspase-1 substrates such as components of the cytoskeleton and glycolysis pathway may contribute to caspase-1-dependent inflammation.

NLRP3-dependent ASC specks are released into the extracellular environment where they can activate caspase-1, induce processing of caspase-1 substrates and propagate inflammation.

Active cytokines derived from NLRP3 inflammasome activation are important drivers of inflammation and interact with other cytokine pathways to shape the immune response to infection and injury. For example, IL-1 signalling induces the secretion of the pro-inflammatory cytokines IL-6 and TNF. IL-1β and IL-18 synergise with IL-23 to induce IL-17 production by memory CD4 Th17 cells and by γδ T cells in the absence of T cell receptor engagement. IL-18 and IL-12 also synergise to induce IFN-γ production from memory T cells and NK cells driving a Th1 response.

The inherited CAPS diseases Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID) are caused by gain-of-function mutations in NLRP3, thus defining NLRP3 as a critical component of the inflammatory process. NLRP3 has also been implicated in the pathogenesis of a number of complex diseases, notably including metabolic disorders such as type 2 diabetes, atherosclerosis, obesity and gout.

A role for NLRP3 in diseases of the central nervous system is emerging, and lung diseases have also been shown to be influenced by NLRP3. Furthermore, NLRP3 has a role in the development of liver disease, kidney disease and aging. Many of these associations were defined using Nlr3^(−/−) mice, but there have also been insights into the specific activation of NLRP3 in these diseases. In type 2 diabetes mellitus (T2D), the deposition of islet amyloid polypeptide in the pancreas activates NLRP3 and IL-1β signalling, resulting in cell death and inflammation.

Several small molecules have been shown to inhibit the NLRP3 inflammasome. Glyburide inhibits IL-1β production at micromolar concentrations in response to the activation of NLRP3 but not NLRC4 or NLRP1. Other previously characterised weak NLRP3 inhibitors include parthenolide, 3,4-methylenedioxy-p-nitrostyrene and dimethyl sulfoxide (DMSO), although these agents have limited potency and are nonspecific.

Current treatments for NLRP3-related diseases include biologic agents that target IL-1.

These are the recombinant IL-1 receptor antagonist anakinra, the neutralizing IL-1β antibody canakinumab and the soluble decoy IL-1 receptor rilonacept. These approaches have proven successful in the treatment of CAPS, and these biologic agents have been used in clinical trials for other IL-1β-associated diseases.

Some diarylsulfonylurea-containing compounds have been identified as cytokine release inhibitory drugs (CRIDs) (Perregaux et al., J Pharmacol Exp Ther, 299: 187-197, 2001). CRIDs are a class of diarylsulfonylurea-containing compounds that inhibit the post-translational processing of IL-1β. Post-translational processing of IL-1p is accompanied by activation of caspase-1 and cell death. CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved.

Certain sulfonylurea-containing compounds are also disclosed as inhibitors of NLRP3 (see for example, Baldwin et al., J. Med. Chem., 59(5), 1691-1710, 2016; and WO 2016/131098 A1, WO 2017/129897 A1, WO 2017/140778 A1, WO 2017/184623 A1, WO 2017/184624 A1, WO 2018/015445 A1, WO 2018/136890 A1, WO 2018/215818 A1, WO 2019/008025 A1, WO 2019/008029 A1, WO 2019/034686 A1, WO 2019/034688 A1, WO 2019/034690 A1, WO 2019/034692 A1, WO 2019/034693 A1, WO 2019/034696 A1, WO 2019/034697 A1, WO 2019/043610 A, WO 2019/092170 A, WO 2019/092171 A1, and WO 2019/092172 A1). In addition, WO 2017/184604 A1 and WO 2019/079119 A1 disclose a number of sulfonylamide-containing compounds as inhibitors of NLRP3. Certain sulfoximine-containing compounds are also disclosed as inhibitors of NLRP3 (WO 2018/225018 A1, WO 2019/023145 A1, WO 2019/023147 A1, and WO 2019/068772 A1).

There is a need to provide compounds with improved pharmacological and/or physiological and/or physicochemical properties and/or those that provide a useful alternative to known compounds.

Definitions

In the context of the present specification, a “hydrocarbyl” substituent group or a hydrocarbyl moiety in a substituent group only includes carbon and hydrogen atoms but, unless stated otherwise, does not include any heteroatoms, such as N, O or S in its carbon skeleton. A hydrocarbyl group/moiety may be saturated or unsaturated (including aromatic), and may be straight-chained or branched, or be or include cyclic groups wherein, unless stated otherwise, the cyclic group does not include any heteroatoms, such as N, O or S, in its carbon skeleton. Examples of hydrocarbyl groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and aryl groups/moieties and combinations of all of these groups/moieties. Typically a hydrocarbyl group is a C₁-C₂₀ hydrocarbyl group. More typically a hydrocarbyl group is a C₁-C₁₅ hydrocarbyl group. More typically a hydrocarbyl group is a C₁-C₁₀ hydrocarbyl group. A “hydrocarbylene” group is similarly defined as a divalent hydrocarbyl group.

An “alkyl” substituent group or an alkyl moiety in a substituent group may be linear (i.e. straight-chained) or branched. Examples of alkyl groups/moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl and n-pentyl groups/moieties. Unless stated otherwise, the term “alkyl” does not include “cycloalkyl”. Typically an alkyl group is a C₁-C₁₂ alkyl group. More typically an alkyl group is a C₁-C₆ alkyl group. An “alkylene” group is similarly defined as a divalent alkyl group.

An “alkenyl” substituent group or an alkenyl moiety in a substituent group refers to an unsaturated alkyl group or moiety having one or more carbon-carbon double bonds. Examples of alkenyl groups/moieties include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl and 1,4-hexadienyl groups/moieties. Unless stated otherwise, the term “alkenyl” does not include “cycloalkenyl”. Typically an alkenyl group is a C₂-C₁₂ alkenyl group. More typically an alkenyl group is a C₂-C₆ alkenyl group. An “alkenylene” group is similarly defined as a divalent alkenyl group.

An “alkynyl” substituent group or an alkynyl moiety in a substituent group refers to an unsaturated alkyl group or moiety having one or more carbon-carbon triple bonds. Examples of alkynyl groups/moieties include ethynyl, propargyl, but-1-ynyl and but-2-ynyl groups/moieties. Typically an alkynyl group is a C₂-C₁₂ alkynyl group. More typically an alkynyl group is a C₂-C₆ alkynyl group. An “alkynylene” group is similarly defined as a divalent alkynyl group.

A “cyclic” substituent group or a cyclic moiety in a substituent group refers to any hydrocarbyl ring, wherein the hydrocarbyl ring may be saturated or unsaturated (including aromatic) and may include one or more heteroatoms, e.g. N, O or S, in its carbon skeleton. Examples of cyclic groups include cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl groups as discussed below. A cyclic group may be monocyclic, bicyclic (e.g. bridged, fused or spiro), or polycyclic. Typically, a cyclic group is a 3- to 12-membered cyclic group, which means it contains from 3 to 12 ring atoms. More typically, a cyclic group is a 3- to 7-membered monocyclic group, which means it contains from 3 to 7 ring atoms.

A “heterocyclic” substituent group or a heterocyclic moiety in a substituent group refers to a cyclic group or moiety including one or more carbon atoms and one or more (such as one, two, three or four) heteroatoms, e.g. N, O or S, in the ring structure. Examples of heterocyclic groups include heteroaryl groups as discussed below and non-aromatic heterocyclic groups such as azetinyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, dioxolanyl, oxathiolanyl, piperidinyl, tetrahydropyranyl, thianyl, piperazinyl, dioxanyl, morpholinyl and thiomorpholinyl groups.

A “cycloalkyl” substituent group or a cycloalkyl moiety in a substituent group refers to a saturated hydrocarbyl ring containing, for example, from 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Unless stated otherwise, a cycloalkyl substituent group or moiety may include monocyclic, bicyclic or polycyclic hydrocarbyl rings.

A “cycloalkenyl” substituent group or a cycloalkenyl moiety in a substituent group refers to a non-aromatic unsaturated hydrocarbyl ring having one or more carbon-carbon double bonds and containing, for example, from 3 to 7 carbon atoms, examples of which include cyclopent-1-en-1-yl, cyclohex-1-en-1-yl and cyclohex-1,3-dien-1-yl. Unless stated otherwise, a cycloalkenyl substituent group or moiety may include monocyclic, bicyclic or polycyclic hydrocarbyl rings.

An “aryl” substituent group or an aryl moiety in a substituent group refers to an aromatic hydrocarbyl ring. The term “aryl” includes monocyclic aromatic hydrocarbons and polycyclic fused ring aromatic hydrocarbons wherein all of the fused ring systems (excluding any ring systems which are part of or formed by optional substituents) are aromatic. Examples of aryl groups/moieties include phenyl, naphthyl, anthracenyl and phenanthrenyl. Unless stated otherwise, the term “aryl” does not include “heteroaryl”.

A “heteroaryl” substituent group or a heteroaryl moiety in a substituent group refers to an aromatic heterocyclic group or moiety. The term “heteroaryl” includes monocyclic aromatic heterocycles and polycyclic fused ring aromatic heterocycles wherein all of the fused ring systems (excluding any ring systems which are part of or formed by optional substituents) are aromatic. Examples of heteroaryl groups/moieties include the following:

wherein G=O, S or NH.

For the purposes of the present specification, where a combination of moieties is referred to as one group, for example, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl, the last mentioned moiety contains the atom by which the group is attached to the rest of the molecule. An example of an arylalkyl group is benzyl.

For the purposes of the present specification, in an optionally substituted group or moiety:

(i) each hydrogen atom may optionally be replaced by a monovalent substituent independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SO₂R^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —Si(R^(β))₃; —O—Si(R^(β))₃; —R^(α)—Si(R^(β))₃; —R^(α)—O—Si(R^(β))₃; —NH₂; —NHR^(β); —N(R^(β))₂; —N(O)(R^(β))₂; —N⁺(R^(β))₃; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —R^(α)—N(O)(R^(β))₂; —R^(α)—N⁺(R^(β))₃; —CHO; —CORI; —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); —R^(α)—OCOR^(β); —C(═NH)R^(β); —C(═NH)NH₂; —C(═NH)NHR^(β); —C(═NH)N(R^(β))₂; —C(═NR)R^(β); —C(═NR)NHR^(β); —C(═NR)N(R^(β))₂; —C(═NOH)R^(β); —C(═NOR^(β))R^(β); —C(N₂)R^(β); —R^(α)—C(═NH)R^(β); —R^(α)—C(═NH)NH₂; —R^(α)—C(═NH)NHR^(β); —R^(α)—C(═NH)N(R^(β))₂; —R^(α)—C(═NR)R^(β); —R^(α)—C(═NR)NHR^(β); —R^(α)—C(═NR^(β))N(R^(β))₂; —R^(α)—C(═NOH)R^(β); —R^(α)—C(═NOR^(β))R^(β); —R^(α)—C(N2)R^(β); —NH—CHO; —NR^(β)—CHO; —NH—COR^(β); —NR^(β)—COR^(β); —NH—COOR^(β); —NR^(β)—COOR^(β); —NH—C(═NH)R^(β); —NR^(β)—C(═NH)R^(β); —NH—C(═NH)NH₂; —NR^(β)—C(═NH)NH₂; —NH—C(═NH)NHR^(β); —NR^(β)—C(═NH)NHR^(β); —NH—C(═NH)N(R^(β))₂; —NR^(β)—C(═NH)N(R^(β))₂; —NH—C(═NR^(β))R^(β); —NR^(β)—C(═NR^(β))R^(β); —NH—C(═NR^(β))NHR^(β); —NR^(β)—C(═NR^(β))NHR^(β); —NH—C(═NR^(β))N(R^(β))₂; —NR^(β)—C(═NR^(β))N(R^(β))₂; —NH—C(═NOH)R^(β); —NR^(β)—C(═NOH)R^(β); —NH—C(═NOR^(β))R^(β); —NR^(β)—C(═NOR^(β))R^(β); —CONH₂; —CONHR^(β); —CON(R^(β))₂; —NH—CONH₂; —NR^(β)—CONH₂; —NH—CONHR^(β); —NR^(β)—CONHR^(β); —NH—CON(R^(β))₂; —NR^(β)—CON(R^(β))₂; —R^(α)—NH—CHO; —R^(α)—NR^(β)—CHO; —R^(α)—NH—COR^(β); —R^(α)—NR^(β)—COR^(β); —R^(α)—NH—COOR^(β); —R^(α)—NR^(β)—COOR^(β); —R^(α)—NH—C(═NH)R^(β); —R^(α)—NR^(β)—C(═NH)R^(β); —R^(α)—NH—C(═NH)NH₂; —R^(α)—NR^(β)—C(═NH)NH₂; —R^(α)—NH—C(═NH)NHR^(β); —R^(α)—NR^(β)—C(═NH)NHR^(β); —R^(α)—NH—C(═NH)N(R^(β))₂; —R^(α)—NR^(β)—C(═NH)N(R^(β))₂; —R^(α)—NH—C(═NR)R^(β); —R^(α)—NR^(β)—C(═NR)R^(β); —R^(α)—NH—C(═NR^(β))NHR^(β); —R^(α)—NR^(β)—C(═NR^(β))NHR^(β); —R^(α)—NH—C(═NR^(β))N(R^(β))₂; —R^(α)—NR^(β)—C(═NR^(β))N(R^(β))₂; —R^(α)—NH—C(═NOH)R^(β); —R^(α)—NR^(β)—C(═NOH)R^(β); —R^(α)—NH—C(═NOR^(β))R^(β); —R^(α)—NR^(β)—C(═NOR^(β))R^(β); —R^(α)—CONH₂; —R^(α)—CONHR^(β); —R^(a)—CON(R^(β))₂; —R^(α)—NH—CONH₂; —R^(α)—NR^(β)—CONH₂; —R^(α)—NH—CONHR^(β); —R^(α)—NR^(β)—CONHR^(β); —R^(α)—NH—CON(R^(β))₂; —R^(α)—NR^(β)—CON(R^(β))₂; —O—R^(α)—OH; —O—R^(α)—OR^(β); —O—R^(α)—NH₂; —O—R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —R^(α)—N(O)(R^(β))₂; —O—R^(α)—N⁺(R^(β))₃; —NH—R^(α)—OH; —NH—R^(α)—OR^(β); —NH—R^(α)—NH₂; —NH—R^(α)—NHR^(β); —NH—R^(α)—N(R^(β))₂; —NH—R^(α)—N(O)(R^(β))₂; —NH—R^(α)—N⁺(R^(β))₃; —NR^(β)—R^(α)—OH; —NR^(β)—R^(α)—OR^(β); —NR^(β)—R^(α)—NH₂; —NR^(β)—R^(α)—NHR^(β); —NR^(β)—R^(α)—N(R^(β))₂; —NR^(β)—R^(α)—N(O)(R^(β))₂; —NR^(β)—R^(α)—N⁺(R^(β))₃; —N(O)R^(β)—R^(α)—OH; —N(O)R^(β)—R^(α)—OR^(β); —N(O)R^(β)—R^(α)—NH₂; —N(O)R^(β)—R^(α)—NHR^(β); —N(O)R^(β)—R^(α)—N(R^(β))₂; —N(O)R^(β)—R^(α)—N(O)(R^(β))₂; —N(O)R^(β)—R^(α)—N⁺(R^(β))₃; —N⁺(R^(β))₂—R^(α)—OH; —N⁺(R^(β))₂—R^(α)—OR^(β); —N⁺(R^(β))₂—R^(α)—NH₂; —N⁺(R^(β))₂—R^(α)—NHR^(β); —N⁺(R^(β))₂—R^(a)—N(R^(β))₂; or —N⁺(R^(β))₂—R^(α)—N(O)(R^(β))₂; and/or (ii) any two hydrogen atoms attached to the same carbon or nitrogen atom may optionally be replaced by a π-bonded substituent independently selected from oxo (═O), ═S, ═NH or ═NR^(β); and/or (iii) any sulfur atom may optionally be substituted with one or two π-bonded substituents independently selected from oxo (═O), ═NH or ═NR^(β); and/or (iv) any two hydrogen atoms attached to the same or different atoms, within the same optionally substituted group or moiety, may optionally be replaced by a bridging substituent independently selected from —O—, —S—, —NH—, —N═N—, —N(R^(β))—, —N(O)(R^(β))—, —N⁺(R^(β))₂— or —R^(α)—;

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, wherein one or         more —CH₂— groups in the backbone of the alkylene, alkenylene or         alkynylene group may optionally be replaced by one or more         —N(O)(R^(β))— or —N⁺(R^(β))₂— groups, and wherein the alkylene,         alkenylene or alkynylene group may optionally be substituted         with one or more halo and/or —R^(β) groups; and     -   wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, or         wherein any two or three —R^(β) attached to the same nitrogen         atom may, together with the nitrogen atom to which they are         attached, form a C₂-C₇ cyclic group, and wherein any —R^(β) may         optionally be substituted with one or more C₁-C₄ alkyl, C₁-C₄         haloalkyl, C₃-C₇ cycloalkyl, C₃-C₇ halocycloalkyl, —O(C₁-C₄         alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), —O(C₃-C₇         halocycloalkyl), —CO(C₁-C₄ alkyl), —CO(C₁-C₄ haloalkyl),         —CO(C₃-C₇ cycloalkyl), —CO(C₃-C₇ halocycloalkyl), —COO(C₁-C₄         alkyl), —COO(C₁-C₄ haloalkyl), —COO(C₃-C₇ cycloalkyl),         —COO(C₃-C₇ halocycloalkyl), halo, —OH, —NH₂, —CN, —C≡CH, oxo         (═O), phenyl, halophenyl, or optionally halo-substituted 4- to         6-membered heterocyclic group.

Typically, the compounds of the present invention comprise at most one quaternary ammonium group such as —N⁺(R^(β))₃ or —N⁺(R^(β))₂—.

Where reference is made to a —R^(α)—C(N₂)R^(β) group, what is intended is:

Typically, in an optionally substituted group or moiety:

(i) each hydrogen atom may optionally be replaced by a monovalent substituent independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —NH₂; —NHR^(β); —N(R^(β))₂; —N⁺(R^(β))₃; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —R^(α)—N⁺(R^(β))₃; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); or —R^(α)—OCOR^(β); and/or (ii) any two hydrogen atoms attached to the same carbon atom may optionally be replaced by a π-bonded substituent independently selected from oxo (═O), ═S, ═NH or ═NR^(β); and/or (iii) any two hydrogen atoms attached to the same or different atoms, within the same optionally substituted group or moiety, may optionally be replaced by a bridging substituent independently selected from —O—, —S—, —NH—, —N(R^(β))—, —N⁺(R^(β))₂— or —R^(α)—;

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, wherein a single         —CH₂— group in the backbone of the alkylene, alkenylene or         alkynylene group may optionally be replaced by a —N⁺(R^(β))₂—         group, and wherein the alkylene, alkenylene or alkynylene group         may optionally be substituted with one or more halo and/or         —R^(β) groups; and     -   wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, or         wherein any two or three —R^(β) attached to the same nitrogen         atom may, together with the nitrogen atom to which they are         attached, form a C₂-C₇ cyclic group, and wherein any —R^(β) may         optionally be substituted with one or more C₁-C₄ alkyl, C₁-C₄         haloalkyl, C₃-C₇ cycloalkyl, —O(C₁-C₄ alkyl), —O(C₁-C₄         haloalkyl), —O(C₃-C₇ cycloalkyl), halo, —OH, —NH₂, —CN, —C≡CH,         oxo (═O), or 4- to 6-membered heterocyclic group.

Typically, in an optionally substituted group or moiety:

(i) each hydrogen atom may optionally be replaced by a monovalent substituent independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —NH₂; —NHR^(β); —N(R^(β))₂; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); or —R^(α)—OCOR^(β); and/or (ii) any two hydrogen atoms attached to the same carbon atom may optionally be replaced by a π-bonded substituent independently selected from oxo (═O), ═S, ═NH or ═NR^(β); and/or (iii) any two hydrogen atoms attached to the same or different atoms, within the same optionally substituted group or moiety, may optionally be replaced by a bridging substituent independently selected from —O—, —S—, —NH—, —N(R^(β))— or —R^(α)—;

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, and wherein the         alkylene, alkenylene or alkynylene group may optionally be         substituted with one or more halo and/or —R^(β) groups; and     -   wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, or         wherein any two —R^(β) attached to the same nitrogen atom may,         together with the nitrogen atom to which they are attached, form         a C₂-C₆ cyclic group, and wherein any —R^(β) may optionally be         substituted with one or more C₁-C₄ alkyl, halo, —OH, or 4- to         6-membered heterocyclic group.

Typically a substituted group comprises 1, 2, 3 or 4 substituents, more typically 1, 2 or 3 substituents, more typically 1 or 2 substituents, and more typically 1 substituent.

Unless stated otherwise, any divalent bridging substituent (e.g. —O—, —S—, —NH—, —N(R^(β))—, —N(O)(R^(β))—, —N⁺(R^(β))₂— or —R^(α)—) of an optionally substituted group or moiety (e.g. R¹) must only be attached to the specified group or moiety and may not be attached to a second group or moiety (e.g. R²), even if the second group or moiety can itself be optionally substituted.

The term “halo” includes fluoro, chloro, bromo and iodo.

Unless stated otherwise, where a group is prefixed by the term “halo”, such as a haloalkyl or halomethyl group, it is to be understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution on the corresponding group without the halo prefix. For example, a halomethyl group may contain one, two or three halo substituents. A haloethyl or halophenyl group may contain one, two, three, four or five halo substituents. Similarly, unless stated otherwise, where a group is prefixed by a specific halo group, it is to be understood that the group in question is substituted with one or more of the specific halo groups. For example, the term “fluoromethyl” refers to a methyl group substituted with one, two or three fluoro groups.

Similarly, unless stated otherwise, where a group is said to be “halo-substituted”, it is to be understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution on the group said to be halo-substituted. For example, a halo-substituted methyl group may contain one, two or three halo substituents. A halo-substituted ethyl or halo-substituted phenyl group may contain one, two, three, four or five halo substituents.

Unless stated otherwise, any reference to an element is to be considered a reference to all isotopes of that element. Thus, for example, unless stated otherwise any reference to hydrogen is considered to encompass all isotopes of hydrogen including deuterium and tritium.

Unless stated otherwise, any reference to a compound or group is to be considered a reference to all tautomers of that compound or group.

Where reference is made to a hydrocarbyl or other group including one or more heteroatoms N, O or S in its carbon skeleton, or where reference is made to a carbon atom of a hydrocarbyl or other group being replaced by an N, O or S atom, what is intended is that:

is replaced by

-   -   —CH₂— is replaced by —NH—, —O— or —S—;     -   —CH₃ is replaced by —NH₂, —OH or —SH;     -   —CH═ is replaced by —N═;     -   CH₂═ is replaced by NH═, O═ or S═; or     -   CH≡ is replaced by N≡;         provided that the resultant group comprises at least one carbon         atom. For example, methoxy, dimethylamino and aminoethyl groups         are considered to be hydrocarbyl groups including one or more         heteroatoms N, O or S in their carbon skeleton.

Where reference is made to a —CH₂— group in the backbone of a hydrocarbyl or other group being replaced by a —N(O)(R^(β))— or —N⁺(R^(β))₂— group, what is intended is that:

-   -   —CH₂— is replaced by

or

-   -   —CH₂— is replaced by

In the context of the present specification, unless otherwise stated, a C_(x)-C_(y) group is defined as a group containing from x to y carbon atoms. For example, a C₁-C₄ alkyl group is defined as an alkyl group containing from 1 to 4 carbon atoms. Optional substituents and moieties are not taken into account when calculating the total number of carbon atoms in the parent group substituted with the optional substituents and/or containing the optional moieties. For the avoidance of doubt, replacement heteroatoms, e.g. N, O or S, are to be counted as carbon atoms when calculating the number of carbon atoms in a C_(x)-C_(y) group. For example, a morpholinyl group is to be considered a C₆ heterocyclic group, not a C₄ heterocyclic group.

For the purposes of the present specification, where it is stated that a first atom or group is “directly attached” to a second atom or group it is to be understood that the first atom or group is covalently bonded to the second atom or group with no intervening atom(s) or group(s) being present. So, for example, for the group —(C═O)N(CH₃)₂, the carbon atom of each methyl group is directly attached to the nitrogen atom and the carbon atom of the carbonyl group is directly attached to the nitrogen atom, but the carbon atom of the carbonyl group is not directly attached to the carbon atom of either methyl group.

For the avoidance of doubt, where it is stated that a compound or a group, such as R¹, contains from x to y atoms other than hydrogen, it is to be understood that the compound or group as a whole, including any optional substituents, contains from x to y atoms other than hydrogen. Such a compound or group may contain any number of hydrogen atoms.

SUMMARY OF THE INVENTION

A first aspect of the invention provides a compound of formula (I):

wherein:

-   -   A is a phenyl or 5- or 6-membered heteroaryl group, wherein A is         substituted in the α position with B and in the α′ position with         R⁴, and wherein A is optionally further substituted;     -   B is a phenyl, 5- or 6-membered heteroaryl, or 4- to 6-membered         saturated heterocyclic group, wherein B is substituted with         -L-R², and wherein B is optionally further substituted;     -   X is O, NH or N(CN);     -   Y is O or S;     -   R¹ is a C₁-C₄ alkyl, C₂-C₄ alkenyl, —NH(C₁-C₄ alkyl), —N(C₁-C₄         alkyl)₂, or —R²⁰-R²¹ group, all optionally halo-substituted;     -   L is a bond, —O—, —OC(R¹²)₂—, —OC(Ph)(R¹²)—, —OC(R¹²)₂C(R¹²)₂—,         —C(R¹²)₂—, —C≡C— or —NR¹³—;     -   R² is a C₃-C₆ cycloalkyl, phenyl, 4- to 6-membered saturated         heterocyclic, or 5- or 6-membered heteroaryl group, all         optionally halo-substituted and/or optionally substituted with         one, two or three substituents independently selected from         cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl, C₂-C₄         alkenyl, C₂-C₄ haloalkenyl, phenyl, benzyl, 4- to 6-membered         saturated heterocyclyl, —CO(C₁-C₄ alkyl), —CO(C₁-C₄ haloalkyl),         —CO₂(C₁-C₄ alkyl), —CO₂(C₁-C₄ haloalkyl), —CO₂(benzyl), —OH,         —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —NH₂, —NH(C₁-C₄ alkyl),         —NH(C₁-C₄ haloalkyl), —N(C₁-C₄ alkyl)₂, —N(C₁-C₄ alkyl)(C₁-C₄         haloalkyl) and —N(C₁-C₄ haloalkyl)₂;     -   either R⁴ is monovalent, and attached to A in the α′ position,         and selected from C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl,         C₃-C₆ cycloalkyl and phenyl, all optionally halo-substituted         and/or optionally substituted with one or two substituents         independently selected from oxo, —OH, —O(C₁-C₄ alkyl) and         —O(C₁-C₄ haloalkyl);     -   or R⁴ is divalent, and attached to A in the α′ and β′ positions,         and selected from —CH₂CH₂CH₂—, —CH═CHCH₂—, —CH₂CH═CH—,         —CH₂CH₂O—, —OCH₂CH₂—, —CH₂CH₂CH₂CH₂— and —CH═CH—CH═CH—, all         optionally halo-substituted and/or optionally substituted with         one or two substituents independently selected from oxo, —OH,         —O(C₁-C₄ alkyl) and —O(C₁-C₄ haloalkyl);     -   each R¹² is independently selected from hydrogen, halogen,         methyl and halomethyl;     -   R¹³ is hydrogen or methyl;     -   R²⁰ is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene;     -   R²¹ is a C₃-C₆ cycloalkyl, phenyl, 4- to 6-membered saturated         heterocyclic, or 5- or 6-membered heteroaryl group, all         optionally halo-substituted and/or optionally substituted with         one or two substituents independently selected from cyano, C₁-C₄         alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl,         —R²²—OH, —R²²—O(C₁-C₄ alkyl), —R²²—O(C₁-C₄ haloalkyl), —R²²—NH₂,         —R²²—NH(C₁-C₄ alkyl), —R²²—NH(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄         alkyl)₂, —R²²—N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄         haloalkyl)₂ and —R²²-R²³;     -   R²² is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene; and     -   R²³ is a C₃-C₆ cycloalkyl or 4- to 6-membered saturated         heterocyclic group, all optionally halo-substituted.

A is a phenyl or 5- or 6-membered heteroaryl group, wherein A is substituted in the α position with B and in the α′ position with R⁴ (relative to the point of attachment of A to R¹—S(X)(O)—NH—CY—NH—), and wherein A is optionally further substituted. In one embodiment, A is phenyl or a 5- or 6-membered heteroaryl group comprising one, two or three nitrogen and/or oxygen and/or sulfur ring atoms, wherein A is substituted in the α position with B and in the α′ position with R⁴, and wherein A is optionally further substituted. In one embodiment, A is phenyl or a 5- or 6-membered heteroaryl group comprising one or two nitrogen and/or oxygen ring atoms, wherein A is substituted in the α position with B and in the α′ position with R⁴, and wherein A is optionally further substituted. In one embodiment, A is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl or isothiazolyl group, wherein A is substituted in the α position with B and in the α′ position with R⁴, and wherein A is optionally further substituted. In one embodiment, A is a phenyl, pyrimidinyl, pyrazolyl or imidazolyl group, wherein A is substituted in the α position with B and in the α′ position with R⁴, and wherein A is optionally further substituted. In one embodiment, A is a phenyl group, substituted in the α position with B, substituted in the α′ position with R⁴, and optionally further substituted.

A is optionally further substituted. In one embodiment, A is further substituted with one or two substituents independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, halogen and cyano. In one embodiment, A is further substituted with one or two substituents independently selected from methyl, ethyl, halomethyl, haloethyl, cyclopropyl, halocyclopropyl, halogen and cyano. In one embodiment, A is further substituted with one or two substituents independently selected from methyl, trifluoromethyl, cyclopropyl, fluoro, chloro and cyano. In one embodiment, A is further substituted with one or two substituents independently selected from methyl and fluoro.

In one embodiment, A is substituted in the β position (relative to the point of attachment of A to R¹—S(X)(O)—NH—CY—NH—) with C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl or halogen. In one embodiment, A is substituted in the β position with methyl, ethyl, halomethyl, haloethyl, cyclopropyl, halocyclopropyl or halogen. In one embodiment, A is substituted in the β position with methyl, trifluoromethyl, cyclopropyl or fluoro. In one embodiment, A is substituted in the β position with methyl, cyclopropyl or fluoro. In one embodiment, A is substituted in the β position with methyl.

In one embodiment, A is substituted in the γ position (relative to the point of attachment of A to R¹—S(X)(O)—NH—CY—NH—) with halogen or cyano. In one embodiment, A is substituted in the γ position with fluoro, chloro or cyano. In one embodiment, A is substituted in the γ position with fluoro.

B is a phenyl, 5- or 6-membered heteroaryl, or 4- to 6-membered saturated heterocyclic group, wherein B is substituted with -L-R², and wherein B is optionally further substituted. In one embodiment, B is a phenyl group, or a 5- or 6-membered heteroaryl group comprising one, two or three nitrogen and/or oxygen and/or sulfur ring atoms, or a 4- to 6-membered saturated heterocyclic group comprising one or two nitrogen and/or oxygen and/or sulfur ring atoms, wherein B is substituted with -L-R², and wherein B is optionally further substituted. In one embodiment, B is a phenyl group, or a 5- or 6-membered heteroaryl group comprising one or two nitrogen and/or oxygen ring atoms, or a 4- to 6-membered saturated heterocyclic group comprising one nitrogen or oxygen ring atom, wherein B is substituted with -L-R², and wherein B is optionally further substituted. In one embodiment, B is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group, wherein B is substituted with -L-R², and wherein B is optionally further substituted. In one embodiment, B is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl or oxadiazolyl group, wherein B is substituted with -L-R², and wherein B is optionally further substituted. In one embodiment, B is a phenyl, pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl, isoxazolyl or thiazolyl group, wherein B is substituted with -L-R², and wherein B is optionally further substituted. In one embodiment, B is a phenyl, pyridinyl, pyrimidinyl or pyrazolyl group, wherein B is substituted with -L-R², and wherein B is optionally further substituted. In one embodiment, B is a phenyl or pyridinyl group, wherein B is substituted with -L-R², and wherein B is optionally further substituted. In one embodiment, B is a pyridinyl group, substituted with -L-R², and optionally further substituted. In one embodiment, B is a pyridin-4-yl group, substituted with -L-R², and optionally further substituted.

B may be substituted with -L-R² in the α, β or γ position (relative to the point of attachment of B to A). In one embodiment, B is substituted with -L-R² in the β or γ position. In one embodiment, B is substituted with -L-R² in the β position.

In one embodiment, B is a pyridin-4-yl group, substituted with -L-R² in the β position, and optionally further substituted.

B is optionally further substituted. In one embodiment, B is further substituted with one or two substituents independently selected from halo, C₁-C₃ alkyl, —O(C₁-C₃ alkyl), —OH, —NH₂ and —CN. In one embodiment, B is further substituted with one or two substituents independently selected from fluoro, chloro, methyl, ethyl, —OMe, —OEt, —OH, —NH₂ and —CN. In one embodiment, B is further substituted with methyl.

X is O, NH or N(CN). In one embodiment, X is O or NH. In one embodiment, X is O.

Y is O or S. In one embodiment, Y is O.

R¹ is a C₁-C₄ alkyl, C₂-C₄ alkenyl, —NH(C₁-C₄ alkyl), —N(C₁-C₄ alkyl)₂, or —R²⁰-R²¹ group, all optionally halo-substituted; wherein R²⁰ is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene; R²¹ is a C₃-C₆ cycloalkyl, phenyl, 4- to 6-membered saturated heterocyclic, or 5- or 6-membered heteroaryl group, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, —R²²—OH, —R²²—O(C₁-C₄ alkyl), —R²²—O(C₁-C₄ haloalkyl), —R²²—NH₂, —R²²—NH(C₁-C₄ alkyl), —R²²—NH(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄ alkyl)₂, —R²²—N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄ haloalkyl)₂ and —R²²-R²³; R²² is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene; and R²³ is a C₃-C₆ cycloalkyl or 4- to 6-membered saturated heterocyclic group, all optionally halo-substituted.

In one embodiment, R¹ is a C₁-C₄ alkyl, C₂-C₄ alkenyl, —NH(C₁-C₃ alkyl), —N(C₁-C₃ alkyl)₂, or —R²⁰-R²¹ group, all optionally halo-substituted; wherein R²⁰ is a bond, C₁-C₃ alkylene or C₁-C₃ haloalkylene; R²¹ is a C₃-C₆ cycloalkyl or phenyl group, or a 4- to 6-membered saturated heterocyclic group comprising one or two nitrogen and/or oxygen and/or sulfur ring atoms, or a 5- or 6-membered heteroaryl group comprising one, two or three nitrogen and/or oxygen and/or sulfur ring atoms, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, —R²²—OH, —R²²—O(C₁-C₄ alkyl), —R²²—O(C₁-C₄ haloalkyl), —R²²—NH₂, —R²²—NH(C₁-C₄ alkyl), —R²²—NH(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄ alkyl)₂, —R²²—N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄ haloalkyl)₂ and —R²²-R²³; R²² is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene; and R²³ is C₃-C₆ cycloalkyl or a 4- to 6-membered saturated heterocyclic group comprising one or two nitrogen and/or oxygen and/or sulfur ring atoms, all optionally halo-substituted.

In one embodiment, R¹ is a C₁-C₄ alkyl, C₂-C₄ alkenyl, —NHMe, —NMe₂, —NHEt, —NEt₂, —NMeEt or —R²⁰-R²¹ group, all optionally halo-substituted; wherein R²⁰ is a bond or C₁-C₂ alkylene; R²¹ is a C₃-C₆ cycloalkyl, phenyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl or oxadiazolyl group, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from cyano, C₁-C₄ alkyl, —R²²—OH, —R²²—O(C₁-C₄ alkyl), —R²²—NH(C₁-C₄ alkyl), —R²²—N(C₁-C₄ alkyl)₂ and —R²²-R²³; R²² is a bond or C₁-C₄ alkylene; and R²³ is a C₃-C₆ cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group.

In one embodiment, R¹ is C₁-C₄ alkyl, C₂-C₄ alkenyl, —NHMe, —NMe₂, —NHEt, —NEt₂ or —NMeEt, all optionally halo-substituted; or R¹ is a C₃-C₆ cycloalkyl, phenyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl or oxadiazolyl group, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from cyano, C₁-C₄ alkyl, —R²²—OH, —R²²—O(C₁-C₄ alkyl), —R²²—NH(C₁-C₄ alkyl), —R²²—N(C₁-C₄ alkyl)₂ and —R²²-R²³; wherein R²² is a bond or C₁-C₄ alkylene; and R²³ is a C₃-C₆ cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group.

In one embodiment, R¹ is C₁-C₄ alkyl, C₂-C₄ alkenyl, —NHMe, —NMe₂, —NHEt, —NEt₂ or —NMeEt, all optionally halo-substituted; or R¹ is a C₃-C₆ cycloalkyl, phenyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, furanyl, thiophenyl, pyrazolyl or imidazolyl group, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from C₁-C₃ alkyl, —R²²—OH, —R²²—O(C₁-C₃ alkyl), —R²²—NH(C₁-C₃ alkyl), —R²²—N(C₁-C₃ alkyl)₂ and —R²²-R²³; wherein R²² is a bond or C₁-C₄ alkylene; and R²³ is a C₃-C₆ cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group.

In one embodiment, R¹ is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, —CH₂—CH═CH₂, —CH₂—CH═CH₂—CH₃, —CH₂CH₂—CH═CH₂, —NHMe, —NMe₂, —NHEt, —NEt₂ or —NMeEt; or R¹ is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, furanyl, thiophenyl, pyrazolyl or imidazolyl group, all optionally substituted with C₁-C₃ alkyl, —R²²—OH, —R²²—O(C₁-C₃ alkyl), —R²²—NH(C₁-C₃ alkyl), —R²²—N(C₁-C₃ alkyl)₂ or —R²²-R²³; wherein R²² is a bond or C₁-C₄ alkylene; and R²³ is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group.

In one embodiment, R¹ is methyl, ethyl, —CH₂—CH═CH₂ or —NMe₂; or R¹ is a cyclopropyl, phenyl, furanyl or pyrazolyl group, all optionally substituted with methyl, ethyl, isopropyl, CMe₂(OH), CMe₂-CH₂—NMe₂, CMe₂-CH₂-(azetidinyl), cyclopropyl or cyclobutyl.

In one embodiment, when R¹ is a pyrrolidinyl, piperidinyl, pyrazolyl or imidazolyl group, the pyrrolidinyl, piperidinyl, pyrazolyl or imidazolyl group is substituted on the nitrogen ring atom.

L is a bond, —O—, —OC(R¹²)₂—, —OC(Ph)(R¹²)—, —OC(R¹²)₂C(R¹²)₂—, —C(R¹²)₂—, —C≡C— or —NR¹³—; wherein each R¹² is independently selected from hydrogen, halogen, methyl and halomethyl; and R¹³ is hydrogen or methyl. In one embodiment, L is a bond, —O—, —OC(R¹²)₂— or —NR¹³—; wherein each R¹² is independently selected from hydrogen, halogen, methyl and halomethyl; and R¹³ is hydrogen or methyl. In one embodiment, L is a bond, —O—, —OCH₂—, —OCHF—, —OCF₂—, —OCHMe-, —NH— or —NMe-. In one embodiment, L is a bond, —O—, —OCH₂—, —OCHF—, —OCF₂— or —OCHMe-. In one embodiment, L is a bond, —O— or —OCH₂—. In one embodiment, L is —O— or —OCH₂—. In one embodiment, L is —O—.

R² is a C₃-C₆ cycloalkyl, phenyl, 4- to 6-membered saturated heterocyclic, or 5- or 6-membered heteroaryl group, all optionally halo-substituted and/or optionally substituted with one, two or three substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, phenyl, benzyl, 4- to 6-membered saturated heterocyclyl, —CO(C₁-C₄ alkyl), —CO(C₁-C₄ haloalkyl), —CO₂(C₁-C₄ alkyl), —CO₂(C₁-C₄ haloalkyl), —CO₂(benzyl), —OH, —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —NH₂, —NH(C₁-C₄ alkyl), —NH(C₁-C₄ haloalkyl), —N(C₁-C₄ alkyl)₂, —N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl) and —N(C₁-C₄ haloalkyl)₂.

In one embodiment, R² is a C₃-C₆ cycloalkyl or 4- to 6-membered saturated heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally halo-substituted and/or optionally substituted with one, two or three substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, phenyl, benzyl, —OH, —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —NH₂, —NH(C₁-C₄ alkyl), —NH(C₁-C₄ haloalkyl), —N(C₁-C₄ alkyl)₂, —N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl) and —N(C₁-C₄ haloalkyl)₂.

In one embodiment, R² is C₃-C₆ cycloalkyl or a 4- to 6-membered saturated heterocyclic group comprising one or two nitrogen and/or oxygen and/or sulfur ring atoms, wherein the cycloalkyl or heterocyclic group is optionally halo-substituted and/or optionally substituted with one, two or three substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, phenyl, benzyl, —OH, —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —NH₂, —NH(C₁-C₄ alkyl), —NH(C₁-C₄ haloalkyl), —N(C₁-C₄ alkyl)₂, —N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl) and —N(C₁-C₄ haloalkyl)₂.

In one embodiment, R² is C₃-C₆ cycloalkyl or a 4- to 6-membered saturated heterocyclic group comprising one nitrogen or oxygen ring atom, wherein the cycloalkyl or heterocyclic group is optionally halo-substituted and/or optionally substituted with one, two or three substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, phenyl, benzyl, —OH, —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —NH₂, —NH(C₁-C₄ alkyl), —NH(C₁-C₄ haloalkyl), —N(C₁-C₄ alkyl)₂, —N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl) and —N(C₁-C₄ haloalkyl)₂.

In one embodiment, R² is a C₃-C₆ cycloalkyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₃-C₄ cycloalkyl, C₂-C₃ alkenyl, C₂-C₃ haloalkenyl, phenyl, benzyl, —OH, —O(C₁-C₃ alkyl), —O(C₁-C₃ haloalkyl), —NH₂, —NH(C₁-C₃ alkyl), —NH(C₁-C₃ haloalkyl), —N(C₁-C₃ alkyl)₂, —N(C₁-C₃ alkyl)(C₁-C₃ haloalkyl) and —N(C₁-C₃ haloalkyl)₂.

In one embodiment, R² is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group, all optionally substituted with one or two substituents independently selected from fluoro, C₁-C₃ alkyl, C₂-C₃ alkenyl, phenyl, benzyl, —OH, —O(C₁-C₃ alkyl), —NH₂, —NH(C₁-C₃ alkyl) and —N(C₁-C₃ alkyl)₂.

In one embodiment, R² is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group, all optionally substituted with one or two substituents independently selected from fluoro, methyl, —CH₂—CH═CH₂, benzyl, —OH, —OMe, —NHMe and —NMe₂.

In one embodiment, when R² is a pyrrolidinyl or piperidinyl group, the pyrrolidinyl or piperidinyl group is substituted on the nitrogen ring atom.

In one embodiment, R⁴ is monovalent, and attached to A in the α′ position (relative to the point of attachment of A to R¹—S(X)(O)—NH—CY—NH—), and selected from C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl and phenyl, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from oxo (═O), —OH, —O(C₁-C₄ alkyl) and —O(C₁-C₄ haloalkyl). In one embodiment, R⁴ is monovalent, and attached to A in the α′ position, and selected from C₁-C₄ alkyl, C₃-C₆ cycloalkyl and phenyl, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from oxo (═O), —OH, —O(C₁-C₄ alkyl) and —O(C₁-C₄ haloalkyl). In one embodiment, R⁴ is monovalent, and attached to A in the α′ position, and selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl, all optionally halo-substituted and/or optionally substituted with one substituent selected from oxo, —OH, —O(C₁-C₄ alkyl) and —O(C₁-C₄ haloalkyl). In one embodiment, R⁴ is monovalent, and attached to A in the α′ position, and selected from isopropyl, sec-butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl, all optionally halo-substituted. In one embodiment, R⁴ is monovalent, and attached to A in the α′ position, and selected from isopropyl, cyclopentyl, cyclohexyl and phenyl, all optionally halo-substituted. In one embodiment, R⁴ is monovalent, and attached to A in the α′ position, and selected from isopropyl, cyclopentyl, cyclohexyl and phenyl. In one embodiment, R⁴ is an isopropyl group attached to A in the α′ position.

In an alternative embodiment, R⁴ is divalent, and attached to A in the α¹ and β′ positions (relative to the point of attachment of A to R¹—S(X)(O)—NH—CY—NH—), and selected from —CH₂CH₂CH₂—, —CH═CHCH₂—, —CH₂CH═CH—, —CH₂CH₂O—, —OCH₂CH₂—, —CH₂CH₂CH₂CH₂— and —CH═CH—CH═CH—, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from oxo (═O), —OH, —O(C₁-C₄ alkyl) and —O(C₁-C₄ haloalkyl). In one embodiment, R⁴ is divalent, and attached to A in the α′ and β′ positions, and selected from —CH₂CH₂CH₂—, —CH₂CH₂O— and —OCH₂CH₂—, all optionally halo-substituted and/or optionally substituted with one substituent selected from oxo, —OH, —O(C₁-C₄ alkyl) and —O(C₁-C₄ haloalkyl). In one embodiment, R⁴ is divalent, and attached to A in the α′ and β′ positions, and selected from —CH₂CH₂CH₂—, —CH₂CH₂O— and —OCH₂CH₂—, all optionally halo-substituted. In one embodiment, R⁴ is divalent, and attached to A in the α′ and β′ positions, and selected from —CH₂CH₂CH₂—, —CH₂CH₂O— and —OCH₂CH₂—. In one embodiment, R⁴ is a —CH₂CH₂CH₂— group attached to A in the α′ and β′ positions.

The first aspect of the invention also provides a compound of formula (II):

wherein:

-   -   X is O, NH or N(CN);     -   R¹ is a C₁-C₄ alkyl, C₂-C₄ alkenyl, —NH(C₁-C₄ alkyl), —N(C₁-C₄         alkyl)₂, or —R²⁰-R²¹ group, all optionally halo-substituted;     -   L is a bond, —O—, —OC(R¹²)₂— or —NR¹³—;     -   R² is a C₃-C₆ cycloalkyl or 4- to 6-membered saturated         heterocyclic group, wherein the cycloalkyl or heterocyclic group         is optionally halo-substituted and/or optionally substituted         with one, two or three substituents independently selected from         cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl, C₂-C₄         alkenyl, C₂-C₄ haloalkenyl, phenyl, benzyl, —OH, —O(C₁-C₄         alkyl), —O(C₁-C₄ haloalkyl), —NH₂, —NH(C₁-C₄ alkyl), —NH(C₁-C₄         haloalkyl), —N(C₁-C₄ alkyl)₂, —N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl)         and —N(C₁-C₄ haloalkyl)₂;     -   R³ is hydrogen or methyl;     -   R^(4a) is C₁-C₄ alkyl, C₃-C₆ cycloalkyl or phenyl, all         optionally halo-substituted;     -   R⁵ is hydrogen; or     -   R^(4a) and R⁵ together form —CH₂CH₂CH₂—, —CH═CHCH₂—, —CH₂CH═CH—,         —CH₂CH₂—, —OCH₂CH₂—, —CH₂CH₂CH₂CH₂— or —CH═CH—CH═CH—, all         optionally halo-substituted;     -   R⁶ is hydrogen, halogen or cyano;     -   R⁷ is hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₆ cycloalkyl,         C₃-C₆ halocycloalkyl or halogen;     -   each R¹² is independently selected from hydrogen, halogen,         methyl and halomethyl;     -   R¹³ is hydrogen or methyl;     -   R²⁰ is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene;     -   R²¹ is a C₃-C₆ cycloalkyl, phenyl, 4- to 6-membered saturated         heterocyclic, or 5- or 6-membered heteroaryl group, all         optionally halo-substituted and/or optionally substituted with         one or two substituents independently selected from cyano, C₁-C₄         alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl,         —R²²—OH, —R²²—O(C₁-C₄ alkyl), —R²²—O(C₁-C₄ haloalkyl), —R²²—NH₂,         —R²²—NH(C₁-C₄ alkyl), —R²²—NH(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄         alkyl)₂, —R²²—N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄         haloalkyl)₂ and —R²²-R²³;     -   R²² is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene; and     -   R²³ is a C₃-C₆ cycloalkyl or 4- to 6-membered saturated         heterocyclic group, all optionally halo-substituted.

The embodiments of X, L, R¹, R², R¹², R¹³, R²⁰, R²¹, R²² and R²³ described above in relation to the compounds of formula (I) apply equally to the compounds of formula (II).

R³ is hydrogen or methyl. In one embodiment, R³ is hydrogen. In one embodiment, R³ is methyl.

In one embodiment, R⁵ is hydrogen and R^(4a) is C₁-C₄ alkyl, C₃-C₆ cycloalkyl or phenyl, all optionally halo-substituted. In one embodiment, R^(4a) is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl, all optionally halo-substituted. In one embodiment, R^(4a) is isopropyl, sec-butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl, all optionally halo-substituted. In one embodiment, R^(4a) is isopropyl, cyclopentyl, cyclohexyl or phenyl, all optionally halo-substituted. In one embodiment, R^(4a) is isopropyl, cyclopentyl, cyclohexyl or phenyl. In one embodiment, R^(4a) is isopropyl.

In an alternative embodiment, R^(4a) and R⁵ together form —CH₂CH₂CH₂—, —CH═CHCH₂—, —CH₂CH═CH—, —CH₂CH₂O—, —OCH₂CH₂—, —CH₂CH₂CH₂CH₂— or —CH═CH—CH═CH—, all optionally halo-substituted. In one embodiment, R^(4a) and R⁵ together form —CH₂CH₂CH₂—, —CH₂CH₂— or —OCH₂CH₂—, all optionally halo-substituted. In one embodiment, R^(4a) and R⁵ together form —CH₂CH₂CH₂—, —CH₂CH₂— or —OCH₂CH₂—.

R⁶ is hydrogen, halogen or cyano. In one embodiment, R⁶ is hydrogen, fluoro, chloro or cyano. In one embodiment, R⁶ is hydrogen or fluoro.

R⁷ is hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl or halogen. In one embodiment, R⁷ is hydrogen, methyl, ethyl, halomethyl, haloethyl, cyclopropyl, halocyclopropyl or halogen. In one embodiment, R⁷ is hydrogen, methyl, trifluoromethyl, cyclopropyl or fluoro. In one embodiment, R⁷ is hydrogen, methyl, cyclopropyl or fluoro. In one embodiment, R⁷ is hydrogen or methyl.

In one embodiment, the present invention provides a compound of formula (II), wherein:

-   -   X is O or NH;     -   R¹ is C₁-C₄ alkyl, C₂-C₄ alkenyl, —NHMe, —NMe₂, —NHEt, —NEt₂ or         —NMeEt, all optionally halo-substituted; or R¹ is a C₃-C₆         cycloalkyl, phenyl, pyrrolidinyl, piperidinyl,         tetrahydrofuranyl, tetrahydropyranyl, furanyl, thiophenyl,         pyrazolyl or imidazolyl group, all optionally halo-substituted         and/or optionally substituted with one or two substituents         independently selected from C₁-C₃ alkyl, —R²²—OH, —R²²—O(C₁-C₃         alkyl), —R²²—NH(C₁-C₃ alkyl), —R²²—N(C₁-C₃ alkyl)₂ and —R²²-R²³;     -   L is a bond, —O— or —OCH₂—;     -   R² is a C₃-C₆ cycloalkyl, pyrrolidinyl, piperidinyl,         tetrahydrofuranyl or tetrahydropyranyl group, all optionally         halo-substituted and/or optionally substituted with one or two         substituents independently selected from C₁-C₃ alkyl, C₁-C₃         haloalkyl, C₃-C₄ cycloalkyl, C₂-C₃ alkenyl, C₂-C₃ haloalkenyl,         phenyl, benzyl, —OH, —O(C₁-C₃ alkyl), —O(C₁-C₃ haloalkyl), —NH₂,         —NH(C₁-C₃ alkyl), —NH(C₁-C₃ haloalkyl), —N(C₁-C₃ alkyl)₂,         —N(C₁-C₃ alkyl)(C₁-C₃ haloalkyl) and —N(C₁-C₃ haloalkyl)₂;     -   R³ is hydrogen or methyl;     -   R^(4a) is isopropyl, cyclopentyl, cyclohexyl or phenyl;     -   R⁵ is hydrogen; or     -   R^(4a) and R⁵ together form —CH₂CH₂CH₂—, —CH₂CH₂— or —OCH₂CH₂—;     -   R⁶ is hydrogen, halogen or cyano;     -   R⁷ is hydrogen, methyl, cyclopropyl or fluoro;     -   R²² is a bond or C₁-C₄ alkylene; and     -   R²³ is a C₃-C₆ cycloalkyl, azetidinyl, pyrrolidinyl,         piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group.

In one aspect of any of the above embodiments, R¹ contains from 1 to 30 atoms other than hydrogen. More typically, R¹ contains from 1 to 25 atoms other than hydrogen. More typically, R¹ contains from 1 to 20 atoms other than hydrogen. More typically, R¹ contains from 1 to 16 atoms other than hydrogen.

In one aspect of any of the above embodiments, A, B, L, R² and R⁴ together contain from 13 to 50 atoms other than hydrogen. More typically, A, B, L, R² and R⁴ together contain from 14 to 45 atoms other than hydrogen. More typically, A, B, L, R² and R⁴ together contain from 15 to 40 atoms other than hydrogen. Most typically, A, B, L, R² and R⁴ together contain from 16 to 35 atoms other than hydrogen.

In one aspect of any of the above embodiments, the compound of formula (I) or (II) has a molecular weight of from 250 to 2,000 Da. Typically, the compound of formula (I) or (II) has a molecular weight of from 300 to 1,000 Da. Typically, the compound of formula (I) or (II) has a molecular weight of from 340 to 800 Da. More typically, the compound of formula (I) or (II) has a molecular weight of from 380 to 650 Da.

A second aspect of the invention provides a compound selected from the group consisting of:

A third aspect of the invention provides a pharmaceutically acceptable salt, solvate or prodrug of any compound of the first or second aspect of the invention.

The compounds of the present invention can be used both, in their free base form and their acid addition salt form. For the purposes of this invention, a “salt” of a compound of the present invention includes an acid addition salt. Acid addition salts are preferably pharmaceutically acceptable, non-toxic addition salts with suitable acids, including but not limited to inorganic acids such as hydrohalogenic acids (for example, hydrofluoric, hydrochloric, hydrobromic or hydroiodic acid) or other inorganic acids (for example, nitric, perchloric, sulfuric or phosphoric acid); or organic acids such as organic carboxylic acids (for example, propionic, butyric, glycolic, lactic, mandelic, citric, acetic, benzoic, salicylic, succinic, malic or hydroxysuccinic, tartaric, fumaric, maleic, hydroxymaleic, mucic or galactaric, gluconic, pantothenic or pamoic acid), organic sulfonic acids (for example, methanesulfonic, trifluoromethanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, toluene-p-sulfonic, naphthalene-2-sulfonic or camphorsulfonic acid) or amino acids (for example, ornithinic, glutamic or aspartic acid). The acid addition salt may be a mono-, di-, tri- or multi-acid addition salt. A preferred salt is a hydrohalogenic, sulfuric, phosphoric or organic acid addition salt. A preferred salt is a hydrochloric acid addition salt.

Where a compound of the invention includes a quaternary ammonium group, typically the compound is used in its salt form. The counter ion to the quaternary ammonium group may be any pharmaceutically acceptable, non-toxic counter ion. Examples of suitable counter ions include the conjugate bases of the protic acids discussed above in relation to acid addition salts.

The compounds of the present invention can also be used both, in their free acid form and their salt form. For the purposes of this invention, a “salt” of a compound of the present invention includes one formed between a protic acid functionality (such as a carboxylic acid group) of a compound of the present invention and a suitable cation. Suitable cations include, but are not limited to lithium, sodium, potassium, magnesium, calcium and ammonium. The salt may be a mono-, di-, tri- or multi-salt. Preferably the salt is a mono- or di-lithium, sodium, potassium, magnesium, calcium or ammonium salt. More preferably the salt is a mono- or di-sodium salt or a mono- or di-potassium salt.

Preferably any salt is a pharmaceutically acceptable non-toxic salt. However, in addition to pharmaceutically acceptable salts, other salts are included in the present invention, since they have potential to serve as intermediates in the purification or preparation of other, for example, pharmaceutically acceptable salts, or are useful for identification, characterisation or purification of the free acid or base.

The compounds and/or salts of the present invention may be anhydrous or in the form of a hydrate (e.g. a hemihydrate, monohydrate, dihydrate or trihydrate) or other solvate. Such other solvates may be formed with common organic solvents, including but not limited to, alcoholic solvents e.g. methanol, ethanol or isopropanol.

In some embodiments of the present invention, therapeutically inactive prodrugs are provided. Prodrugs are compounds which, when administered to a subject such as a human, are converted in whole or in part to a compound of the invention. In most embodiments, the prodrugs are pharmacologically inert chemical derivatives that can be converted in vivo to the active drug molecules to exert a therapeutic effect. Any of the compounds described herein can be administered as a prodrug to increase the activity, bioavailability, or stability of the compound or to otherwise alter the properties of the compound. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include, but are not limited to, compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, and/or dephosphorylated to produce the active compound. The present invention also encompasses salts and solvates of such prodrugs as described above.

The compounds, salts, solvates and prodrugs of the present invention may contain at least one chiral centre. The compounds, salts, solvates and prodrugs may therefore exist in at least two isomeric forms. The present invention encompasses racemic mixtures of the compounds, salts, solvates and prodrugs of the present invention as well as enantiomerically enriched and substantially enantiomerically pure isomers. For the purposes of this invention, a “substantially enantiomerically pure” isomer of a compound comprises less than 5% of other isomers of the same compound, more typically less than 2%, and most typically less than 0.5% by weight.

The compounds, salts, solvates and prodrugs of the present invention may contain any stable isotope including, but not limited to ¹²C, ¹³C, ¹H, ²H (D), ¹⁴N, ¹⁵N, ¹⁶O, ¹⁷O, ¹⁸O, ¹⁹F and ¹²⁷I, and any radioisotope including, but not limited to ¹¹C, ¹⁴C, ³H (T), ¹³N, ¹⁵O, ¹⁸F, ¹²³I, ¹²⁴I, ¹²⁵I and ¹³¹I.

The compounds, salts, solvates and prodrugs of the present invention may be in any polymorphic or amorphous form.

A fourth aspect of the invention provides a pharmaceutical composition comprising a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, and a pharmaceutically acceptable excipient.

Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, “Aulton's Pharmaceutics—The Design and Manufacture of Medicines”, M. E. Aulton and K. M. G. Taylor, Churchill Livingstone Elsevier, 4^(th) Ed., 2013.

Pharmaceutically acceptable excipients including adjuvants, diluents or carriers that may be used in the pharmaceutical compositions of the invention are those conventionally employed in the field of pharmaceutical formulation, and include, but are not limited to, sugars, sugar alcohols, starches, ion exchangers, alumina, aluminium stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycerine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

In one embodiment, the pharmaceutical composition of the fourth aspect of the invention additionally comprises one or more further active agents.

In a further embodiment, the pharmaceutical composition of the fourth aspect of the invention may be provided as a part of a kit of parts, wherein the kit of parts comprises the pharmaceutical composition of the fourth aspect of the invention and one or more further pharmaceutical compositions, wherein the one or more further pharmaceutical compositions each comprise a pharmaceutically acceptable excipient and one or more further active agents.

A fifth aspect of the invention provides a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, for use in medicine, and/or for use in the treatment or prevention of a disease, disorder or condition. Typically, the use comprises the administration of the compound, salt, solvate, prodrug or pharmaceutical composition to a subject. In one embodiment, the use comprises the co-administration of one or more further active agents.

The term “treatment” as used herein refers equally to curative therapy, and ameliorating or palliative therapy. The term includes obtaining beneficial or desired physiological results, which may or may not be established clinically. Beneficial or desired clinical results include, but are not limited to, the alleviation of symptoms, the prevention of symptoms, the diminishment of extent of disease, the stabilisation (i.e., not worsening) of a condition, the delay or slowing of progression/worsening of a condition/symptom, the amelioration or palliation of a condition/symptom, and remission (whether partial or total), whether detectable or undetectable. The term “palliation”, and variations thereof, as used herein, means that the extent and/or undesirable manifestations of a physiological condition or symptom are lessened and/or time course of the progression is slowed or lengthened, as compared to not administering a compound, salt, solvate, prodrug or pharmaceutical composition of the present invention. The term “prevention” as used herein in relation to a disease, disorder or condition, relates to prophylactic or preventative therapy, as well as therapy to reduce the risk of developing the disease, disorder or condition. The term “prevention” includes both the avoidance of occurrence of the disease, disorder or condition, and the delay in onset of the disease, disorder or condition. Any statistically significant (p≤0.05) avoidance of occurrence, delay in onset or reduction in risk as measured by a controlled clinical trial may be deemed a prevention of the disease, disorder or condition. Subjects amenable to prevention include those at heightened risk of a disease, disorder or condition as identified by genetic or biochemical markers. Typically, the genetic or biochemical markers are appropriate to the disease, disorder or condition under consideration and may include for example, inflammatory biomarkers such as C-reactive protein (CRP) and monocyte chemoattractant protein 1 (MCP-1) in the case of inflammation; total cholesterol, triglycerides, insulin resistance and C-peptide in the case of NAFLD and NASH; and more generally IL-1β and IL-18 in the case of a disease, disorder or condition responsive to NLRP3 inhibition.

A sixth aspect of the invention provides the use of a compound of the first or second aspect, or a pharmaceutically effective salt, solvate or prodrug of the third aspect, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition. Typically, the treatment or prevention comprises the administration of the compound, salt, solvate, prodrug or medicament to a subject. In one embodiment, the treatment or prevention comprises the co-administration of one or more further active agents.

A seventh aspect of the invention provides a method of treatment or prevention of a disease, disorder or condition, the method comprising the step of administering an effective amount of a compound of the first or second aspect, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect, or a pharmaceutical composition of the fourth aspect, to thereby treat or prevent the disease, disorder or condition. In one embodiment, the method further comprises the step of co-administering an effective amount of one or more further active agents. Typically, the administration is to a subject in need thereof.

An eighth aspect of the invention provides a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, for use in the treatment or prevention of a disease, disorder or condition in an individual, wherein the individual has a germline or somatic non-silent mutation in NLRP3. The mutation may be, for example, a gain-of-function or other mutation resulting in increased NLRP3 activity. Typically, the use comprises the administration of the compound, salt, solvate, prodrug or pharmaceutical composition to the individual. In one embodiment, the use comprises the co-administration of one or more further active agents. The use may also comprise the diagnosis of an individual having a germline or somatic non-silent mutation in NLRP3, wherein the compound, salt, solvate, prodrug or pharmaceutical composition is administered to an individual on the basis of a positive diagnosis for the mutation. Typically, identification of the mutation in NLRP3 in the individual may be by any suitable genetic or biochemical means.

A ninth aspect of the invention provides the use of a compound of the first or second aspect, or a pharmaceutically effective salt, solvate or prodrug of the third aspect, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition in an individual, wherein the individual has a germline or somatic non-silent mutation in NLRP3. The mutation may be, for example, a gain-of-function or other mutation resulting in increased NLRP3 activity. Typically, the treatment or prevention comprises the administration of the compound, salt, solvate, prodrug or medicament to the individual. In one embodiment, the treatment or prevention comprises the co-administration of one or more further active agents. The treatment or prevention may also comprise the diagnosis of an individual having a germline or somatic non-silent mutation in NLRP3, wherein the compound, salt, solvate, prodrug or medicament is administered to an individual on the basis of a positive diagnosis for the mutation. Typically, identification of the mutation in NLRP3 in the individual may be by any suitable genetic or biochemical means.

A tenth aspect of the invention provides a method of treatment or prevention of a disease, disorder or condition, the method comprising the steps of diagnosing of an individual having a germline or somatic non-silent mutation in NLRP3, and administering an effective amount of a compound of the first or second aspect, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect, or a pharmaceutical composition of the fourth aspect, to the positively diagnosed individual, to thereby treat or prevent the disease, disorder or condition. In one embodiment, the method further comprises the step of co-administering an effective amount of one or more further active agents. Typically, the administration is to a subject in need thereof.

In general embodiments, the disease, disorder or condition may be a disease, disorder or condition of the immune system, the cardiovascular system, the endocrine system, the gastrointestinal tract, the renal system, the hepatic system, the metabolic system, the respiratory system, the central nervous system, may be a cancer or other malignancy, and/or may be caused by or associated with a pathogen.

It will be appreciated that these general embodiments defined according to broad categories of diseases, disorders and conditions are not mutually exclusive. In this regard any particular disease, disorder or condition may be categorized according to more than one of the above general embodiments. A non-limiting example is type I diabetes which is an autoimmune disease and a disease of the endocrine system.

In one embodiment of the fifth, sixth, seventh, eighth, ninth or tenth aspect of the invention, the disease, disorder or condition is responsive to NLRP3 inhibition. As used herein, the term “NLRP3 inhibition” refers to the complete or partial reduction in the level of activity of NLRP3 and includes, for example, the inhibition of active NLRP3 and/or the inhibition of activation of NLRP3.

There is evidence for a role of NLRP3-induced IL-1 and IL-18 in the inflammatory responses occurring in connection with, or as a result of, a multitude of different disorders (Menu et al., Clinical and Experimental Immunology, 166: 1-15, 2011; Strowig et al., Nature, 481: 278-286, 2012).

Genetic diseases in which a role for NLRP3 has been suggested include sickle cell disease (Vogel et al., Blood, 130 (Suppl1): 2234, 2017), and Valosin Containing Protein disease (Nalbandian et al., Inflammation, 40(1): 21-41, 2017).

NLRP3 has been implicated in a number of autoinflammatory diseases, including Familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), and acne vulgaris (Cook et al., Eur J Immunol, 40: 595-653, 2010). In particular, NLRP3 mutations have been found to be responsible for a set of rare autoinflammatory diseases known as CAPS (Ozaki et al., J Inflammation Research, 8: 15-27, 2015; Schroder et al., Cell, 140: 821-832, 2010; and Menu et al., Clinical and Experimental Immunology, 166: 1-15, 2011). CAPS are heritable diseases characterized by recurrent fever and inflammation and are comprised of three autoinflammatory disorders that form a clinical continuum. These diseases, in order of increasing severity, are familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic infantile cutaneous neurological articular syndrome (CINCA; also called neonatal-onset multisystem inflammatory disease, NOMID), and all have been shown to result from gain-of-function mutations in the NLRP3 gene, which leads to increased secretion of IL-1β.

A number of autoimmune diseases have been shown to involve NLRP3 including, in particular, multiple sclerosis, type 1 diabetes (T1D), psoriasis, rheumatoid arthritis (RA), Behcet's disease, Schnitzler's syndrome, macrophage activation syndrome (Masters, Clin Immunol, 147(3): 223-228, 2013; Braddock et al., Nat Rev Drug Disc, 3: 1-10, 2004; Inoue et al., Immunology, 139: 11-18, 2013; Coll et al., Nat Med, 21(3): 248-55, 2015; Scott et al., Clin Exp Rheumatol, 34(1): 88-93, 2016; and Guo et al., Clin Exp Immunol, 194(2): 231-243, 2018), systemic lupus erythematosus (Lu et al., J Immunol, 198(3): 1119-29, 2017) including lupus nephritis (Zhao et al., Arthritis and Rheumatism, 65(12): 3176-3185, 2013), multiple sclerosis (Xu et al., J Cell Biochem, 120(4): 5160-5168, 2019), and systemic sclerosis (Artlett et al., Arthritis Rheum, 63(11): 3563-74, 2011).

NLRP3 has also been shown to play a role in a number of lung diseases including chronic obstructive pulmonary disorder (COPD), asthma (including steroid-resistant asthma and eosinophilic asthma), asbestosis, and silicosis (De Nardo et al., Am J Pathol, 184: 42-54, 2014; Lv et al., J Biol Chem, 293(48): 18454, 2018; and Kim et al., Am J Respir Crit Care Med, 196(3): 283-97, 2017).

NLRP3 has also been suggested to have a role in a number of central nervous system conditions, including Parkinson's disease (PD), Alzheimer's disease (AD), dementia, Huntington's disease, cerebral malaria, brain injury from pneumococcal meningitis (Walsh et al., Nature Reviews, 15: 84-97, 2014, and Dempsey et al., Brain Behav Immun, 61: 306-316, 2017), intracranial aneurysms (Zhang et al., J Stroke & Cerebrovascular Dis, 24(5): 972-979, 2015), intracerebral haemorrhages (ICH) (Ren et al., Stroke, 49(1): 184-192, 2018), cerebral ischemia-reperfusion injuries (Fauzia et al., Front Pharmacol, 9: 1034, 2018), sepsis-associated encephalopathy (SAE) (Fu et al., Inflammation, 42(1): 306-318, 2019), postoperative cognitive dysfunction (POCD) (Fan et al., Front Cell Neurosci, 12: 426, 2018), early brain injury (subarachnoid haemorrhage SAH) (Luo et al., Brain Res Bull, 146: 320-326, 2019), and traumatic brain injury (Ismael et al., J Neurotrauma, 35(11): 1294-1303, 2018).

NRLP3 activity has also been shown to be involved in various metabolic diseases including type 2 diabetes (T2D), atherosclerosis, obesity, gout, pseudo-gout, metabolic syndrome (Wen et al., Nature Immunology, 13: 352-357, 2012; Duewell et al., Nature, 464: 1357-1361, 2010; Strowig et al., Nature, 481: 278-286, 2012), and non-alcoholic steatohepatitis (NASH) (Mridha et al., J Hepatol, 66(5): 1037-46, 2017).

A role for NLRP3 via IL-1p has also been suggested in atherosclerosis, myocardial infarction (van Hout et al., Eur Heart J, 38(11): 828-36, 2017), cardiovascular disease (Janoudi et al., European Heart Journal, 37(25): 1959-1967, 2016), cardiac hypertrophy and fibrosis (Gan et al., Biochim Biophys Acta, 1864(1): 1-10, 2018), heart failure (Sano et al., J Am Coll Cardiol, 71(8): 875-66, 2018), aortic aneurysm and dissection (Wu et al., Arterioscler Thromb Vasc Biol, 37(4): 694-706, 2017), cardiac injury induced by metabolic dysfunction (Pavillard et al., Oncotarget, 8(59): 99740-99756, 2017), atrial fibrillation (Yao et al., Circulation, 138(20): 2227-2242, 2018), hypertension (Gan et al., Biochim Biophys Acta, 1864(1): 1-10, 2018), and other cardiovascular events (Ridker et al., N Engl J Med, doi: 10.1056/NEJMoa1707914, 2017).

Other diseases in which NLRP3 has been shown to be involved include:

-   -   ocular diseases such as both wet and dry age-related macular         degeneration (Doyle et al., Nature Medicine, 18: 791-798, 2012;         and Tarallo et al., Cell, 149(4): 847-59, 2012), diabetic         retinopathy (Loukovaara et al., Acta Ophthalmol, 95(8):         803-808, 2017) and optic nerve damage (Puyang et al., Sci Rep,         6: 20998, 2016 Feb. 19);     -   liver diseases including non-alcoholic steatohepatitis (NASH)         (Henao-Meija et al., Nature, 482: 179-185, 2012), ischemia         reperfusion injury of the liver (Yu et al., Transplantation,         103(2): 353-362, 2019), fulminant hepatitis (Pourcet et al.,         Gastroenterology, 154(5): 1449-1464, e20, 2018), liver fibrosis         (Zhang et al., Parasit Vectors, 12(1): 29, 2019), and liver         failure (Wang et al., Hepatol Res, 48(3): E194-E202, 2018);     -   kidney diseases including nephrocalcinosis (Anders et al.,         Kidney Int, 93(3): 656-669, 2018), kidney fibrosis including         chronic crystal nephropathy (Ludwig-Portugall et al., Kidney         Int, 90(3): 525-39, 2016), and renal hypertension (Krishnan et         al., Br J Pharmacol, 173(4): 752-65, 2016);     -   conditions associated with diabetes including diabetic         encephalopathy (Zhai et al., Molecules, 23(3): 522, 2018),         diabetic retinopathy (Zhang et al., Cell Death Dis, 8(7): e2941,         2017), and diabetic hypoadiponectinemia (Zhang et al.,         Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease,         1863(6): 1556-1567, 2017);     -   inflammatory reactions in the lung and skin (Primiano et al., J         Immunol, 197(6): 2421-33, 2016) including lung         ischemia-reperfusion injury (Xu et al., Biochemical and         Biophysical Research Communications, 503(4): 3031-3037, 2018),         epithelial to mesenchymal transition (EMT) (Li et al.,         Experimental Cell Research, 362(2): 489-497, 2018), contact         hypersensitivity (such as bullous pemphigoid (Fang et al., J         Dermatol Sci, 83(2): 116-23, 2016)), atopic dermatitis (Niebuhr         et al., Allergy, 69(8): 1058-67, 2014), Hidradenitis suppurativa         (Alikhan et al., J Am Acad Dermatol, 60(4): 539-61, 2009), acne         vulgaris (Qin et al., J Invest Dermatol, 134(2): 381-88, 2014),         and sarcoidosis (Jager et al., Am J Respir Crit Care Med, 191:         A5816, 2015);     -   inflammatory reactions in the joints (Braddock et al., Nat Rev         Drug Disc, 3: 1-10, 2004) and osteoarthritis (Jin et al., PNAS,         108(36): 14867-14872, 2011);     -   amyotrophic lateral sclerosis (Gugliandolo et al., Inflammation,         41(1): 93-103, 2018);     -   cystic fibrosis (Iannitti et al., Nat Commun, 7: 10791, 2016);     -   stroke (Walsh et al., Nature Reviews, 15: 84-97, 2014);     -   chronic kidney disease (Granata et al., PLoS One, 10(3):         e0122272, 2015);     -   Sjögren's syndrome (Vakrakou et al., Journal of Autoimmunity,         91: 23-33, 2018);     -   sickle cell disease (Vogel et al., Blood, 130 (Suppl1): 2234,         2017); and     -   colitis and inflammatory bowel diseases including ulcerative         colitis and Crohn's disease (Braddock et al., Nat Rev Drug Disc,         3: 1-10, 2004; Neudecker et al., J Exp Med, 214(6): 1737-52,         2017; Wu et al., Mediators Inflamm, 2018: 3048532, 2018; and         Lazaridis et al., Dig Dis Sci, 62(9): 2348-56, 2017), and sepsis         (intestinal epithelial disruption) (Zhang et al., Dig Dis Sci,         63(1): 81-91, 2018).

Genetic ablation of NLRP3 has been shown to protect from HSD (high sugar diet), HFD (high fat diet) and HSFD-induced obesity (Pavillard et al., Oncotarget, 8(59): 99740-99756, 2017).

The NLRP3 inflammasome has been found to be activated in response to oxidative stress, sunburn (Hasegawa et al., Biochemical and Biophysical Research Communications, 477(3): 329-335, 2016), and UVB irradiation (Schroder et al., Science, 327: 296-300, 2010).

NLRP3 has also been shown to be involved in inflammatory hyperalgesia (Dolunay et al., Inflammation, 40: 366-386, 2017), wound healing (Ito et al., Exp Dermatol, 27(1): 80-86, 2018), pain including multiple sclerosis-associated neuropathic pain (Khan et al., Inflammopharmacology, 26(1): 77-86, 2018), and intra-amniotic inflammation/infection associated with preterm birth (Faro et al., Biol Reprod, 100(5): 1290-1305, 2019; and Gomez-Lopez et al., Biol Reprod, 100(5): 1306-1318, 2019).

The inflammasome, and NLRP3 specifically, has also been proposed as a target for modulation by various pathogens including bacterial pathogens such as Staphylococcus aureus (Cohen et al., Cell Reports, 22(9): 2431-2441, 2018), Bacillus cereus (Mathur et al., Nat Microbiol, 4: 362-374, 2019), Salmonella typhimurium (Diamond et al., Sci Rep, 7(1): 6861, 2017), and group A streptococcus (LaRock et al., Science Immunology, 1(2): eaah3539, 2016); viruses such as DNA viruses (Amsler et al., Future Virol, 8(4): 357-370, 2013), influenza A virus (Coates et al., Front Immunol, 8: 782, 2017), chikungunya, Ross river virus, and alpha viruses (Chen et al., Nat Microbiol, 2(10): 1435-1445, 2017); fungal pathogens such as Candida albicans (Tucey et al., mSphere, 1(3), pii: e00074-16, 2016); and other pathogens such as T. gondii (Gov et al., J Immunol, 199(8): 2855-2864, 2017), helminth worms (Alhallaf et al., Cell Reports, 23(4): 1085-1098, 2018), leishmania (Novais et al., PLoS Pathogens, 13(2): e1006196, 2017), and plasmodium (Strangward et al., PNAS, 115(28): 7404-7409, 2018). NLRP3 has been shown to be required for the efficient control of viral, bacterial, fungal, and helminth pathogen infections (Strowig et al., Nature, 481: 278-286, 2012).

NLRP3 has also been implicated in the pathogenesis of many cancers (Menu et al., Clinical and Experimental Immunology, 166: 1-15, 2011; and Masters, Clin Immunol, 147(3): 223-228, 2013). For example, several previous studies have suggested a role for IL-1p in cancer invasiveness, growth and metastasis, and inhibition of IL-1p with canakinumab has been shown to reduce the incidence of lung cancer and total cancer mortality in a randomised, double-blind, placebo-controlled trial (Ridker et al., Lancet, S0140-6736(17)32247-X, 2017). Inhibition of the NLRP3 inflammasome or IL-1p has also been shown to inhibit the proliferation and migration of lung cancer cells in vitro (Wang et al., Oncol Rep, 35(4): 2053-64, 2016). A role for the NLRP3 inflammasome has been suggested in myelodysplastic syndromes (Basiorka et al., Blood, 128(25): 2960-2975, 2016) and also in the carcinogenesis of various other cancers including glioma (Li et al., Am J Cancer Res, 5(1): 442-449, 2015), colon cancer (Allen et al., J Exp Med, 207(5): 1045-56, 2010), melanoma (Dunn et al., Cancer Lett, 314(1): 24-33, 2012), breast cancer (Guo et al., Scientific Reports, 6: 36107, 2016), inflammation-induced tumours (Allen et al., J Exp Med, 207(5): 1045-56, 2010; and Hu et al., PNAS, 107(50): 21635-40, 2010), multiple myeloma (Li et al., Hematology, 21(3): 144-51, 2016), and squamous cell carcinoma of the head and neck (Huang et al., J Exp Clin Cancer Res, 36(1): 116, 2017). Activation of the NLRP3 inflammasome has also been shown to mediate chemoresistance of tumour cells to 5-fluorouracil (Feng et al., J Exp Clin Cancer Res, 36(1): 81, 2017), and activation of the NLRP3 inflammasome in peripheral nerves contributes to chemotherapy-induced neuropathic pain (Jia et al., Mol Pain, 13: 1-11, 2017).

Accordingly, examples of diseases, disorders or conditions which may be responsive to NLRP3 inhibition and which may be treated or prevented in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention include:

(i) inflammation, including inflammation occurring as a result of an inflammatory disorder, e.g. an autoinflammatory disease, inflammation occurring as a symptom of a non-inflammatory disorder, inflammation occurring as a result of infection, or inflammation secondary to trauma, injury or autoimmunity; (ii) auto-immune diseases such as acute disseminated encephalitis, Addison's disease, ankylosing spondylitis, antiphospholipid antibody syndrome (APS), anti-synthetase syndrome, aplastic anemia, autoimmune adrenalitis, autoimmune hepatitis, autoimmune oophoritis, autoimmune polyglandular failure, autoimmune thyroiditis, Coeliac disease, Crohn's disease, type 1 diabetes (T1D), Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, idiopathic thrombocytopenic purpura, Kawasaki's disease, lupus erythematosus including systemic lupus erythematosus (SLE), multiple sclerosis (MS) including primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS) and relapsing remitting multiple sclerosis (RRMS), myasthenia gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord's thyroiditis, pemphigus, pernicious anaemia, polyarthritis, primary biliary cirrhosis, rheumatoid arthritis (RA), psoriatic arthritis, juvenile idiopathic arthritis or Still's disease, refractory gouty arthritis, Reiter's syndrome, Sjögren's syndrome, systemic sclerosis a systemic connective tissue disorder, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, alopecia universalis, Behcet's disease, Chagas' disease, dysautonomia, endometriosis, hidradenitis suppurativa (HS), interstitial cystitis, neuromyotonia, psoriasis, sarcoidosis, scleroderma, ulcerative colitis, Schnitzler's syndrome, macrophage activation syndrome, Blau syndrome, vitiligo or vulvodynia; (iii) cancer including lung cancer, pancreatic cancer, gastric cancer, myelodysplastic syndrome, leukaemia including acute lymphocytic leukaemia (ALL) and acute myeloid leukaemia (AML), adrenal cancer, anal cancer, basal and squamous cell skin cancer, bile duct cancer, bladder cancer, bone cancer, brain and spinal cord tumours, breast cancer, cervical cancer, chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), chronic myelomonocytic leukaemia (CMML), colorectal cancer, endometrial cancer, oesophagus cancer, Ewing family of tumours, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumours, gastrointestinal stromal tumour (GIST), gestational trophoblastic disease, glioma, Hodgkin lymphoma, Kaposi sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung carcinoid tumour, lymphoma including cutaneous T cell lymphoma, malignant mesothelioma, melanoma skin cancer, Merkel cell skin cancer, multiple myeloma, nasal cavity and paranasal sinuses cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cavity and oropharyngeal cancer, osteosarcoma, ovarian cancer, penile cancer, pituitary tumours, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, stomach cancer, testicular cancer, thymus cancer, thyroid cancer including anaplastic thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, and Wilms tumour; (iv) infections including viral infections (e.g. from influenza virus, human immunodeficiency virus (HIV), alphavirus (such as Chikungunya and Ross River virus), flaviviruses (such as Dengue virus and Zika virus), herpes viruses (such as Epstein Barr virus, cytomegalovirus, Varicella-zoster virus, and KSHV), poxviruses (such as vaccinia virus (Modified vaccinia virus Ankara) and Myxoma virus), adenoviruses (such as Adenovirus 5), or papillomavirus), bacterial infections (e.g. from Staphylococcus aureus, Helicobacter pylori, Bacillus anthracis, Bordatella pertussis, Burkholderia pseudomallei, Corynebacterium diptheriae, Clostridium tetani, Clostridium botulinum, Streptococcus pneumoniae, Streptococcus pyogenes, Listeria monocytogenes, Hemophilus influenzae, Pasteurella multicida, Shigella dysenteriae, Mycobacterium tuberculosis, Mycobacterium leprae, Mycoplasma pneumoniae, Mycoplasma hominis, Neisseria meningitidis, Neisseria gonorrhoeae, Rickettsia rickettsii, Legionella pneumophila, Klebsiella pneumoniae, Pseudomonas aeruginosa, Propionibacterium acnes, Treponema pallidum, Chlamydia trachomatis, Vibrio cholerae, Salmonella typhimurium, Salmonella typhi, Borrelia burgdorferi or Yersinia pestis), fungal infections (e.g. from Candida or Aspergillus species), protozoan infections (e.g. from Plasmodium, Babesia, Giardia, Entamoeba, Leishmania or Trypanosomes), helminth infections (e.g. from schistosoma, roundworms, tapeworms or flukes) and prion infections; (v) central nervous system diseases such as Parkinson's disease, Alzheimer's disease, dementia, motor neuron disease, Huntington's disease, cerebral malaria, brain injury from pneumococcal meningitis, intracranial aneurysms, intracerebral haemorrhages, sepsis-associated encephalopathy, postoperative cognitive dysfunction, early brain injury, traumatic brain injury, and amyotrophic lateral sclerosis; (vi) metabolic diseases such as type 2 diabetes (T2D), atherosclerosis, obesity, gout, and pseudo-gout; (vii) cardiovascular diseases such as hypertension, ischaemia, reperfusion injury including post-MI ischemic reperfusion injury, stroke including ischemic stroke, transient ischemic attack, myocardial infarction including recurrent myocardial infarction, heart failure including congestive heart failure and heart failure with preserved ejection fraction, cardiac hypertrophy and fibrosis, embolism, aneurysms including abdominal aortic aneurysm, and pericarditis including Dressler's syndrome; (viii) respiratory diseases including chronic obstructive pulmonary disorder (COPD), asthma such as allergic asthma, eosinophilic asthma, and steroid-resistant asthma, asbestosis, silicosis, nanoparticle induced inflammation, cystic fibrosis and idiopathic pulmonary fibrosis; (ix) liver diseases including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) including advanced fibrosis stages F3 and F4, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), ischemia reperfusion injury of the liver, fulminant hepatitis, liver fibrosis, and liver failure; (x) renal diseases including chronic kidney disease, oxalate nephropathy, nephrocalcinosis, glomerulonephritis, diabetic nephropathy, kidney fibrosis including chronic crystal nephropathy, and renal hypertension; (xi) ocular diseases including those of the ocular epithelium, age-related macular degeneration (AMD) (dry and wet), uveitis, corneal infection, diabetic retinopathy, optic nerve damage, dry eye, and glaucoma; (xii) skin diseases including dermatitis such as contact dermatitis and atopic dermatitis, contact hypersensitivity, sunburn, skin lesions, hidradenitis suppurativa (HS), other cyst-causing skin diseases, and acne conglobata; (xiii) lymphatic conditions such as lymphangitis and Castleman's disease; (xiv) psychological disorders such as depression and psychological stress; (xv) graft versus host disease; (xvi) allodynia including mechanical allodynia; (xvii) conditions associated with diabetes including diabetic encephalopathy, diabetic retinopathy, and diabetic hypoadiponectinemia; and (xviii) any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

In one embodiment, the disease, disorder or condition is selected from:

(i) cancer; (ii) an infection; (iii) a central nervous system disease; (iv) a cardiovascular disease; (v) a liver disease; (vi) an ocular disease; or (vii) a skin disease.

More typically, the disease, disorder or condition is selected from:

(i) cancer; (ii) an infection; (iii) a central nervous system disease; or (iv) a cardiovascular disease.

In one embodiment, the disease, disorder or condition is selected from:

(i) acne conglobata; (ii) atopic dermatitis; (iii) Alzheimer's disease; (iv) amyotrophic lateral sclerosis; (v) age-related macular degeneration (AMD); (vi) anaplastic thyroid cancer; (vii) cryopyrin-associated periodic syndromes (CAPS); (viii) contact dermatitis; (ix) cystic fibrosis; (x) congestive heart failure; (xi) chronic kidney disease; (xii) Crohn's disease; (xiii) familial cold autoinflammatory syndrome (FCAS); (xiv) Huntington's disease; (xv) heart failure; (xvi) heart failure with preserved ejection fraction; (xvii) ischemic reperfusion injury; (xviii) juvenile idiopathic arthritis; (xix) myocardial infarction; (xx) macrophage activation syndrome; (xxi) myelodysplastic syndrome; (xxii) multiple myeloma; (xxiii) motor neuron disease; (xxiv) multiple sclerosis; (xxv) Muckle-Wells syndrome; (xxvi) non-alcoholic steatohepatitis (NASH); (xxvii) neonatal-onset multisystem inflammatory disease (NOMID); (xxviii) Parkinson's disease; (xxix) sickle cell disease; (xxx) systemic juvenile idiopathic arthritis; (xxxi) systemic lupus erythematosus; (xxxii) traumatic brain injury; (xxxiii) transient ischemic attack; (xxxiv) ulcerative colitis; or (xxxv) Valosin Containing Protein disease.

In a further typical embodiment of the invention, the disease, disorder or condition is inflammation. Examples of inflammation that may be treated or prevented in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention include inflammatory responses occurring in connection with, or as a result of:

(i) a skin condition such as contact hypersensitivity, bullous pemphigoid, sunburn, psoriasis, atopical dermatitis, contact dermatitis, allergic contact dermatitis, seborrhoetic dermatitis, lichen planus, scleroderma, pemphigus, epidermolysis bullosa, urticaria, erythemas, or alopecia; (ii) a joint condition such as osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, relapsing polychondritis, rheumatoid arthritis, juvenile chronic arthritis, gout, or a seronegative spondyloarthropathy (e.g. ankylosing spondylitis, psoriatic arthritis or Reiter's disease); (iii) a muscular condition such as polymyositis or myasthenia gravis; (iv) a gastrointestinal tract condition such as inflammatory bowel disease (including Crohn's disease and ulcerative colitis), colitis, gastric ulcer, coeliac disease, proctitis, pancreatitis, eosinopilic gastro-enteritis, mastocytosis, antiphospholipid syndrome, or a food-related allergy which may have effects remote from the gut (e.g., migraine, rhinitis or eczema); (v) a respiratory system condition such as chronic obstructive pulmonary disease (COPD), asthma (including eosinophilic, bronchial, allergic, intrinsic, extrinsic or dust asthma, and particularly chronic or inveterate asthma, such as late asthma and airways hyper-responsiveness), bronchitis, rhinitis (including acute rhinitis, allergic rhinitis, atrophic rhinitis, chronic rhinitis, rhinitis caseosa, hypertrophic rhinitis, rhinitis pumlenta, rhinitis sicca, rhinitis medicamentosa, membranous rhinitis, seasonal rhinitis e.g. hay fever, and vasomotor rhinitis), sinusitis, idiopathic pulmonary fibrosis (IPF), sarcoidosis, farmer's lung, silicosis, asbestosis, adult respiratory distress syndrome, hypersensitivity pneumonitis, or idiopathic interstitial pneumonia; (vi) a vascular condition such as atherosclerosis, Behcet's disease, vasculitides, or Wegener's granulomatosis; (vii) an autoimmune condition such as systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, Hashimoto's thyroiditis, type I diabetes, idiopathic thrombocytopenia purpura, or Graves disease; (viii) an ocular condition such as uveitis, allergic conjunctivitis, or vernal conjunctivitis; (ix) a nervous condition such as multiple sclerosis or encephalomyelitis; (x) an infection or infection-related condition, such as Acquired Immunodeficiency Syndrome (AIDS), acute or chronic bacterial infection, acute or chronic parasitic infection, acute or chronic viral infection, acute or chronic fungal infection, meningitis, hepatitis (A, B or C, or other viral hepatitis), peritonitis, pneumonia, epiglottitis, malaria, dengue hemorrhagic fever, leishmaniasis, streptococcal myositis, Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Pneumocystis carinii pneumonia, orchitis/epidydimitis, legionella, Lyme disease, influenza A, Epstein-Barr virus infection, viral encephalitis/aseptic meningitis, or pelvic inflammatory disease; (xi) a renal condition such as mesangial proliferative glomerulonephritis, nephrotic syndrome, nephritis, glomerular nephritis, acute renal failure, uremia, nephritic syndrome, kidney fibrosis including chronic crystal nephropathy, or renal hypertension; (xii) a lymphatic condition such as Castleman's disease; (xiii) a condition of, or involving, the immune system, such as hyper IgE syndrome, lepromatous leprosy, familial hemophagocytic lymphohistiocytosis, or graft versus host disease; (xiv) a hepatic condition such as chronic active hepatitis, non-alcoholic steatohepatitis (NASH), alcohol-induced hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), primary biliary cirrhosis, fulminant hepatitis, liver fibrosis, or liver failure; (xv) a cancer, including those cancers listed above; (xvi) a burn, wound, trauma, haemorrhage or stroke; (xvii) radiation exposure; (xviii) obesity; and/or (xix) pain such as inflammatory hyperalgesia.

In one embodiment of the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention, the disease, disorder or condition is an autoinflammatory disease such as cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), familial Mediterranean fever (FMF), neonatal onset multisystem inflammatory disease (NOMID), Tumour Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor antagonist (DIRA), Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA), adult-onset Still's disease (AOSD), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammatory, antibody deficiency and immune dysregulation (APLAID), or sideroblastic anaemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD).

Examples of diseases, disorders or conditions which may be responsive to NLRP3 inhibition and which may be treated or prevented in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention are listed above. Some of these diseases, disorders or conditions are substantially or entirely mediated by NLRP3 inflammasome activity, and NLRP3-induced IL-1p and/or IL-18. As a result, such diseases, disorders or conditions may be particularly responsive to NLRP3 inhibition and may be particularly suitable for treatment or prevention in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention. Examples of such diseases, disorders or conditions include cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), neonatal onset multisystem inflammatory disease (NOMID), familial Mediterranean fever (FMF), pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), Tumour Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS), systemic juvenile idiopathic arthritis, adult-onset Still's disease (AOSD), relapsing polychondritis, Schnitzler's syndrome, Sweet's syndrome, Behcet's disease, anti-synthetase syndrome, deficiency of interleukin 1 receptor antagonist (DIRA), and haploinsufficiency of A20 (HA20).

Moreover, some of the diseases, disorders or conditions mentioned above arise due to mutations in NLRP3, in particular, resulting in increased NLRP3 activity. As a result, such diseases, disorders or conditions may be particularly responsive to NLRP3 inhibition and may be particularly suitable for treatment or prevention in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention. Examples of such diseases, disorders or conditions include cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), and neonatal onset multisystem inflammatory disease (NOMID).

An eleventh aspect of the invention provides a method of inhibiting NLRP3, the method comprising the use of a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, to inhibit NLRP3.

In one embodiment of the eleventh aspect of the present invention, the method comprises the use of a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, in combination with one or more further active agents.

In one embodiment of the eleventh aspect of the present invention, the method is performed ex vivo or in vitro, for example in order to analyse the effect on cells of NLRP3 inhibition.

In another embodiment of the eleventh aspect of the present invention, the method is performed in vivo. For example, the method may comprise the step of administering an effective amount of a compound of the first or second aspect, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect, or a pharmaceutical composition of the fourth aspect, to thereby inhibit NLRP3. In one embodiment, the method further comprises the step of co-administering an effective amount of one or more further active agents. Typically, the administration is to a subject in need thereof.

Alternately, the method of the eleventh aspect of the invention may be a method of inhibiting NLRP3 in a non-human animal subject, the method comprising the steps of administering the compound, salt, solvate, prodrug or pharmaceutical composition to the non-human animal subject and optionally subsequently mutilating or sacrificing the non-human animal subject. Typically, such a method further comprises the step of analysing one or more tissue or fluid samples from the optionally mutilated or sacrificed non-human animal subject. In one embodiment, the method further comprises the step of co-administering an effective amount of one or more further active agents.

A twelfth aspect of the invention provides a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, for use in the inhibition of NLRP3. Typically, the use comprises the administration of the compound, salt, solvate, prodrug or pharmaceutical composition to a subject. In one embodiment, the compound, salt, solvate, prodrug or pharmaceutical composition is co-administered with one or more further active agents.

A thirteenth aspect of the invention provides the use of a compound of the first or second aspect of the invention, or a pharmaceutically effective salt, solvate or prodrug of the third aspect of the invention, in the manufacture of a medicament for the inhibition of NLRP3. Typically, the inhibition comprises the administration of the compound, salt, solvate, prodrug or medicament to a subject. In one embodiment, the compound, salt, solvate, prodrug or medicament is co-administered with one or more further active agents.

In any embodiment of any of the fifth to thirteenth aspects of the present invention that comprises the use or co-administration of one or more further active agents, the one or more further active agents may comprise for example one, two or three different further active agents.

The one or more further active agents may be used or administered prior to, simultaneously with, sequentially with or subsequent to each other and/or to the compound of the first or second aspect of the invention, the pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or the pharmaceutical composition of the fourth aspect of the invention. Where the one or more further active agents are administered simultaneously with the compound of the first or second aspect of the invention, or the pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, a pharmaceutical composition of the fourth aspect of the invention may be administered wherein the pharmaceutical composition additionally comprises the one or more further active agents.

In one embodiment of any of the fifth to thirteenth aspects of the present invention that comprises the use or co-administration of one or more further active agents, the one or more further active agents are selected from:

(i) chemotherapeutic agents; (ii) antibodies; (iii) alkylating agents; (iv) anti-metabolites; (v) anti-angiogenic agents; (vi) plant alkaloids and/or terpenoids; (vii) topoisomerase inhibitors; (viii) mTOR inhibitors; (ix) stilbenoids; (x) STING agonists; (xi) cancer vaccines; (xii) immunomodulatory agents; (xiii) antibiotics; (xiv) anti-fungal agents; (xv) anti-helminthic agents; and/or (xvi) other active agents.

It will be appreciated that these general embodiments defined according to broad categories of active agents are not mutually exclusive. In this regard any particular active agent may be categorized according to more than one of the above general embodiments. A non-limiting example is urelumab which is an antibody that is an immunomodulatory agent for the treatment of cancer.

In some embodiments, the one or more chemotherapeutic agents are selected from abiraterone acetate, altretamine, amsacrine, anhydrovinblastine, auristatin, azathioprine, adriamycin, bexarotene, bicalutamide, BMS 184476, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, cisplatin, carboplatin, carboplatin cyclophosphamide, chlorambucil, cachectin, cemadotin, cyclophosphamide, carmustine, cryptophycin, cytarabine, docetaxel, doxetaxel, doxorubicin, dacarbazine (DTIC), dactinomycin, daunorubicin, decitabine, dolastatin, etoposide, etoposide phosphate, enzalutamide (MDV3100), 5-fluorouracil, fludarabine, flutamide, gemcitabine, hydroxyurea and hydroxyureataxanes, idarubicin, ifosfamide, irinotecan, leucovorin, lonidamine, lomustine (CCNU), larotaxel (RPR109881), mechlorethamine, mercaptopurine, methotrexate, mitomycin C, mitoxantrone, melphalan, mivobulin, 3′,4′-didehydro-4′-deoxy-8′-norvin-caleukoblastine, nilutamide, oxaliplatin, onapristone, prednimustine, procarbazine, paclitaxel, platinum-containing anti-cancer agents, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulfonamide, prednimustine, procarbazine, rhizoxin, sertenef, streptozocin, stramustine phosphate, tretinoin, tasonermin, taxol, topotecan, tamoxifen, teniposide, taxane, tegafur/uracil, vincristine, vinblastine, vinorelbine, vindesine, vindesine sulfate, and/or vinflunine.

Alternatively or in addition, the one or more chemotherapeutic agents may be selected from CD59 complement fragment, fibronectin fragment, gro-beta (CXCL2), heparinases, heparin hexasaccharide fragment, human chorionic gonadotropin (hCG), interferon alpha, interferon beta, interferon gamma, interferon inducible protein (IP-10), interleukin-12, kringle 5 (plasminogen fragment), metalloproteinase inhibitors (TIMPs), 2-methoxyestradiol, placental ribonuclease inhibitor, plasminogen activator inhibitor, platelet factor-4 (PF4), prolactin 16 kD fragment, proliferin-related protein (PRP), various retinoids, tetrahydrocortisol-S, thrombospondin-1 (TSP-1), transforming growth factor-beta (TGF-β), vasculostatin, vasostatin (calreticulin fragment), and/or cytokines (including interleukins, such as interleukin-2 (IL-2), or IL-10).

In some embodiments, the one or more antibodies may comprise one or more monoclonal antibodies. In some embodiments, the one or more antibodies are selected from abciximab, adalimumab, alemtuzumab, atlizumab, basiliximab, belimumab, bevacizumab, bretuximab vedotin, canakinumab, cetuximab, ceertolizumab pegol, daclizumab, denosumab, eculizumab, efalizumab, gemtuzumab, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, muromonab-CD3, natalizumab, ofatumumab, omalizumab, palivizumab, panitumuab, ranibizumab, rituximab, tocilizumab, tositumomab, and/or trastuzumab.

In some embodiments, the one or more alkylating agents may comprise an agent capable of alkylating nucleophilic functional groups under conditions present in cells, including, for example, cancer cells. In some embodiments, the one or more alkylating agents are selected from cisplatin, carboplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide and/or oxaliplatin. In some embodiments, the alkylating agent may function by impairing cell function by forming covalent bonds with amino, carboxyl, sulfhydryl, and/or phosphate groups in biologically important molecules. In some embodiments, the alkylating agent may function by modifying a cell's DNA.

In some embodiments, the one or more anti-metabolites may comprise an agent capable of affecting or preventing RNA or DNA synthesis. In some embodiments, the one or more anti-metabolites are selected from azathioprine and/or mercaptopurine.

In some embodiments, the one or more anti-angiogenic agents are selected from endostatin, angiogenin inhibitors, angiostatin, angioarrestin, angiostatin (plasminogen fragment), basement-membrane collagen-derived anti-angiogenic factors (tumstatin, canstatin, or arrestin), anti-angiogenic antithrombin III, and/or cartilage-derived inhibitor (CDI).

In some embodiments, the one or more plant alkaloids and/or terpenoids may prevent microtubule function. In some embodiments, the one or more plant alkaloids and/or terpenoids are selected from a vinca alkaloid, a podophyllotoxin and/or a taxane. In some embodiments, the one or more vinca alkaloids may be derived from the Madagascar periwinkle, Catharanthus roseus (formerly known as Vinca rosea), and may be selected from vincristine, vinblastine, vinorelbine and/or vindesine. In some embodiments, the one or more taxanes are selected from taxol, paclitaxel, docetaxel and/or ortataxel. In some embodiments, the one or more podophyllotoxins are selected from an etoposide and/or teniposide.

In some embodiments, the one or more topoisomerase inhibitors are selected from a type I topoisomerase inhibitor and/or a type II topoisomerase inhibitor, and may interfere with transcription and/or replication of DNA by interfering with DNA supercoiling. In some embodiments, the one or more type I topoisomerase inhibitors may comprise a camptothecin, which may be selected from exatecan, irinotecan, lurtotecan, topotecan, BNP 1350, CKD 602, DB 67 (AR67) and/or ST 1481. In some embodiments, the one or more type II topoisomerase inhibitors may comprise an epipodophyllotoxin, which may be selected from an amsacrine, etoposid, etoposide phosphate and/or teniposide.

In some embodiments, the one or more mTOR (mammalian target of rapamycin, also known as the mechanistic target of rapamycin) inhibitors are selected from rapamycin, everolimus, temsirolimus and/or deforolimus.

In some embodiments, the one or more stilbenoids are selected from resveratrol, piceatannol, pinosylvin, pterostilbene, alpha-viniferin, ampelopsin A, ampelopsin E, diptoindonesin C, diptoindonesin F, epsilon-vinferin, flexuosol A, gnetin H, hemsleyanol D, hopeaphenol, trans-diptoindonesin B, astringin, piceid and/or diptoindonesin A.

In some embodiments, the one or more STING (Stimulator of interferon genes, also known as transmembrane protein (TMEM) 173) agonists may comprise cyclic di-nucleotides, such as cAMP, cGMP, and cGAMP, and/or modified cyclic di-nucleotides that may include one or more of the following modification features: 2′-O/3′-O linkage, phosphorothioate linkage, adenine and/or guanine analogue, and/or 2′-OH modification (e.g. protection of the 2′-OH with a methyl group or replacement of the 2′-OH by —F or —N₃).

In some embodiments, the one or more cancer vaccines are selected from an HPV vaccine, a hepatitis B vaccine, Oncophage, and/or Provenge.

In some embodiments, the one or more immunomodulatory agents may comprise an immune checkpoint inhibitor. The immune checkpoint inhibitor may target an immune checkpoint receptor, or combination of receptors comprising, for example, CTLA-4, PD-1, PD-L1, PD-L2, T cell immunoglobulin and mucin 3 (TIM3 or HAVCR2), galectin 9, phosphatidylserine, lymphocyte activation gene 3 protein (LAG3), MHC class I, MHC class II, 4-1BB, 4-1BBL, OX40, OX40L, GITR, GITRL, CD27, CD70, TNFRSF25, TL1A, CD40, CD40L, HVEM, LIGHT, BTLA, CD160, CD80, CD244, CD48, ICOS, ICOSL, B7-H3, B7-H4, VISTA, TMIGD2, HHLA2, TMIGD2, a butyrophilin (including BTNL2), a Siglec family member, TIGIT, PVR, a killer-cell immunoglobulin-like receptor, an ILT, a leukocyte immunoglobulin-like receptor, NKG2D, NKG2A, MICA, MICB, CD28, CD86, SIRPA, CD47, VEGF, neuropilin, CD30, CD39, CD73, CXCR4, and/or CXCL12.

In some embodiments, the immune checkpoint inhibitor is selected from urelumab, PF-05082566, MEDI6469, TRX518, varlilumab, CP-870893, pembrolizumab (PD1), nivolumab (PD1), atezolizumab (formerly MPDL3280A) (PD-L1), MEDI4736 (PD-L1), avelumab (PD-L1), PDR001 (PD1), BMS-986016, MGA271, lirilumab, IPH2201, emactuzumab, INCB024360, galunisertib, ulocuplumab, BKT140, bavituximab, CC-90002, bevacizumab, and/or MNRP1685A.

In some embodiments, the one or more antibiotics are selected from amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, streptomycin, spectinomycin, geldanamycin, herbimycin, rifaximin, loracarbef, ertapenem, doripenem, imipenem, cilastatin, meropenem, cefadroxil, cefazolin, cefalotin, cefalothin, cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftaroline fosamil, ceftobiprole, teicoplanin, vancomycin, telavancin, dalbavancin, oritavancin, clindamycin, lincomycin, daptomycin, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spiramycin, aztreonam, furazolidone, nitrofurantoin, linezolid, posizolid, radezolid, torezolid, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, temocillin, ticarcillin, calvulanate, ampicillin, subbactam, tazobactam, ticarcillin, clavulanate, bacitracin, colistin, polymyxin B, ciprofloxacin, enoxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin, temafloxacin, mafenide, sulfacetamide, sulfadiazine, silver sulfadiazine, sulfadimethoxine, sulfamethoxazole, sulfanamide, sulfasalazine, sulfisoxazole, trimethoprim-sulfamethoxazole, sulfonamideochrysoidine, demeclocycline, minocycline, oytetracycline, tetracycline, clofazimine, dapsone, dapreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazinamide, rifampicin, rifabutin, rifapentine, streptomycin, arsphenamine, chloramphenicol, fosfomycin, fusidic acid, metronidazole, mupirocin, platensimycin, quinupristin, dalopristin, thiamphenicol, tigecycyline, tinidazole, trimethoprim, and/or teixobactin.

In some embodiments, the one or more antibiotics may comprise one or more cytotoxic antibiotics. In some embodiments, the one or more cytotoxic antibiotics are selected from an actinomycin, an anthracenedione, an anthracycline, thalidomide, dichloroacetic acid, nicotinic acid, 2-deoxyglucose, and/or chlofazimine. In some embodiments, the one or more actinomycins are selected from actinomycin D, bacitracin, colistin (polymyxin E) and/or polymyxin B. In some embodiments, the one or more antracenediones are selected from mitoxantrone and/or pixantrone. In some embodiments, the one or more anthracyclines are selected from bleomycin, doxorubicin (Adriamycin), daunorubicin (daunomycin), epirubicin, idarubicin, mitomycin, plicamycin and/or valrubicin.

In some embodiments, the one or more anti-fungal agents are selected from bifonazole, butoconazole, clotrimazole, econazole, ketoconazole, luliconazole, miconazole, omoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, albaconazole, efinaconazole, epoziconazole, fluconazole, isavuconazole, itraconazole, posaconazole, propiconazole, ravusconazole, terconazole, voriconazole, abafungin, amorolfin, butenafine, naftifine, terbinafine, anidulafungin, caspofungin, micafungin, benzoic acid, ciclopirox, flucytosine, 5-fluorocytosine, griseofulvin, haloprogin, tolnaflate, undecylenic acid, and/or balsam of Peru.

In some embodiments, the one or more anti-helminthic agents are selected from benzimidazoles (including albendazole, mebendazole, thiabendazole, fenbendazole, triclabendazole, and flubendazole), abamectin, diethylcarbamazine, ivermectin, suramin, pyrantel pamoate, levamisole, salicylanilides (including niclosamide and oxyclozanide), and/or nitazoxanide.

In some embodiments, other active agents are selected from growth inhibitory agents, anti-inflammatory agents (including nonsteroidal anti-inflammatory agents), anti-psoriatic agents (including anthralin and its derivatives), vitamins and vitamin-derivatives (including retinoinds, and VDR receptor ligands), corticosteroids, ion channel blockers (including potassium channel blockers), immune system regulators (including cyclosporin, FK 506, and glucocorticoids), lutenizing hormone releasing hormone agonists (such as leuprolidine, goserelin, triptorelin, histrelin, bicalutamide, flutamide and/or nilutamide), and/or hormones (including estrogen).

Unless stated otherwise, in any of the fifth to thirteenth aspects of the invention, the subject may be any human or other animal. Typically, the subject is a mammal, more typically a human or a domesticated mammal such as a cow, pig, lamb, sheep, goat, horse, cat, dog, rabbit, mouse etc. Most typically, the subject is a human.

Any of the medicaments employed in the present invention can be administered by oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intraarticular, intracranial and epidural), airway (aerosol), rectal, vaginal, ocular or topical (including transdermal, buccal, mucosal, sublingual and topical ocular) administration.

Typically, the mode of administration selected is that most appropriate to the disorder, disease or condition to be treated or prevented. Where one or more further active agents are administered, the mode of administration may be the same as or different to the mode of administration of the compound, salt, solvate, prodrug or pharmaceutical composition of the invention.

For oral administration, the compounds, salts, solvates or prodrugs of the present invention will generally be provided in the form of tablets, capsules, hard or soft gelatine capsules, caplets, troches or lozenges, as a powder or granules, or as an aqueous solution, suspension or dispersion.

Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose. Corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatine. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material, such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. Tablets may also be effervescent and/or dissolving tablets.

Capsules for oral use include hard gelatine capsules in which the active ingredient is mixed with a solid diluent, and soft gelatine capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

Powders or granules for oral use may be provided in sachets or tubs. Aqueous solutions, suspensions or dispersions may be prepared by the addition of water to powders, granules or tablets.

Any form suitable for oral administration may optionally include sweetening agents such as sugar, flavouring agents, colouring agents and/or preservatives.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

For parenteral use, the compounds, salts, solvates or prodrugs of the present invention will generally be provided in a sterile aqueous solution or suspension, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride or glucose. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate. The compounds of the invention may also be presented as liposome formulations.

For ocular administration, the compounds, salts, solvates or prodrugs of the invention will generally be provided in a form suitable for topical administration, e.g. as eye drops. Suitable forms may include ophthalmic solutions, gel-forming solutions, sterile powders for reconstitution, ophthalmic suspensions, ophthalmic ointments, ophthalmic emulsions, ophthalmic gels and ocular inserts. Alternatively, the compounds, salts, solvates or prodrugs of the invention may be provided in a form suitable for other types of ocular administration, for example as intraocular preparations (including as irrigating solutions, as intraocular, intravitreal or juxtascleral injection formulations, or as intravitreal implants), as packs or corneal shields, as intracameral, subconjunctival or retrobulbar injection formulations, or as iontophoresis formulations.

For transdermal and other topical administration, the compounds, salts, solvates or prodrugs of the invention will generally be provided in the form of ointments, cataplasms (poultices), pastes, powders, dressings, creams, plasters or patches.

Suitable suspensions and solutions can be used in inhalers for airway (aerosol) administration.

The dose of the compounds, salts, solvates or prodrugs of the present invention will, of course, vary with the disease, disorder or condition to be treated or prevented. In general, a suitable dose will be in the range of 0.01 to 500 mg per kilogram body weight of the recipient per day. The desired dose may be presented at an appropriate interval such as once every other day, once a day, twice a day, three times a day or four times a day. The desired dose may be administered in unit dosage form, for example, containing 1 mg to 50 g of active ingredient per unit dosage form.

For the avoidance of doubt, insofar as is practicable any embodiment of a given aspect of the present invention may occur in combination with any other embodiment of the same aspect of the present invention. In addition, insofar as is practicable it is to be understood that any preferred, typical or optional embodiment of any aspect of the present invention should also be considered as a preferred, typical or optional embodiment of any other aspect of the present invention.

EXAMPLES—COMPOUND SYNTHESIS

All solvents, reagents and compounds were purchased and used without further purification unless stated otherwise.

Abbreviations

-   2-MeTHF 2-methyltetrahydrofuran -   Ac₂O acetic anhydride -   AcOH acetic acid -   aq aqueous -   B₂Pin₂ bis(pinacolato)diboron, also called     4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) -   Boc tert-butyloxycarbonyl -   br broad -   Cbz carboxybenzyl -   CDI 1,1-carbonyl-diimidazole -   conc concentrated -   d doublet -   DABCO 1,4-diazabicyclo[2.2.2]octane -   DCE 1,2-dichloroethane, also called ethylene dichloride -   DCM dichloromethane -   DIPEA N,N-diisopropylethylamine, also called Hünig's base -   DMA dimethylacetamide -   DMAP 4-dimethylaminopyridine, also called     N,N-dimethylpyridin-4-amine -   DME dimethoxyethane -   DMF N,N-dimethylformamide -   DMSO dimethyl sulfoxide -   EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide -   eq or equiv equivalent -   (ES⁺) electrospray ionization, positive mode -   Et ethyl -   EtOAc ethyl acetate -   EtOH ethanol -   h hour(s) -   HATU     1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium     3-oxid hexafluorophosphate -   HPLC high performance liquid chromatography -   LC liquid chromatography -   m multiplet -   m-CPBA 3-chloroperoxybenzoic acid -   Me methyl -   MeCN acetonitrile -   MeOH methanol -   (M+H)⁺ protonated molecular ion -   MHz megahertz -   min minute(s) -   MS mass spectrometry -   Ms mesyl, also called methanesulfonyl -   MsCl mesyl chloride, also called methanesulfonyl chloride -   MTBE methyl tert-butyl ether, also called tert-butyl methyl ether -   m/z mass-to-charge ratio -   NaOtBu sodium tert-butoxide -   NBS 1-bromopyrrolidine-2,5-dione, also called N-bromosuccinimide -   NCS 1-chloropyrrolidine-2,5-dione, also called N-chlorosuccinimide -   NMP N-methylpyrrolidine -   NMR nuclear magnetic resonance (spectroscopy) -   Pd₂(dba)₃ tris(dibenzylideneacetone) dipalladium(o) -   PdCl₂ (dppf) [1,1′-bis(diphenylphosphino)ferrocene]     dichloropalladium(II), also called Pd(dppf)Cl₂ -   PE petroleum ether -   Ph phenyl -   PMB p-methoxybenzyl, also called 4-methoxybenzyl -   prep HPLC preparative high performance liquid chromatography -   prep-TLC preparative thin layer chromatography -   PTSA p-toluenesulfonic acid -   q quartet -   RP reversed phase -   RT room temperature -   s singlet -   sat saturated -   SCX solid supported cation exchange (resin) -   sept septuplet -   t triplet -   T3P propylphosphonicanhydride -   TBME tert-butyl methyl ether, also called methyl tert-butyl ether -   TEA triethylamine -   TFA 2,2,2-trifluoroaceticacid -   THF tetrahydrofuran -   TLC thin layer chromatography -   wt % weight percent or percent by weight -   Xphos 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl

Experimental Methods Nuclear Magnetic Resonance

NMR spectra were recorded at 300, 400 or 500 MHz. Spectra were measured at 298 K, unless indicated otherwise, and were referenced relative to the solvent resonance. The chemical shifts are reported in parts per million. Spectra were recorded using one of the following machines:

-   -   a Bruker Avance III spectrometer at 400 MHz fitted with a BBO 5         mm liquid probe,     -   a Bruker 400 MHz spectrometer using ICON-NMR, under TopSpin         program control,     -   a Bruker Avance III HD spectrometer at 500 MHz, equipped with a         Bruker 5 mm SmartProbe™,     -   an Agilent VNMRS 300 instrument fitted with a 7.05 Tesla magnet         from Oxford instruments, indirect detection probe and direct         drive console including PFG module, or     -   an Agilent MercuryPlus 300 instrument fitted with a 7.05 Tesla         magnet from Oxford instruments, 4 nuclei auto-switchable probe         and Mercury plus console.

LC-MS

LC-MS Methods: Using SHIMADZU LCMS-2020, Agilent 1200 LC/G1956A MSD and Agilent 1200\G6110A, Agilent 1200 LC & Agilent 6110 MSD. Mobile Phase: A: 0.025% NH₃.H₂ in water (v/v); B: acetonitrile. Column: Kinetex EVO C18 2.1×30 mm, 5 μm.

Preparative Reversed Phase HPLC General Methods

Acidic prep HPLC (x-y % MeCN in water): Waters X-Select CSH column C18.5 μm (19×50 mm), flow rate 28 mL min-1 eluting with a H₂O-MeCN gradient containing 0.1% v/v formic acid over 6.5 min using UV detection at 254 nm. Gradient information: 0.0-0.2 min, x % MeCN; 0.2-5.5 min, ramped from x % MeCN to y % MeCN; 5.5-5.6 min, ramped from y % MeCN to 95% MeCN; 5.6-6.5 min, held at 95% MeCN.

Acidic prep HPLC (x-y % MeOH in water): Waters X-Select CSH column C18.5 μm (19×50 mm), flow rate 28 mL min-1 eluting with a 10 mM aq formic acid-MeOH gradient over 7.5 min using UV detection at 254 nm. Gradient information: 0.0-1.5 min, x % MeOH; 1.5-6.8 min, ramped from x % MeOH to y % MeOH; 6.8-6.9 min, ramped from y % MeOH to 95% MeOH; 6.9-7.5 min. held at 95% MeOH.

Basic prep HPLC (x-y % MeCN in water): Waters X-Bridge Prep column C18.5 μm (19×50 mm), flow rate 28 mL min-1 eluting with a 10 mM NH₄HCO₃-MeCN gradient over 6.5 min using UV detection at 254 nm. Gradient information: 0.0-0.2 min, x % MeCN; 0.2-5.5 min, ramped from x % MeCN to y % MeCN; 5.5-5.6 min, ramped from y % MeCN to 95% MeCN; 5.6-6.5 min, held at 95% MeCN.

Synthesis of Intermediates Intermediate L1: (4-(Dimethylamino)pyridin-1-ium-1-carbonyl)(methylsulfonyl)amide

A solution of methanesulfonamide (1.7 g, 17.87 mmol) and DMAP (4.37 g, 35.7 mmol) in MeCN (25 mL) was stirred at room temperature for 10 minutes. Diphenyl carbonate (4.21 g, 19.66 mmol) was then added and the reaction was stirred at room temperature for 5 days. The precipitate was filtered off, washed with MTBE and dried in vacuo to afford the title compound (1.67 g, 38%) as a white solid.

¹H NMR (CDCl₃) δ 9.07 (d, J=7.4 Hz, 2H), 6.74 (d, J=7.5 Hz, 2H), 3.35 (s, 6H), 3.20 (s, 3H).

The following intermediates were prepared according to the general procedure of Intermediate L1:

Int. Structure and name Characterisation and procedure L2

¹H NMR (CDCl₃) δ 9.08 (d, J = 7.4 Hz, 2H), 6.72 (d, J = 7.5 Hz, 2H), 3.34 (s, 6H), 3.03 (tt, J = 8.1, 4.9 Hz, 1H), 1.36-1.29 (m, 2H), 0.99-0.90 (m, 2H). From cyclopropanesulfonamide L3

From (N-methyl-N- aminosulfoamino)methane L4

From benzenesulfonamide L5

¹H NMR (CDCl₃) δ 8.24 (s, 2H), 6.55 (s, 2H), 3.06 (s, 6H), 1.48 (s, 9H). From 2-methyl-2-propanesulfonamide

Intermediate L6: N′-(tert-Butyldimethylsilyl)benzenesulfonimidamide

Triphenylphosphine (4.07 g, 15.51 mmol) and perchloroethane (3.67 g, 15.51 mmol) were dissolved in chloroform (45 mL) under N₂ and stirred at 70° C. for 6 hours. Then the reaction was cooled to 0° C. and triethylamine (2.5 mL, 17.90 mmol) was added, followed by N-(tert-butyldimethylsilyl)benzenesulfonamide (3.25 g, 11.97 mmol) in chloroform (5 mL). The reaction mixture was stirred for 15 minutes. Then ammonia gas was bubbled through the reaction mixture for 15 minutes. The reaction mixture was stirred for 2 hours, and then filtered and the filtrate concentrated in vacuo. The resulting crude product was purified by flash chromatography (120 g cartridge, 0-50% EtOAc/isohexane) to afford the title compound (3.18 g, 49%) as a white powder.

¹H NMR (DMSO-d6) δ 7.88-7.84 (m, 2H), 7.52-7.47 (m, 3H), 6.62 (br s, 2H), 0.87 (s, 9H), 0.01 (s, 3H), 0.01 (s, 3H).

LCMS m/z 271.2 (M+H)⁺ (ES⁺).

Intermediate L7: Benzenesulfinamide

To a solution of methyl benzenesulfinate (500 mg, 3.20 mmol, 1 eq) in THF (1 mL) was added with LiHMDS (1M, 4.80 mL, 1.5 eq) at −78° C. The reaction mixture was stirred at −78° C. for 2 hours. Then a solution of NH₄Cl (342 mg, 6.40 mmol, 2 eq) in H₂O (5 mL) was added, and the resulting mixture was stirred at 25° C. for 1 hour. The reaction mixture was quenched with water (20 mL), and extracted with ethyl acetate (3×20 mL). The organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated to give the title compound (400 mg, 89%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 7.78-7.74 (m, 2H), 7.54-7.51 (m, 3H) and 4.36 (br s, 2H).

LCMS: m/z 141.9 (M+H)⁺(ES⁺).

Intermediate L8: Methanesulfinamide

Ammonia gas (15 psi) was bubbled into THF (10 mL) at −78° C. for 10 minutes. Oxalyl chloride (39.18 mmol, 3.4 mL, 2 eq) was added into a solution of sodium methanesulfinate (2 g, 19.59 mmol, 1 eq) in THF (20 mL) at 0° C. under nitrogen. The mixture was stirred at 0° C. for 1 hour. Then the mixture was dropped into the above NH₃/THF solution at 0° C. The resulting mixture was stirred at 20° C. for 12 hours. A solid formed. The reaction mixture was filtered, and the filtrate was concentrated in vacuo to afford the title compound (0.9 g, crude) as a yellow solid.

¹H NMR (400 MHz, CDCl₃) δ 4.30 (br s, 2H) and 2.66 (s, 3H).

Intermediate R¹: 5-(2-Fluoropyridin-4-yl)-2,3-dihydro-1H-inden-4-amine

A mixture of 5-bromo-2,3-dihydro-1H-inden-4-amine (10 g, 47.2 mmol), (2-fluoropyridin-4-yl)boronic acid (6.64 g, 47.2 mmol) and K₂CO₃ (19.6 g, 142 mmol) in dioxane (200 mL) and water (50 mL) was degassed with N₂. PdC₂ (dppf) (1.7 g, 2.323 mmol) was added and the reaction heated at 80° C. for 20 hours. After cooling to room temperature, the reaction mixture was partitioned between EtOAc (100 mL) and water (50 mL). The organic layer was dried (MgSO₄) and evaporated in vacuo. The residue was purified by flash chromatography (0-50% EtOAc/isohexane) to afford the title compound (8.64 g, 79%) as a white solid.

¹H NMR (DMSO-d6) δ 8.24 (d, J=5.2 Hz, 1H), 7.38 (ddd, J=5.2, 2.2, 1.4 Hz, 1H), 7.16 (d, J=1.4 Hz, 1H), 6.90 (d, J=7.6 Hz, 1H), 6.60 (d, J=7.6 Hz, 1H), 4.82 (s, 2H), 2.84 (t, J=7.5 Hz, 2H), 2.71 (t, J=7.4 Hz, 2H), 2.03 (p, J=7.5 Hz, 2H).

LCMS m/z 299.1 (M+H)⁺ (ES⁺).

Intermediate R2: 2-Bromo-4-fluoro-6-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)aniline

A solution of 4-bromo-2-((1-methylpiperidin-4-yl)oxy)pyridine (5.98 g, 22.05 mmol), potassium acetate (8.66 g, 88 mmol), B₂Pin₂ (5.60 g, 22.05 mmol) and PdCl₂ (dppf)-CH₂C12 adduct (0.900 g, 1.103 mmol) in anhydrous 1,4-dioxane (100 mL) was evacuated and backfilled with nitrogen three times. The reaction mixture was stirred at 100° C. for 2 hours, and then cooled to room temperature. A solution of 2,6-dibromo-4-fluoroaniline (5.93 g, 22.05 mmol) in anhydrous 1,4-dioxane (20 mL) was added, followed by a solution of potassium carbonate (12.19 g, 88 mmol) in water (10 mL). Then the reaction mixture was stirred at 100° C. for 18 hours, diluted with EtOAc (250 mL), and washed with water (300 mL) and brine (300 mL). The organic phase was separated, dried (MgSO₄) and filtered. Activated charcoal (10 g) was added to the filtrate. The slurry was stirred at 70° C. for 30 minutes, then filtered through a plug of Celite® whilst hot, directly loaded onto silica and concentrated under reduced pressure.

The crude product was purified by flash chromatography (0-10% (0.7 M ammonia/MeOH)/DCM) to afford the title compound (2.74 g, 31%) as a brown solid upon standing.

¹HNMR(CDCl₃) δ 8.21 (d, J=5.2 Hz, 1H), 7.24 (dd, J=7.7, 2.9 Hz, 1H), 6.91 (dd, J=5.2, 1.5 Hz, 1H), 6.84 (dd, J=8.6, 2.9 Hz, 1H), 6.78-6.77 (m, 1H), 5.17-5.09 (m, 1H), 4.08 (s, 2H), 2.80-2.70 (m, 2H), 2.43-2.31 (m, 5H), 2.15-2.07 (m, 2H), 1.94-1.83 (m, 2H).

LCMS m/z 380.1/382.1 (M+H)⁺ (ES⁺).

Intermediate R³: 4-Bromo-3-methyl-2-((1-methylpiperidin-4-yl)oxy)pyridine

1-Methylpiperidin-4-ol (0.67 g, 5.79 mmol) was added to a mixture of KO^(t)Bu (0.89 g, 7.89 mmol) in THF (5 mL) at room temperature. The reaction mixture was stirred for 1 hour, and then cooled in an ice bath. A solution of 4-bromo-2-fluoro-3-methylpyridine (1 g, 5.26 mmol) in THF (5 mL) was added. The mixture was warmed to room temperature, stirred for 2 days, and then partitioned between EtOAc (20 mL) and water (20 mL). The aqueous phase was extracted with EtOAc (20 mL). The organic phases were combined, dried (MgSO₄) and concentrated in vacuo. The crude product was purified by flash chromatography (0-10% (0.7 M ammonia/MeOH)/DCM) to afford the title compound (1.30 g, 86%) as a colourless oil.

¹H NMR (DMSO-d6) δ 7.85 (dd, J=5.4, 0.8 Hz, 1H), 7.19 (d, J=5.4 Hz, 1H), 5.02 (tt, J=8.1, 4.0 Hz, 1H), 2.59-2.52 (m, 2H), 2.26-2.20 (m, 5H), 2.17 (s, 3H), 1.97-1.86 (m, 2H), 1.74-1.62 (m, 2H).

LCMS m/z 285.1/287.1 (M+H)⁺ (ES⁺).

Intermediate R4: 5-([2,2′-Bipyridin]-4-yl)-2,3-dihydro-1H-inden-4-amine

To a solution of 5-bromo-2,3-dihydro-1H-inden-4-amine (300 mg, 1.415 mmol) in dioxane (6 mL) was added B₂Pin₂ (395 mg, 1.556 mmol), potassium acetate (555 mg, 5.66 mmol), and PdC₂ (dppf)-CH₂Cl₂ adduct (58 mg, 0.071 mmol). The reaction mixture was degassed (N₂, 5 minutes) and evacuated and backfilled with N₂ (×3) and stirred at 100° C. for 2 hours. Then the reaction mixture was cooled to ambient temperature, diluted with EtOAc (20 mL), and filtered through Celite® washing with EtOAc. The organics were concentrated in vacuo and to the residue was added 4-bromo-2,2′-bipyridine (0.111 mL, 0.707 mmol), Pd(PPh₃)₄ (82 mg, 0.071 mmol), 2M aqueous solution of sodium carbonate (0.707 mL, 1.415 mmol), and toluene (9.5 mL).

Then the reaction mixture was heated to 100° C. for 16 hours, cooled to room temperature, diluted with EtOAc (30 mL), and washed with water (2×30 mL) and brine (30 mL). The organic extract was dried (phase separator) and concentrated in vacuo. The crude product was purified by flash chromatography (0-30% EtOAc/isohexane) to afford the title compound (52 mg, 23%) as a brown oil.

¹H NMR (DMSO-d6) δ 8.74-8.67 (m, 2H), 8.48 (d, J=1.7 Hz, 1H), 8.45-8.41 (m, 1H), 7.97 (td, J=7.7, 1.8 Hz, 1H), 7.50 (dd, J=5.0, 1.8 Hz, 1H), 7.48-7.44 (m, 1H), 6.94 (d, J=7.6 Hz, 1H), 6.64 (d, J=7.6 Hz, 1H), 4.76 (br s, 2H), 2.86 (t, J=7.5 Hz, 2H), 2.74 (t, J=7.4 Hz, 2H), 2.10-2.01 (m, 2H).

LCMS m/z 288.1 (M+H)⁺ (ES⁺).

The following intermediates were prepared according to the general procedure of Intermediate R⁴:

Int. Structure and name Characterisation and procedure R5

¹H NMR (DMSO-d6) δ 8.68 (dd, J = 5.1, 0.8 Hz, 1H), 8.13-8.07 (m, 2H), 7.93-7.90 (m, 1H), 7.52-7.47 (m, 2H), 7.46-7.42 (m, 1H), 7.39 (dd, J = 5.0, 1.6 Hz, 1H), 6.96 (d, J = 7.6 Hz, 1H), 6.62 (d, J = 7.6 Hz, 1H), 2.85 (t, J = 7.5 Hz, 2H), 2.73 (t, J = 7.3 Hz, 2H), 2.04 (p, J = 7.5 Hz, 2H). Two exchangeable protons not observed. LCMS m/z 287.2 (M + H)⁺ (ES⁺). R6

¹H NMR (DMSO-d6) δ 8.52 (d, J = 5.0 Hz, 1H), 7.36-7.16 (m, 2H), 6.87 (d, J = 7.6 Hz, 1H), 6.60 (d, J = 7.6 Hz, 1H), 4.67 (s, 2H), 4.01-3.89 (m, 2H), 3.52-3.39 (m, 2H), 3.01- 2.91 (m, 1H), 2.83 (t, J = 7.5 Hz, 2H), 2.71 (t, J = 7.3 Hz, 2H), 2.03 (p, J = 7.4 Hz, 2H), 1.88-1.76 (m, 4H). LCMS m/z 295.3 (M + H)⁺ (ES⁺). R7

¹H NMR (Methanol-d4) δ 8.63 (dd, J = 5.2, 0.8 Hz, 1H), 7.59-7.56 (m, 1H), 7.53 (dd, J = 5.3, 1.7 Hz, 1H), 7.43-7.40 (m, 1H), 7.38- 7.29 (m, 3H), 7.00 (d, J = 7.7 Hz, 1H), 6.74 (d, J = 7.7 Hz, 1H), 2.94 (t, J = 7.6 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H), 2.36 (s, 3H), 2.15 (p, J = 7.5 Hz, 2H). Two exchangeable protons not observed. LCMS m/z 301.1 (M + H)⁺ (ES⁺). R8

¹H NMR (DMSO-d6) δ 8.63-8.55 (m, 1H), 7.72-7.60 (m, 3H), 7.52-7.44 (m, 4H), 6.91 (d, J = 7.6 Hz, 1H), 6.62 (dd, J = 7.7, 2.6 Hz, 1H), 4.79 (s, 2H), 2.84 (t, J = 7.6 Hz, 2H), 2.72 (t, J = 7.4 Hz, 2H), 2.12-1.97 (m, 2H). LCMS m/z 311.2 (M + H)⁺ (ES⁺).

Intermediate R9: 5-(2-((Tetrahydro-2H-pyran-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-amine

Tetrahydro-2H-pyran-4-ol (98 mg, 0.964 mmol) in THF (1 mL) was added to a suspension of KO^(t)Bu (108 mg, 0.964 mmol) in dry THF (1 mL). The reaction mixture was stirred at room temperature for 1 hour, and then cooled to 0° C. 5-(2-Fluoropyridin-4-yl)-2,3-dihydro-H-inden-4-amine (Intermediate R1) (200 mg, 0.876 mmol) in THF (1 mL) was added. The reaction mixture was allowed to warm to room temperature, stirred for 16 hours, and then partitioned between EtOAc (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), dried using a phase separator and concentrated in vacuo. The crude product was purified by flash chromatography (0-5% (0.7 M ammonia/MeOH)/DCM) to afford the title compound (131 mg, 46%) as a colourless solid.

¹H NMR (DMSO-d6) δ 8.16 (d, J=5.3 Hz, 1H), 7.00 (dd, J=5.3, 1.5 Hz, 1H), 6.85 (d, J=7.6 Hz, 1H), 6.75 (d, J=1.4 Hz, 1H), 6.58 (d, J=7.6 Hz, 1H), 5.25-5.18 (m, 1H), 4.66 (s, 2H), 3.91-3.83 (m, 2H), 3.54-3.47 (m, 2H), 2.83 (t, J=7.5 Hz, 2H), 2.70 (t, J=7.4 Hz, 2H), 2.04-1.99 (m, 4H), 1.72-1.60 (m, 2H).

LCMS m/z 311.2 (M+H)⁺ (ES⁺).

The following intermediates were prepared according to the general procedure of Intermediate R⁹:

Int. Structure and name Characterisation and procedure R10

¹H NMR (DMSO-d6) δ 8.16 (dd, J = 5.2, 0.7 Hz, 1H), 7.01 (dd, J = 5.3, 1.5 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.76-6.74 (m, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.08- 4.98 (m, 1H), 4.66 (s, 2H), 3.92-3.87 (m, 1H), 3.69-3.61 (m, 1H), 3.56-3.48 (m, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.11-2.00 (m, 3H), 1.85- 1.71 (m, 2H), 1.61-1.51 (m, 1H). LCMS m/z 311.0 (M + H)⁺ (ES⁺). R11

¹H NMR (DMSO-d6) δ 8.17 (d, J = 5.2 Hz, 1H), 7.43 (t, J = 7.3 Hz, 2H), 7.26- 7.14 (m, 4H), 6.99 (s, 1H), 6.89 (d, J = 7.6 Hz, 1H), 6.60 (d, J = 7.6 Hz, 1H), 4.76 (s, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.71 (t, J = 7.3 Hz, 2H), 2.02 (p, J = 7.4 Hz, 2H). LCMS m/z 303.2 (M + H)⁺ (ES⁺). R12

¹H NMR (DMSO-d6) δ 8.14 (dd, J = 5.2, 0.7 Hz, 1H), 7.00 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.74-6.70 (m, 1H), 6.57 (d, J = 7.6 Hz, 1H), 5.02 (p, J = 7.1 Hz, 1H), 4.71-4.61 (m, 4H), 4.55 (s, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.79-2.73 (m, 2H), 2.70 (t, J = 7.4 Hz, 2H), 2.30-2.23 (m, 2H), 2.05-2.00 (m, 2H). LCMS m/z 323.2 (M + H)⁺ (ES⁺). R13

¹H NMR (DMSO-d6) δ 8.61-8.53 (m, 2H), 8.16 (d, J = 5.3 Hz, 1H), 7.44 (s, 2H), 7.06 (dd, J = 5.3, 1.4 Hz, 1H), 6.94 (s, 1H), 6.88 (d, J = 7.6 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 5.46 (s, 2H), 4.71 (s, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.71 (t, J = 7.3 Hz, 2H), 2.03 (p, J = 7.5 Hz, 2H). LCMS m/z 318.52 (M + H)⁺ (ES⁺). R14

¹H NMR (DMSO-d6) δ 8.13 (d, J = 5.3 Hz, 1H), 6.99 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.74-6.73 (m, 1H), 6.57 4.65 (s, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.63- 2.55 (m, 2H), 2.39-2.30 (m, 1H), 2.08- 1.99 (m, 8H), 1.89-1.80 (m, 2H). LCMS m/z 324.2 (M + H)⁺ (ES⁺). R15

¹H NMR (DMSO-d6) δ 8.16 (d, J = 5.2 Hz, 1H), 6.99 (dd, J = 5.3, 1.5 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.71 (d, J = 1.4 Hz, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.07 (tt, J = 8.4, 4.0 Hz, 1H), 4.65 (s, 2H), 2.94-2.88 (m, 1H), 2.83 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.58-2.52 (m, 1H), 2.18 (s, 3H), 2.12-1.94 (m, 5H), 1.77-1.67 (m, 1H), 1.60-1.48 (m, 1H), 1.45-1.35 (m, 1H). LCMS m/z 324.2 (M + H)⁺ (ES⁺). R16

¹H NMR (CDCl₃) δ 8.16 (d, J = 5.2 Hz, 1H), 7.02-6.92 (m, 2H), 6.82 (d, J = 1.4 Hz, 1H), 6.75 (d, J = 7.6 Hz, 1H), 5.11 (s, 1H), 3.74 (s, 2H), 2.95 (t, J = 7.5 Hz, 2H), 2.76 (t, J = 7.4 Hz, 4H), 2.46-2.26 (m, 5H), 2.22-2.04 (m, 4H), 1.95-1.78 (m, 2H). LCMS m/z 324.2 (M + H)⁺ (ES⁺). R17

¹H NMR (DMSO-d6) δ 8.16 (d, J = 5.3 Hz, 1H), 7.00 (dd, J = 5.3, 1.5 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.77 (d, J = 1.4 Hz, 1H), 6.58 (d, J = 7.6 Hz, 1H), 4.66 (s, 2H), 4.14 (d, J = 6.6 Hz, 2H), 3.92- 3.85 (m, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.09-1.98 (m, 3H), 1.71-1.64 (m, 2H), 1.39-1.27 (m, 2H). Two protons under water peak. LCMS m/z 325.2 (M + H)⁺ (ES⁺). R18

¹H NMR (DMSO-d6) δ 8.16 (d, J = 5.3 Hz, 1H), 6.99 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.74-6.73 (m, 1H), 6.57 (d, J = 7.6 Hz, 1H), 5.19-5.15 (m, 1H), 4.65 (s, 2H), 3.94-3.90 (m, 1H), 3.58-3.42 (m, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.69 (t, J = 7.3 Hz, 2H), 2.16-2.12 (m, 1H), 2.07-1.99 (m, 4H), 1.59-1.46 (m, 1H), 1.14 (d, J = 6.2 Hz, 3H). LCMS m/z 325.2 (M + H)⁺ (ES⁺). R19

¹H NMR (DMSO-d6) δ 8.19 (d, J = 5.3 Hz, 1H), 7.49 (d, J = 7.1 Hz, 2H), 7.39 (t, J = 7.2 Hz, 2H), 7.33 (t, J = 7.3 Hz, 1H), 7.04 (dd, J = 5.3, 1.5 Hz, 1H), 6.91- 6.81 (m, 2H), 6.58 (d, J = 7.6 Hz, 1H), 5.39 (s, 2H), 4.68 (s, 2H), 2.83 (t, J = 7.4 Hz, 2H), 2.71 (t, J = 7.4 Hz, 2H), 2.02 (p, J = 7.4 Hz, 2H). LCMS m/z 317.2 (M + H)⁺ (ES⁺). R20

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.2 Hz, 1H), 7.00 (dd, J = 5.3, 1.4 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.76 (s, 1H), 6.58 (d, J = 7.6 Hz, 1H), 4.65 (s, 2H), 4.13 (d, J = 6.1 Hz, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.80-2.74 (m, 1H), 2.70 (t, J = 7.4 Hz, 2H), 2.15 (s, 3H), 2.07-1.97 (m, 3H), 1.90-1.81 (m, 2H), 1.77-1.66 (m, 3H), 1.35-1.24 (m, 2H). R21

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.2 Hz, 1H), 6.99 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.77-6.65 (m, 1H), 6.57 (d, J = 7.6 Hz, 1H), 5.44-5.25 (m, 1H), 4.64 (s, 2H), 3.78-3.72 (m, 1H), 3.71-3.63 (m, 1H), 2.82 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.07-1.94 (m, 4H), 1.56-1.42 (m, 2H),), 1.23 (s, 3H), 1.21 (s, 3H). LCMS m/z 339.2 (M + H)⁺ (ES⁺). R22

¹H NMR (DMSO-d6) δ 8.20-8.07 (m, 1H), 6.97 (dt, J = 5.3, 1.1 Hz, 1H), 6.84 (dd, J = 7.6, 4.1 Hz, 1H), 6.70 (ddd, J = 6.1, 1.5, 0.7 Hz, 1H), 6.57 (dd, J = 7.6, 1.6 Hz, 1H), 5.10-4.97 (m, 1H), 4.64 (s, 2H), 3.54-3.37 (m, 1H), 3.19 (d, J = 4.3 Hz, 3H), 2.82 (t, J = 7.5 Hz, 2H), 2.69 (t, J = 7.4 Hz, 2H), 2.09-1.95 (m, 2H), 1.83- 1.58 (m, 4H), 1.51-1.40 (m, 4H). LCMS m/z 339.5 (M + H)⁺ (ES⁺). R23

¹H NMR (DMSO-d6) δ 8.19-8.12 (m, 1H), 7.34-7.14 (m, 5H), 7.00 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.75 (d, J = 1.6 Hz, 1H), 6.57 (d, J = 7.6 Hz, 1H), 4.65 (s, 2H), 4.49 (t, J = 7.0 Hz, 2H), 3.05 (t, J = 6.9 Hz, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.73-2.70 (m, 2H), 2.05-1.98 (m, 2H). LCMS m/z 331.2 (M + H)⁺ (ES⁺). R24

¹H NMR (DMSO-d6) δ 8.17 (d, J = 5.2 Hz, 1H), 7.02 (dd, J = 5.3, 1.5 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 6.78 (d, J = 1.4 Hz, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.28- 5.20 (m, 1H), 4.67 (s, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 2.15-1.95 (m, 8H), 1.92-1.82 (m, 2H). R25

¹H NMR (DMSO-d6) δ 8.15 (dd, J = 5.2, 0.7 Hz, 1H), 6.98 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.76-6.66 (m, 1H), 6.57 (d, J = 7.6 Hz, 1H), 5.06- 4.96 (m, 1H), 4.64 (s, 2H), 2.93-2.77 (m, 4H), 2.69 (t, J = 7.4 Hz, 2H), 2.45- 2.35 (m, 2H), 2.09-1.89 (m, 4H), 1.69- 1.53 (m, 3H), 0.46-0.37 (m, 2H), 0.32- 0.28 (m, 2H). LCMS m/z 350.2 (M + H)⁺ (ES⁺). R26

¹H NMR (DMSO-d6) δ 8.17 (d, J = 5.2 Hz, 1H), 7.01 (dd, J = 5.3, 1.5 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.76 (s, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.28-5.20 (m, 1H), 4.66 (s, 2H), 3.97-3.88 (m, 1H), 3.75-3.66 (m, 1H), 3.38-3.33 (m, 1H), 3.25-3.17 (m, 1H), 2.83 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.4 Hz, 2H), 2.08-1.98 (m, 6H), 1.99-1.92 (m, 1H), 1.72-1.62 (m, 1H), 1.60-1.50 (m, 1H). LCMS m/z 352.2 (M + H)⁺ (ES⁺). R27

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.3 Hz, 1H), 6.97 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.69 (s, 1H), 6.57 (d, J = 7.7 Hz, 1H), 4.98-4.88 (m, 1H), 4.63 (s, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.25-2.17 (m, 7H), 2.16-2.10 (m, 2H), 2.02 (p, J = 7.4 Hz, 2H), 1.89-1.82 (m, 2H), 1.48-1.30 (m, 4H). LCMS m/z 352.3 (M + H)⁺ (ES⁺). R28

¹H NMR (DMSO-d6) δ 8.14 (d, J = 5.3 Hz, 1H), 6.98 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.71 (d, J = 1.4 Hz, 1H), 6.57 (d, J = 7.6 Hz, 1H), 5.83 (ddt, J = 16.7, 10.3, 6.4 Hz, 1H), 5.21- 5.14 (m, 1H), 5.11 (dd, J = 10.2, 2.1 Hz, 1H), 5.01 (dt, J = 8.9, 4.6 Hz, 1H), 4.63 (d, J = 9.1 Hz, 2H), 2.98-2.89 (m, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.77- 2.66 (111, 2H), 2.23-2.14 (m, 2H), 2.05-1.94 (m, 4H), 1.71-1.61 (m, 2H). Two exchangeable protons not observed. LCMS m/z 350.3 (M + H)⁺ (ES⁺). R29

¹H NMR (DMSO-d6) δ 8.17 (d, J = 5.2 Hz, 1H), 7.24-7.18 (m, 2H), 7.00 (dd, J = 5.2, 1.5 Hz, 1H), 6.97 (d, J = 8.2 Hz, 2H), 6.85 (d, J = 7.6 Hz, 1H), 6.79-6.74 (m, 2H), 6.57 (d, J = 7.6 Hz, 1H), 5.23- 5.16 (m, 1H), 4.65 (s, 2H), 3.59-3.51 (m, 2H), 3.06-2.99 (m, 2H), 2.82 (t, J = 7.4 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 2.14-2.08 (m, 2H), 2.02 (p, J = 7.4 Hz, 2H), 1.83-1.73 (m, 2H). LCMS m/z 386.2 (M + H)+ (ES+). R30

¹H NMR (DMSO-d6) δ 8.17 (d, J = 5.3 Hz, 1H), 8.15-8.06 (m, 1H), 7.52 (ddd, J = 8.9, 7.1, 2.0 Hz, 1H), 7.00 (dd, J = 5.3, 1.5 Hz, 1H), 6.90-6.81 (m, 2H), 6.75 (d, J = 1.4 Hz, 1H), 6.63-6.59 (m, 1H), 6.57 (d, J = 7.7 Hz, 1H), 5.27 (tt, J = 8.4, 4.0 Hz, 1H), 4.65 (s, 2H), 4.07-3.98 (m, 2H), 3.31-3.24 (m, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.69 (t, J = 7.4 Hz, 2H), 2.11-1.93 (m, 4H), 1.72-1.59 (m, 2H). LCMS m/z 387.3 (M + H)⁺ (ES⁺). R31

¹H NMR (DMSO-d6) δ 8.14 (d, J = 5.2 Hz, 1H), 7.35-7.29 (m, 4H), 7.27-7.21 (m, 1H), 6.98 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.73-6.71 (m, 1H), 6.57 (d, J = 7.6 Hz, 1H), 5.10-4.97 (m, 1H), 4.64 (s, 2H), 3.49 (s, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.76-2.64 (m, 4H), 2.28-2.18 (m, 2H), 2.07-1.94 (m, 4H), 1.75-1.62 (m, 2H). LCMS m/z 400.2 (M + H)+ (ES+). R32

¹H NMR (DMSO-d6) δ 8.10 (d, J = 5.2 Hz, 1H), 7.53-7.46 (m, 4H), 7.34 (t, J = 7.7 Hz, 4H), 7.28-7.21 (m, 3H), 7.01 (dd, J = 5.3, 1.5 Hz, 1H), 6.97 (d, J = 1.4 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 6.58 (d, J = 7.7 Hz, 1H), 4.68 (s, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.02 (p, J = 7.3 Hz, 2H). LCMS m/z 391.8 (M-H)⁺ (ES⁺). R33

¹H NMR (DMSO-d6) δ 8.37 (d, J = 5.3 Hz, 1H), 7.87 (d, J = 7.6, 2H), 7.64 (d, J = 7.5 Hz, 2H), 7.46 (t, J = 7.5 Hz, 2H), 7.31 (td, J = 7.5, 1.1 Hz, 2H), 7.26 (s, 1H), 7.17 (dd, J = 5.3, 1.5 Hz, 1H), 6.89 (d, J = 7.6 Hz, 1H), 687-6.85 (m, 1H), 6.58 (d, J = 76 Hz, 1H), 4.72 (s, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.4 Hz, 2H), 2.02 (p, J = 7.4 Hz, 2H). LCMS m/z 391.2 (M + H)⁺ (ES⁺). R34

¹H NMR (DMSO-d6) δ 8.16 (d, J = 5.3 Hz, 1H), 7.42-7.30 (m, 5H), 7.01 (dd, J = 5.3, 1.4 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.76 (s, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.27-5.19 (m, 1H), 5.10 (s, 2H), 4.65 (s, 2H), 3.84-3.73 (m, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.4 Hz, 2H), 2.05-1.95 (m, 4H), 1.67- 1.56 (m, 2H). Two protons not observed. LCMS m/z 444.3 (M + H)+ (ES+). R35

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.2 Hz, 1H), 6.96 (dd, J = 5.3, 1.5 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.70 (s, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.00-4.91 (m, 1H), 4.64 (s, 2H), 4.15 (s, 1H), 2.83 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.4 Hz, 2H), 2.02 (p, J = 7.4 Hz, 2H), 1.86-1.72 (m, 4H), 1.65-1.58 (m, 2H), 1.49-1.38 (m, 2H), 1.14 (s, 3H). LCMS m/z 339.3 (M + H)+ (ES+). R36

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.2 Hz, 1H), 6.97 (dd, J = 5.3, 1.5 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.71 (s, 1H), 6.57 (d, J = 7.6 Hz, 1H), 5.17-5.09 (m, 1H), 4.65 (s, 2H), 4.19 (s, 1H), 2.83 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.4 Hz, 2H), 2.08-1.89 (m, 4H), 1.70-1.56 (m, 4H), 1.48-1.39 (m, 2H), 1.16 (s, 3H). LCMS m/z 339.3 (M + H)⁺ (ES⁺). R37

¹H NMR (DMSO-d6) δ 8.15 (dd, J = 5.3, 0.7 Hz, 1H), 6.99 (dd, J = 5.3, 1.5 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 6.73 (dd, J = 1.5, 0.7 Hz, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.41-5.33 (m, 1H), 4.65 (s, 2H), 4.10 (q, J = 5.3 Hz, 1H), 2.87-2.75 (m, 3H), 2.75-2.63 (m, 4H), 2.40-2.30 (m, 1H), 2.27 (s, 3H), 2.02 (p, J = 7.0 Hz, 2H), 1.88-1.80 (m, 1H). LCMS m/z 310.2 (M + H)⁺ (ES⁺).

Intermediate R³⁸: Phenyl (5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamate

5-(2-((i-Methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-amine (Intermediate R⁶)(250 mg, 0.773 mmol) and phenyl carbonochloridate (97 μL, 0.773 mmol) were dissolved in DCM (5 mL), cooled to 0° C. and triethylamine (18 μL, 0.775 mmol) was added dropwise. The reaction was stirred at room temperature for 18 hours, then diluted with EtOAc (50 mL), washed with brine (2×30 mL), dried using a phase separator and concentrated in vacuo. The crude product was purified by flash chromatography (12 g cartridge, 0-10% (0.7 M ammonia/MeOH)/DCM) to afford the title compound (86 mg, 24%) as a tan solid.

¹H NMR (DMSO-d6) δ 8.34 (d, J=5.3 Hz, 1H), 7.45-7.39 (m, 3H), 7.34-7.28 (m, 2H), 7.03 (dd, J=5.3, 1.5 Hz, 1H), 7.01-6.95 (m, 3H), 6.73 (s, 1H), 5.17-5.06 (m, 1H), 3.11-2.99 (m, 4H), 2.80-2.64 (m, 2H), 2.40-2.14 (m, 5H), 2.08-1.95 (m, 2H), 1.81-1.66 (m, 2H). 1H obscured by H₂O peak.

LCMS m/z 444.4 (M+H)⁺ (ES⁺).

Intermediate R³⁹: 2-((1-Allylpiperidin-4-yl)oxy)-4-(4-isocyanato-2,3-dihydro-1H-inden-5-yl)pyridine

Triphosgene 0.14 g, 0.472 mmol) in THF (2 mL) was added dropwise to a cooled solution of 5-(2-((1-allylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-amine (Intermediate R²⁸) (0.25 g, 0.715 mmol) and triethylamine (0.20 mL, 1.435 mmol) in THF (10 mL). The reaction mixture was stirred at room temperature for 3 hours, filtered and the filtrate was concentrated in vacuo. The product was used without analysis in the next step.

The following intermediate was prepared according to the general procedure of Intermediate R³⁹:

Int. Structure and name Characterisation and procedure R40

From Intermediate R60

Intermediate R41: 5-(2-(Morpholinomethyl)pyridin-4-yl)-2,3-dihydro-1H-inden-4-amine Step A: (4-(4-Amino-2,3-dihydro-1H-inden-5-yl)pyridin-2-yl)methanol

To a solution of (4-bromopyridin-2-yl)methanol (200 mg, 1.064 mmol) in dioxane (6 mL) was added B₂Pin₂ (297 mg, 1.170 mmol), potassium acetate (418 mg, 4.25 mmol), and PdCl₂ (dppf)-CH₂Cl₂ adduct (43 mg, 0.053 mmol). The reaction mixture was degassed (N₂, 5 minutes) and evacuated and backfilled with N₂ (×3). The reaction mixture was stirred at 100° C. for 2 hours, and then cooled to room temperature. A solution of 5-bromo-2,3-dihydro-1H-inden-4-amine (226 mg, 1.064 mmol) in dioxane (6 mL) was added, followed by a solution of potassium carbonate (588 mg, 4.25 mmol) in water (3 mL). The reaction mixture was stirred at 100° C. for 16 hours, and then cooled to room temperature, diluted with EtOAc (30 mL), and washed with water (2×30 mL) and brine (30 mL). The organic extract was dried (phase separator) and concentrated in vacuo. The crude product was purified by flash chromatography (0-10% (0.7 M ammonia/MeOH)/DCM) to afford the title compound (168 mg, 53%) as a sticky brown oil.

¹H NMR (DMSO-d6) δ 8.49 (d, J=5.0 Hz, 1H), 7.51 (s, 1H), 7.27 (dd, J=5.1, 1.7 Hz, 1H), 6.87 (d, J=7.6 Hz, 1H), 6.61 (d, J=7.6 Hz, 1H), 5.38 (t, J=6.0 Hz, 1H), 4.67 (s, 2H), 4.60 (d, J=5.9 Hz, 2H), 2.84 (t, J=7.5 Hz, 2H), 2.72 (t, J=7.3 Hz, 2H), 2.04 (p, J=7.5 Hz, 2H).

LCMS m/z 241.1 (M+H)⁺ (ES⁺).

Step B: 5-(2-(Morpholinomethyl)pyridin-4-yl)-2,3-dihydro-1H-inden-4-amine

To an ice cooled solution of (4-(4-amino-2,3-dihydro-H-inden-5-yl)pyridin-2-yl)methanol (169 mg, 0.701 mmol) and TEA (0.195 mL, 1.399 mmol) in DCM (10 mL) was added MsCl (0.065 mL, 0.839 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 3 hours. Then the reaction mixture was diluted with DCM (10 mL), and washed with aqueous NaHCO₃ (10 mL) and brine (10 mL). The organic extract was dried using a phase separator and concentrated under reduced pressure. The residue was dissolved in THF (6 mL) and halved. Morpholine (0.061 mL, 0.700 mmol) was added and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated in vacuo. The crude product was purified by flash chromatography (0-10% (0.7 M ammonia/MeOH)/DCM) to afford the title compound (62.3 mg, 46%) as a dark orange oil.

¹H NMR (DMSO-d6) δ 8.53-8.49 (m, 1H), 7.49-7.46 (m, 1H), 7.29 (dd, J=5.1, 1.7 Hz, 1H), 6.86 (d, J=7.6 Hz, 1H), 6.61 (d, J=7.6 Hz, 1H), 4.67 (s, 2H), 3.62 (d, J=2.0 Hz, 2H), 3.59 (d, J=9.2 Hz, 4H), 2.84 (t, J=7.5 Hz, 2H), 2.71 (t, J=7.4 Hz, 2H), 2.45 (dd, J=8.5, 3.6 Hz, 4H), 2.08-1.99 (m, 2H).

LCMS m/z 310.2 (M+H)⁺ (ES⁺).

Intermediate R42: 4-(4-Amino-2,3-dihydro-1H-inden-5-yl)-N-(1-methylpiperidin-4-yl)pyridin-2-amine

To a microwave vial was added 5-(2-fluoropyridin-4-yl)-2,3-dihydro-1H-inden-4-amine (Intermediate R¹) (500 mg, 2.190 mmol), 1-methylpiperidin-4-amine (2.74 mL, 21.90 mmol), DIPEA (0.765 mL, 4.38 mmol), and NMP (4 mL). The reaction was sealed and heated to 150° C. for 16 hours. The mixture was diluted with EtOAc (20 mL) and washed with water (2×20 mL). The organic extract was separated, dried using a phase separator and concentrated in vacuo. The crude product was purified by flash chromatography (0-10% (0.7 M ammonia/MeOH)/DCM) to afford the title compound (680 mg, 76%) as a pale orange solid.

¹H NMR (DMSO-d6) δ 7.97 (d, J=5.1 Hz, 1H), 6.79 (d, J=7.6 Hz, 1H), 6.56 (d, J=7.5 Hz, 1H), 6.48-6.43 (m, 2H), 6.39 (d, J=7.5 Hz, 1H), 4.53 (s, 2H), 3.72-3.63 (m, 1H), 2.82 (t, J=7.5 Hz, 2H), 2.76-2.66 (m, 4H), 2.16 (s, 3H), 2.06-1.95 (m, 4H), 1.92-1.86 (m, 2H), 1.49-1.38 (m, 2H).

LCMS m/z 323.3 (M+H)⁺ (ES⁺).

Intermediate R⁴³: 4-Fluoro-2-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-6-(prop-1-yn-1-yl)aniline

Prop-1-yn-1-ylmagnesium bromide 0.5 M in THF (5.26 mL, 2.63 mmol) was added to zinc chloride 1.9 M in 2-MeTHF (1.39 mL, 2.64 mmol) dropwise at 0° C. and the resulting pale suspension was stirred at room temperature for 20 minutes. Then PdCl₂ (dppf)-CH₂Cl₂ adduct (0.120 g, 0.147 mmol) and 2-bromo-4-fluoro-6-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)aniline (Intermediate R²) (0.4 g, 1.052 mmol) in anhydrous THF (2 mL) was added and the reaction stirred at 70° C. for 45 minutes. The reaction mixture was diluted with EtOAc (50 mL) and washed with water/brine (1:1, 60 mL). The organic phase was separated, dried (MgSO₄), filtered and the crude directly loaded onto silica for purification. The crude product was purified by flash chromatography (0-10% (0.7 M ammonia/MeOH)/DCM) to afford the title compound (223 mg, 56%) as a purple solid.

¹H NMR (CDCl₃) δ 8.19 (d, J=5.2 Hz, 1H), 7.00 (dd, J=8.7, 3.0 Hz, 1H), 6.96-6.93 (m, 1H), 6.81-6.77 (m, 2H), 5.18-5.11 (m, 1H), 4.20 (br s, 2H), 2.81-2.74 (m, 2H), 2.46-2.35 (m, 5H), 2.18-2.10 (m, 5H), 1.97-1.86 (m, 2H).

LCMS m/z 340.2 (M+H)⁺ (ES⁺).

The following intermediate was prepared according to the general procedure of Intermediate R⁴³:

Int. Structure and name Characterisation and procedure R44

1H NMR (CDCl₃) δ 8.18 (d, J = 5.2 Hz, 1H), 6.95 (dd, J = 5.2, 1.5 Hz, 1H), 6.81- 6.76 (m, 2H), 6.71 (dd, J = 8.8, 3.0 Hz, 1H), 5.21 (br s, 1H), 3.59 (s, 2H), 2.91- 2.83 (m, 2H), 2.62 (br s, 2H), 2.46 (s, 3H), 2.39 (d, J = 7.2 Hz, 2H), 2.32-2.17 (m, 2H), 2.06-1.91 (m, 3H), 0.98 (d, J = 6.6 Hz, 6H). LCMS m/z 358.3 (M + H)⁺ (ES⁺).

Intermediate R45: 4-Fluoro-2-isopropyl-6-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)aniline

Prepared according to the general procedure of 5-([2,2′-bipyridin]-4-yl)-2,3-dihydro-1H-inden-4-amine (Intermediate R⁴) from 2-bromo-4-fluoro-6-isopropylaniline and 4-bromo-2-((1-methylpiperidin-4-yl)oxy)pyridine to afford the title compound (7.26 g, 78%) as a purple solid.

¹H NMR (DMSO-d6) δ 8.19 (d, J=5.2 Hz, 1H), 7.00 (dd, J=5.3, 1.5 Hz, 1H), 6.92 (dd, J=10.2, 3.0 Hz, 1H), 6.76 (s, 1H), 6.73 (dd, J=9.0, 3.0 Hz, 1H), 5.01 (sept, J=8.5, 1H), 4.46 (s, 2H), 3.05 (sept, J=6.1 Hz, 1H), 2.71-2.61 (m, 2H), 2.22-2.13 (m, 5H), 2.04-1.93 (m, 2H), 1.75-1.63 (m, 2H), 1.17 (d, J=6.7 Hz, 6H).

LCMS m/z 344.2 (M+H)⁺ (ES⁺).

The following intermediates were prepared according to the general procedure of Intermediate R⁴⁵:

Int. Structure and name Characterisation and procedure R46

¹H NMR (CDCl₃) δ 8.17 (dd, J = 5.4, 0.7 Hz, 1H), 7.03 (dd, J = 5.3, 1.5 Hz, 1H), 6.96 (d, J = 7.7 Hz, 1H), 6.87 (t, J = 1.0 Hz, 1H), 6.76 (d, J = 7.7 Hz, 1H), 5.62 (ddt, J = 6.6, 4.5, 2.0 Hz, 1H), 4.07 (dd, J = 10.4, 4.6 Hz, 1H), 4.05-3.95 (m, 2H), 3.91 (td, J = 8.3, 4.4 Hz, 1H), 2.96 (t, J = 7.5 Hz, 2H), 2.76 (t, J = 7.4 Hz, 2H), 2.34-2.25 (m, 1H), 2.22-2.12 (m, 3H). Exchangeable NH₂ signal not observed. LCMS 297.0 (M + H)⁺ (ES⁺). R47

¹H NMR (DMSO-d6) δ 8.14 (d, J = 5.3 Hz, 1H), 7.01-6.94 (m, 1H), 6.84 (d, J = 7.6 Hz, 1H), 6.73 (s, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.16 (p, J = 7.4 Hz, 1H), 4.65 (br s, 2H), 2.82 (t, J = 7.3 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 2.45-2.35 (m, 2H), 2.13-1.96 (m, 4H), 1.83-1.71 (m, 1H), 1.71-1.60 (m, 1H). LCMS m/z 281.0 (M + H)⁺ (ES⁺). R48

¹H NMR (DMSO-d6) δ 8.21 (d, J = 5.2 Hz, 1H), 7.05 (dd, J = 5.2, 1.4 Hz, 1H), 6.89-6.81 (m, 2H), 6.58 (d, J = 7.6 Hz, 1H), 4.69 (s, 2H), 4.21 (tt, J = 6.3, 3.1 Hz, 1H), 2.82 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.06-1.99 (m, 2H), 0.81-0.67 (m, 4H). LCMS 267.0 (M + H)⁺ (ES⁺). R49

¹H NMR (DMSO-d6) δ 8.40 (d, J = 5.0 Hz, 1H), 7.31-7.28 (m, 1H), 7.15 (dd, J = 5.1, 1.7 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 4.64 (br s, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.71 (t, J = 7.3 Hz, 2H), 2.12 (tt, J = 7.3, 5.5 Hz, 1H), 2.06-2.00 (m, 2H), 0.97-0.92 (m, 4H) LCMS 251.2 (M + H)⁺ (ES⁺).

Intermediate R⁵⁰: 2-Cyclopentyl-4-fluoro-6-(2-((i-methylpiperidin-4-yl)oxy)pyridin-4-yl) aniline Step A: 2-(Cyclopent-1-en-1-yl)-4-fluoro-6-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)aniline

In an oven-dried round bottom flask, a mixture of PdCl₂ (dppf)-CH₂Cl₂ adduct (0.064 g, 0.079 mmol), potassium carbonate (0.870 g, 6.30 mmol) and cyclopent-1-en-1-ylboronic acid (0.180 g, 1.609 mmol) was evacuated and backfilled with nitrogen twice. Then a solution of 2-bromo-4-fluoro-6-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)aniline (Intermediate R²) (0.6 g, 1.578 mmol) in anhydrous 1,4-dioxane (7 mL) and water (0.7 mL) was added. The resulting solution was evacuated and backfilled with nitrogen twice, before the reaction was stirred at 100° C. for 20 hours. The reaction mixture was diluted with EtOAc (100 mL), and washed with water (100 mL) and brine (100 mL). The organic phase was separated, dried (MgSO₄), filtered and loaded directly onto silica for purification. The crude product was purified by flash chromatography (0-10% (0.7 M ammonia/MeOH)/DCM) to afford the title compound (319 mg, 28%) as a brown gum.

LCMS m/z 368.3 (M+H)⁺ (ES⁺).

Step B: 2-Cyclopentyl-4-fluoro-6-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)aniline

2-(Cyclopent-1-en-1-yl)-4-fluoro-6-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)aniline was dissolved in MeOH/EtOAc (1:1, 30 mL) and the solution passed through the H-Cube (1 mL/min, full H₂, 40° C., 10% Pd/C catcart). The volatiles were removed under reduced pressure to afford the title compound (284 mg, 89%) as a pale yellow solid.

LCMS m/z 370.2 (M+H)⁺ (ES⁺).

The following intermediate was prepared according to the general procedure of Intermediate R⁵⁰:

Int. Structure and name Characterisation and procedure R51

LCMS m/z 384.5 (M + H)⁺ (ES⁺). From Intermediate R2

Intermediate R52: 5-Fluoro-3-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-[1,1′-biphenyl]-2-amine

Prepared according to the general procedure of 2-(cyclopent-1-en-1-yl)-4-fluoro-6-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)aniline (Intermediate R⁵⁰, step A) from 2-bromo-4-fluoro-6-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)aniline (Intermediate R²) and 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane to afford the title compound (300 mg, 33%) as a brown gum.

LCMS m/z 378.2 (M+H)⁺ (ES⁺).

Intermediate R53: 5-(2-Cyclopropoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-amine Step A: 2-Cyclopropoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

A solution of 4-bromo-2-cyclopropoxypyridine (Intermediate R⁵⁷, step A) (1 g, 4.67 mmol), B₂Pin₂ (1.305 g, 5-14 mmol), PdCl₂ (dppf)-CH₂Cl₂ adduct (0.042 g, 0.051 mmol) and potassium acetate (1.375 g, 14.01 mmol) in anhydrous 1,4-dioxane (12 mL) was deoxygenated for 10 minutes, before the mixture was stirred at 100° C. for 2 hours. The reaction mixture was cooled to room temperature, filtered through Celite® rinsing with EtOAc (40 mL), and concentrated under reduced pressure to afford the title compound (1.52 g, 100%).

¹H NMR (Chloroform-d) δ 8.24 (dd, J=4.9, 0.9 Hz, 1H), 7.22 (dd, J=4.9, 0.8 Hz, 1H), 7.16 (s, 1H), 4.34-4.06 (m, 1H), 1.33 (s, 12H), 0.87-0.77 (m, 2H), 0.77-0.72 (m, 2H).

Step B: 5-(2-Cyclopropoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-amine

A mixture of 5-bromo-2,3-dihydrobenzofuran-4-amine (0.417 g, 1-950 mmol), 2-cyclopropoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.7 g, 2.145 mmol), K₂CO₃ (0.8 g, 29.0 mmol in 1.3 mL of water) in anhydrous 1,4-dioxane (6 mL) was deoxygenated for 10 minutes. PdC₂ (dppf)-CH₂Cl₂ adduct (0.080 g, 0.097 mmol) was added and the solution was stirred at 80° C. for 2 hours. The reaction mixture was cooled to room temperature, filtered through a plug of Celite® rinsing with EtOAc (100 mL), directly loaded onto silica gel, and purified by flash chromatography (40 g cartridge, 0-100% EtOAc/isohexane) to afford impure product. The impure product was loaded onto a column of SCX (10 g) in DCM (5 mL). The column was washed with DCM (20 mL) and then the product was eluted with 0.7 M ammonia in MeOH (40 mL). The resultant mixture was concentrated in vacuo to afford the title compound (0.48 g, 74%) as a brown oil.

¹H NMR (DMSO-d6) δ 8.17 (d, J=5.2 Hz, 1H), 7.02 (dd, J=5.3, 1.4 Hz, 1H), 6.89-6.76 (m, 2H), 6.13 (d, J=8.1 Hz, 1H), 4.92 (s, 2H), 4.53 (t, J=8.7 Hz, 2H), 4.20 (tt, J=6.4, 3.1 Hz, 1H), 3.00 (t, J=8.7 Hz, 2H), 0.89-0.72 (m, 2H), 0.71-0.67 (m, 2H).

LCMS m/z 269.0 (M+H)⁺ (ES⁺).

The following intermediates were prepared according to the general procedure of Intermediate R⁵³, step B:

Int. Structure and name Characterisation and procedure R54

¹H NMR (DMSO-d6) δ 7.35-7.30 (m, 1H), 6.96-6.86 (m, 3H), 6.81 (d, J = 7.6 Hz, 1H), 6.56 (d, J = 7.5 Hz, 1H), 4.48-4.30 (m, 3H), 2.83 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.4 Hz, 2H), 2.66-2.56 (m, 2H), 2.26- 2.12 (m, 5H), 2.03 (p, J = 7.4 Hz, 2H), 1.98-1.88 (m, 2H), 1.74-1.57 (m, 2H). R55

¹H NMR (DMSO-d6) δ 7.97 (d, J = 5.1 Hz, 1H), 6.69 (d, J = 5.1 Hz, 1H), 6.65 (d, J = 7.5 Hz, 1H), 6.54 (d, J = 7.5 Hz, 1H), 5.12-5.02 (m, 1H), 4.32 (s, 2H), 2.88-2.78 (m, 2H), 2.73-2.57 (m, 4H), 2.35-2.18 (m, 5H), 2.06-1.94 (m, 4H), 1.93 (s, 3H), 1.82-1.65 (m, 2H). LCMS m/z 338.2 (M + H)⁺ (ES⁺). From Intermediate R3

Intermediate R56: 5-Bromo-6-methyl-2,3-dihydro-1H-inden-4-amine Step A: N-(6-Bromo-4-nitro-2,3-dihydro-H-inden-5-yl)acetamide

Nitric acid (150 mL, 2350 mmol) was slowly added to sulfuric acid (150 mL) cooled to 0° C., while keeping the temperature below 20° C. The mixture was stirred for 10 minutes and added dropwise to a stirred mixture of N-(6-bromo-2,3-dihydro-H-inden-5-yl)acetamide (58 g, 228 mmol) in AcOH (300 mL) and sulfuric acid (150 mL), keeping the temperature below 30° C. The reaction mixture was stirred at room temperature for 4 hours and then poured onto ice/water (4.5 L total volume, 2.5 kg ice) and left to stand at room temperature for 18 hours. The solid was filtered, washed with water (2.5 L), and dried to afford the title compound (55 g, 80%) as an ochre powder.

¹H NMR (DMSO-d6) δ 9.99 (s, 1H), 7.85 (s, 1H), 3.01-2.88 (m, 4H), 2.07 (p, J=7.5 Hz, 2H), 2.00 (s, 3H).

LCMS m/z 299.0/301.0 (M+H)⁺ (ES⁺).

Step B: N-(6-Methyl-4-nitro-2,3-dihydro-1H-inden-5-yl)acetamide

A mixture of N-(6-bromo-4-nitro-2,3-dihydro-1H-inden-5-yl)acetamide (30 g, 100 mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (14.02 mL, 100 mmol) and K₂CO₃ (34-7 g, 251 mmol) in dioxane (500 mL) and H₂O (140 mL) was degassed with N₂ for 15 minutes. PdCl₂ (dppf)-CH₂Cl₂ adduct (4.10 g, 5.01 mmol) was added. The reaction mixture was heated at 100° C. for 16 hours, diluted with brine (300 mL), and extracted with EtOAc (2×800 mL). The organic layers were dried (MgSO₄) and evaporated. The residue was triturated with EtOAc/isohexane (1:1 mixture, 400 mL) and the resultant solid was filtered, rinsing with hexanes, and dried in vacuo to afford the title compound (15.33 g, 56%) as a brown solid.

¹H NMR (DMSO-d6) δ 9.65 (s, 1H), 7.41 (s, 1H), 2.98-2.87 (m, 4H), 2.20 (s, 3H), 2.07-2.03 (m, 2H), 1.99 (s, 3H).

LCMS m/z 235.2 (M+H)⁺ (ES⁺).

Step C: 6-Methyl-4-nitro-2,3-dihydro-1H-inden-5-amine

N-(6-Methyl-4-nitro-2,3-dihydro-1H-inden-5-yl)acetamide (15.33 g, 65.4 mmol) was suspended in a mixture of EtOH (126 mL) and concentrated aq HCl (126 mL). The mixture was heated to reflux overnight and concentrated in vacuo. The residue was basified by portionwise addition of 2M aq NaOH (500 mL). The aqueous layer was extracted with DCM (5×200 mL), dried (MgSO₄) and concentrated in vacuo to afford the title compound (15.18 g, 84%) as a brown solid.

¹H NMR (DMSO-d6) δ 7.21 (s, 1H), 6.61 (s, 2H), 3.16 (t, J=7.5 Hz, 2H), 2.76 (t, J=7.6 Hz, 2H), 2.16 (s, 3H), 2.00-1.94 (m, 2H).

LCMS m/z 193.4 (M+H)⁺ (ES⁺).

Step D: 5-Bromo-6-methyl-4-nitro-2,3-dihydro-1H-indene

A solution of 6-methyl-4-nitro-2,3-dihydro-1H-inden-5-amine (4.9 g, 20.39 mmol) and isopentyl nitrite (3 mL, 22.33 mmol) in MeCN (400 mL) was heated to 55° C., whereupon CuBr₂ (4.56 g, 20.39 mmol) was added. The reaction mixture was heated to 70° C. and stirred for 1 hour. The reaction mixture was allowed to cool to room temperature and 1M HCl (200 mL) was added. The reaction mixture was extracted with DCM (3×200 mL). The organic phases were concentrated in vacuo and the crude product was purified by flash chromatography (0-20% EtOAc/isohexane) to afford the title compound (3.2 g, 60%) as a pale yellow solid.

¹H NMR (DMSO-d6) δ 7.50 (s, 1H), 2.94-2.86 (m, 4H), 2.41 (s, 3H), 2.09 (p, J=7.6 Hz, 2H).

LCMS m/z 279.2 (M+Na)⁺ (ES⁺).

Step E: 5-Bromo-6-methyl-2,3-dihydro-1H-inden-4-amine

A stirred mixture of 5-bromo-6-methyl-4-nitro-2,3-dihydro-1H-indene (8.42 g, 32.9 mmol), saturated aq NH₄Cl (50 mL) and iron powder (7.34 g, 132 mmol) in EtOH/water (3:2, 80 mL) was stirred at 80° C. for 2 hours. After cooling to room temperature, the reaction was diluted with EtOAc (20 mL), and filtered through a pad of Celite®. The filtrate was diluted with water (10 mL). The layers were separated and the organic layer was dried (MgSO₄) and concentrated in vacuo. The residue was purified by flash chromatography (0-50% EtOAc/isohexane) to afford the title compound (6.52 g, 75%) as a pink solid.

¹H NMR (DMSO-d6) δ 6.48 (s, 1H), 4.94 (br s, 2H), 2.73 (t, J=7.5 Hz, 2H), 2.68 (t, J=7.4 Hz, 2H), 2.24 (s, 3H), 2.02-1.95 (m, 2H).

LCMS m/z 226/228 (M+H)⁺ (ES⁺).

Intermediate R57: 5-(2-Cyclopropoxypyridin-4-yl)-6-methyl-2,3-dihydro-1H-inden-4-amine Step A: 4-Bromo-2-cyclopropoxypyridine

To a mixture of cyclopropanol (1 g, 17.22 mmol) and 4-bromo-2-fluoropyridine (1.2 ml, 11.68 mmol) in NMP (13 mL) was added potassium tert-butoxide (1.9 g, 16.93 mmol) portionwise. The resultant mixture was stirred at room temperature for 30 minutes under nitrogen. Then the reaction mixture was diluted with EtOAc (so mL), washed with water (30 mL) and brine (30 mL), dried over anhydrous sodium sulfate, filtered and evaporated to afford the title compound (2.27 g, 83%) as a brown oil.

¹H NMR (DMSO-d6) δ 8.12 (d, J=5.4 Hz, 1H), 7.28 (dd, J=5.4, 1.7 Hz, 1H), 7.16 (d, J=1.6 Hz, 1H), 4.21 (tt, J=6.2, 3.0 Hz, 1H), 0.80-0.74 (m, 2H), 0.70-0.66 (m, 2H). LCMS m/z 214/216 (M+H)⁺ (ES⁺).

Step B: 5-(2-Cyclopropoxypyridin-4-yl)-6-methyl-2,3-dihydro-1H-inden-4-amine

To a solution of 4-bromo-2-cyclopropoxypyridine (189 mg, 0.885 mmol) in dioxane (5 mL) was added B₂Pin₂ (247 mg, 0.973 mmol), followed by potassium acetate (347 mg, 3.54 mmol) and PdC₂ (dppf)-CH₂Cl₂ adduct (36 mg, 0.044 mmol). The reaction was degassed (N₂, 5 minutes), evacuated and backfilled with N₂ (×3) and stirred at 90° C. for 2 hours. Then the reaction mixture was cooled to room temperature. A solution of 5-bromo-6-methyl-2,3-dihydro-H-inden-4-amine (Intermediate R⁵⁶) (200 mg, 0.885 mmol) in dioxane (3 mL) was added, followed by a solution of potassium carbonate (367 mg, 2.65 mmol) in water (1.5 mL). The reaction mixture was stirred at 90° C. for 16 hours, diluted with brine (10 mL), and extracted with DCM (2×20 mL). The organic layer was dried (MgSO4), filtered and evaporated. The crude product was purified by flash chromatography (0-60% EtOAc/isohexane) to afford the title compound (135 mg, 52%) as a yellow oil.

¹H NMR (DMSO-d6) δ 8.26 (d, J=5.1 Hz, 1H), 6.81 (dd, J=5.1, 1.3 Hz, 1H), 6.63 (d, J=1.2 Hz, 1H), 6.45 (s, 1H), 4.22 (tt, J=6.3, 3.1 Hz, 1H), 4.16 (s, 2H), 2.78 (t, J=7.5 Hz, 2H), 2.64 (t, J=7.3 Hz, 2H), 2.02-1.95 (m, 2H), 1.88 (s, 3H), 0.81-0.68 (m, 4H).

LCMS m/z 281.2 (M+H)+ (ES+).

The following intermediates were prepared according to the general procedure of Intermediate R⁵⁷:

Int. Structure and name Characterisation and procedure R58

¹H NMR (DMSO-d6) δ 8.22 (d, J = 5.2 Hz, 1H), 6.77 (dd, J = 5.2, 1.4 Hz, 1H), 6.56 (s, 1H), 6.45 (s, 1H), 5.57-5.52 (m, 1H), 4.16 (s, 2H), 3.96-3.92 (m, 1H), 3.89-3.80 (m, 2H), 3.80-3.74 (m, 1H), 2.78 (t, J = 7.5 Hz, 2H), 2.64 (t, J = 7.3 Hz, 2H), 2.30- 2.21 (m, 1H), 2.09-1.96 (m, 3H), 1.88 (s, 3H). LCMS m/z 311.2 (M + H)⁺ (ES⁺). From Intermediate R56 R59

¹H NMR (DMSO-d6) δ 8.21 (d, J = 5.2 Hz, 1H), 6.75 (dd, J = 5.2, 1.4 Hz, 1H), 6.54 (s, 1H), 6.45 (s, 1H), 5.27-5.15 (m, 1H), 4.14 (s, 2H), 3.93-3.80 (m, 4H), 2.78 (t, J = 7.5 Hz, 2H), 2.65 (t, J = 7.3 Hz, 2H), 2.11-1.93 (m, 4H), 1.88 (s, 3H), 1.72-1.56 (m, 2H). LCMS m/z 325.2 (M + H)⁺ (ES⁺). From Intermediate R56 R60

¹H NMR (DMSO-d6) δ 8.21 (d, J = 5.1 Hz, 1H), 6.73 (dd, J = 5.2, 1.4 Hz, 1H), 6.55- 6.47 (m, 1H), 6.45 (s, 1H), 5.01 (tt, J = 8.8, 4.2 Hz, 1H), 4.14 (s, 2H), 2.78 (t, J = 7.5 Hz, 2H), 2.74-2.58 (m, 4H), 2.27-2.09 (m, 5H), 2.06-1.93 (m, 4H), 1.88 (s, 3H), 1.76-1.63 (m, 2H). LCMS m/z 338.2 (M + H)⁺ (ES⁺). From Intermediate R56 R61

¹H NMR (DMSO-d6) δ 8.20 (d, J = 5.2 Hz, 1H), 6.72 (dd, J = 5.1, 1.4 Hz, 1H), 6.51 (s, 1H), 6.45 (s, 1H), 5.11-5.04 (m, 1H), 4.47 (d, J = 3.9 Hz, 1H), 4.14 (s, 2H), 3.67- 3.62 (m, 1H), 2.78 (t, J = 7.5 Hz, 2H), 2.68- 2.61 (m, 2H), 2.00 (q, J = 7.6 Hz, 2H), 1.94-1.85 (m, 5H), 1.73-1.66 (m, 2H), 1.64-1.58 (m, 4H). LCMS m/z 339.1 (M + H)⁺ (ES⁺). From Intermediate R56 R62

¹H NMR (DMSO-d6) δ 8.21 (d, J = 5.1 Hz, 1H), 6.75 (dd, J = 5.1, 1.4 Hz, 1H), 6.56 (s, 1H), 6.45 (s, 1H), 2.89-2.81 (m, 1H), 2.78 (t, J = 7.5 Hz, 2H), 2.70-2.60 (m, 2H), 2.18 (s, 3H), 2.08-1.95 (m, 4H), 1.96- 1.90 (m, 1H), 1.88 (s, 3H), 1.86-1.77 (m, 2H), 1.77-1.69 (m, 2H), 1.69-1.60 (m, 2H), 1.56-1.44 (m, 2H). LCMS m/z 352.6 (M + H)⁺ (ES⁺). From Intermediate R56 R63

LCMS m/z 352.2 (M + H)⁺ (ES⁺). From Intermediate R56 + Intermediate R3 R64

¹H NMR (DMSO-d6) δ 8.19 (d, J = 5.1 Hz, 1H), 6.71 (dd, J = 5.1, 1.4 Hz, 1H), 6.48 (s, 1H), 6.44 (s, 1H), 4.98-4.87 (m, 1H), 4.12 (s, 2H), 2.78 (t, J = 7.6 Hz, 2H), 2.63 (t, J = 7.4 Hz, 2H), 2.25-2.05 (m, 9H), 1.98 (p, J = 7.5 Hz, 2H), 1.90-1.77 (m, 5H), 1.49- 1.26 (m, 4H). Only one isomer. LCMS m/z 366.6 (M + H)⁺ (ES⁺). From Intermediate R56

Intermediate R65: 5-(2-(Cyclohexyloxy)pyridin-4-yl)-6-methyl-2,3-dihydro-1H-inden-4-amine Step A: 5-(2-Fluoropyrdin-4-yl)-6-methyl-2,3-dihydro-H-inden-4-amine

A solution of 4-bromo-2-fluoropyridine (1.170 g, 6.65 mmol), KOAc (2.60 g, 26.5 mmol), B₂Pin₂ (1.685 g, 6.63 mmol) and PdCl₂ (dppf)-CH₂Cl₂ adduct (0.271 g, 0.332 mmol) in 1,4-dioxane (20 mL) was heated at 100° C. for 2 hours under N₂. Then the reaction mixture was cooled to room temperature and a solution 5-bromo-6-methyl-2,3-dihydro-1H-inden-4-amine (Intermediate R⁵⁶) (1.5 g, 6.63 mmol) in 1,4-dioxane (5 mL) was added, followed by a solution of K₂CO₃ (3.67 g, 26.5 mmol) in water (2.5 mL). The reaction mixture was heated at 100° C. for 2 hours, diluted with EtOAc (75 mL), and washed with water (100 mL) and brine (100 mL). The organic phase was separated, dried (MgSO₄) and evaporated in vacuo. The crude product was purified by flash chromatography (0-50% EtOAc/isohexane) to afford the title compound (940 mg, 55%) as a white solid.

¹H NMR (CDCl₃) δ 8.32 (d, J=5.0 Hz, 1H), 7.12 (dt, J=5.2, 1.6 Hz, 1H), 6.88 (s, 1H), 6.66 (s, 1H), 3.36 (s, 2H), 2.93 (t, J=7.5 Hz, 2H), 2.72 (t, J=7.4 Hz, 2H), 2.14 (p, J=7.5 Hz, 2H), 2.00 (s, 3H).

LCMS m/z 243.2 (M+H)⁺ (ES⁺).

Step B: 5-(2-(Cyclohexyloxy)pyridin-4-yl)-6-methyl-2,3-dihydro-1H-inden-4-amine

KO^(t)Bu (0.132 g, 1.176 mmol) was added to cyclohexanol (0.163 mL, 1.568 mmol) in THF (3 mL). The reaction mixture was stirred at room temperature for 1 hour and then cooled to 0° C. 5-(2-Fluoropyridin-4-yl)-6-methyl-2,3-dihydro-1H-inden-4-amine (0.200 g, 0.784 mmol) was added and the reaction mixture was stirred at room temperature for 18 hours. Then the reaction mixture was partitioned between EtOAc (20 mL) and water (10 mL). The organic layer was washed with water (10 mL), dried (phase separator) and concentrated in vacuo. The crude product was purified by flash chromatography (0-25% EtOAc/isohexane) to afford the title compound (0.177 g, 61%) as a thick colourless oil.

¹H NMR (DMSO-d6) δ 8.19 (d, J=5.1 Hz, 1H), 6.71 (dd, J=5.1, 1.4 Hz, 1H), 6.49 (s, 1H), 6.44 (s, 1H), 5.04-4.96 (m, 1H), 4.12 (s, 2H), 2.77 (t, J=7.5 Hz, 2H), 2.64 (t, J=7.3 Hz, 2H), 2.04-1.94 (m, 4H), 1.88 (s, 3H), 1.78-1.69 (m, 2H), 1.59-1.52 (m, 1H), 1.51-1.33 (m, 4H), 1.30-1.22 (m, 1H).

LCMS m/z 323.3 (M+H)⁺ (ES⁺).

The following intermediate was prepared according to the general procedure of Intermediate R⁶⁵:

Int. Structure and name Characterisation and procedure R66

¹H NMR (DMSO-d6) δ 8.20 (t, J = 4.8 Hz, 1H), 6.73-6.71 (m, 1H), 6.51-6.50 (m, 1H), 6.45 (s, 1H), 5.12-5.06 (m, 0.5H), 5.05-4.98 (m, 0.5H), 4.13 (s, 2H), 3.25 (s, 1.5H), 3.24 (s, 1.5H), 2.78 (t, J = 7.5 Hz, 2H), 2.64 (t, J = 7.3 Hz, 2H), 2.13- 2.04 (m, 1H), 2.05-1.94 (m, 4H), 1.88 (d, J = 3.0 Hz, 3H) 1.84-1.69 (m, 3H), 1.69- 1.58 (m, 1H), 1.54-1.44 (m, 1H), 1.41- 1.30 (m, 1H). 50:50 mixture of cis/trans ring. LCMS m/z 353.3 (M + H)⁺ (ES⁺). From Intermediate R56

Intermediate R⁶⁷ Phenyl (6-methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamate Step A: 4-Bromo-2-((1-methylpiperidin-4-yl)oxy)pyridine

To a solution of KOtBu (41.13 g, 366.51 mmol, 1.5 eq) in THF (500 mL) was added 1-methylpiperidin-4-ol (33.77 g, 293.20 mmol, 1.2 eq) at 20° C. The reaction mixture was stirred for 1 hour. Then 4-bromo-2-fluoropyridine (43 g, 244.34 mmol, 1 eq) was added at 0° C. The reaction mixture was stirred at 20° C. for 12 hours, and then poured into water (500 mL). The aqueous phase was extracted with ethyl acetate (2×500 mL). The combined organic phases were washed with brine (2×500 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO₂, with 0.1% NH₃.H₂O, DCM:methanol 1:0 to 10:1) to give the title compound (61 g, 92%) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.05 (d, 1H), 7.18 (dd, 1H), 7.06 (s, 1H), 4.98-4.93 (m, 1H), 2.62-2.59 (m, 2H), 2.16-2.11 (m, 5H) 1.94-1.91 (m, 2H) and 1.66-1.62 (m, 2H).

LCMS: m/z 273.0 (M+H)⁺ (ES⁺).

Step B: 2-((1-Methylpiperidin-4-yl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

To a mixture of 4-bromo-2-((1-methylpiperidin-4-yl)oxy)pyridine (20 g, 73.76 mmol, 1 eq) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (24.35 g, 95.89 mmol, 1.3 eq) in dioxane (200 mL) was added PdCl₂ (dppf) (3.24 g, 4.43 mmol, 0.06 eq) and KOAc (34.24 g, 348.88 mmol, 4.73 eq) in one portion under N₂. Then the reaction mixture was heated to 100° C. for 2 hours. The reaction mixture was concentrated in vacuo. The residue was purified by reserved phase flash chromatography (0.1% NH₃.H₂O-MeCN) to give the title compound (22.5 g, 96%) as a brown oil.

¹H NMR (400 MHz, DMSO-d₆) δ 8.17-8.12 (m, 1H), 7.08-7.03 (m, 1H), 6.93-6.88 (m, 1H), 5.05-4.90 (m, 1H), 3.92-3.86 (m, 2H), 2.73-2.66 (m, 2H), 2.22 (s, 3H), 1.95-190 (m, 2H), 1.69-1.63 (m, 2H) and 1.06 (s, 12H).

LCMS: m/z 319.0 (M+H)⁺ (ES⁺).

Step C: 6-Methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-amine

To a mixture of 5-bromo-6-methyl-2,3-dihydro-1H-inden-4-amine (Intermediate R⁵⁶) (40 g, 176.90 mmol, 1 eq) and 2-((1-methylpiperidin-4-yl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (78.81 g, 247.66 mmol, 1.4 eq) in dioxane (500 mL) and H₂O (100 mL) was added K₂CO₃ (73.35 g, 530-71 mmol, 3 eq) and PdC₂ (dppf) (7.77 g, 10.61 mmol, 0.06 eq) in one portion under N₂. Then the reaction mixture was stirred at 100° C. for 12 hours. The reaction mixture was quenched with water (500 mL) and extracted with EtOAc (3×500 mL). The combined organic phases were washed with brine (500 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was diluted with DCM (300 mL) and extracted with HCl (3×100 mL, 3 M). The combined aqueous phases were adjusted to pH 8 with saturated aqueous Na₂CO₃ solution, and then extracted with DCM (3×200 mL). The combined organic phases were washed with brine (200 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO₂, PE:EtOAc 1:0 to 5:1, then DCM:MeOH 1:0 to 10:1 with 0.1% NH₃.H₂O) to give the title compound (50 g, 80% yield, 95.6% purity on HPLC) as a brown gum.

¹H NMR (400 MHz, DMSO-d₆) δ 8.20 (d, 1H), 6.72 (dd, 1H), 6.50 (s, 1H), 6.44 (s, 1H), 5.02-4.97 (m, 1H), 4.13 (s, 2H), 2.77 (t, 2H), 2.67-2.61 (m, 4H), 2.17 (s, 3H), 2.16-2.11 (m, 2H), 2.02-1.94 (m, 4H), 1.87 (s, 3H) and 1.72-1.64 (m, 2H).

LCMS: m/z 338.2 (M+H)⁺ (ES⁺).

Step D: Phenyl(6-methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamate

To a solution of 6-methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-amine (1 g, 2.96 mmol, 1 eq) and phenyl carbonochloridate (463 mg, 2.96 mmol, 1 eq) in DCM (20 mL) was added TEA (300 mg, 2.96 mmol, 1 eq) at 0° C. Then the reaction mixture was stirred at 25° C. for 2 hours. The reaction mixture was concentrated in vacuo. The residue was purified by reversed phase flash chromatography (0.1% TFA in water-MeCN) to give the title compound (350 mg, 20% yield, 95% purity on LCMS, TFA salt) as a yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 9.70-9.60 (m, 1H), 9.19 (s, 1H), 8.25 (t, 1H), 7.36-7.34 (m, 2H), 7.23-7.16 (m, 2H), 6.90-6.81 (m, 3H), 6.68-6.62 (m, 1H), 5.36-5.19 (m, 1H), 3.39-3.14 (m, 4H), 2.97-2.91 (m, 2H), 2.87-2.79 (m, 5H), 2.38-233 (m, 1H), 2.27-2.16 (m, 1H), 2.06 (d, 6H) and 1.90-1.78 (m, 1H).

LCMS: m/z 458.1 (M+H)⁺ (ES⁺).

PREPARATION OF EXAMPLES Example 1: N-((5-(2-(((1s,4s)-4-Methoxycyclohexyl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)methanesulfonamide

5-(2-((4-Methoxycyclohexyl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-amine (Intermediate R²²) (33 mg, 0.098 mmol) was added to a suspension of (4-(dimethylamino)pyridin-1-ium-1-carbonyl)(methylsulfonyl)amide (Intermediate L1) (0.1 mmol) in MeCN (1 mL) and the reaction mixture was stirred at 60° C. for 1 hour. The volatiles were evaporated, and the crude product dissolved in DMSO (1 mL), filtered, and purified by basic prep HPLC (20-50% MeCN in water) to afford the title compound (3 mg, 7%) as a white solid.

¹H NMR (DMSO-d6) δ 8.11 (d, J=5.3 Hz, 1H), 7.57 (s, 1H), 7.17 (d, J=7.7 Hz, 1H), 7.10 (d, J=7.7 Hz, 1H), 6.92 (dd, J=5.3, 1.5 Hz, 1H), 6.72 (s, 1H), 5.10-5.02 (m, 1H), 3.24 (s, 3H), 2.93 (t, J=7.4 Hz, 2H), 2.87 (s, 3H), 2.82 (t, J=7.4 Hz, 2H), 2.02 (p, J=7.5 Hz, 2H), 1.83-1.68 (m, 6H), 1.68-1.60 (m, 2H). One exchangeable proton not observed, on proton under DMSO.

LCMS m/z 460.3 (M+H)⁺ (ES⁺).

The following examples were prepared according to the general procedure of Example 1:

Ex. Structure and name Characterisation and procedure  2

¹H NMR (DMSO-d6) δ 8.10 (d, J = 5.2 Hz, 1H), 7.12 (d, J = 7.7 Hz, 1H), 7.07 (d, J = 7.6 Hz, 1H), 6.93 (dd, J = 5.3, 1.5 Hz, 1H), 6.72 (s, 1H), 5.04-4.94 (m, 1H), 3.29- 3.18 (m, 4H), 2.91 (t, J = 7.5 Hz, 2H), 2.83 (t, J = 7.4 Hz, 2H), 2.75 (s, 3H), 2.10- 1.88 (m, 6H), 1.53-1.42 (m, 2H), 1.41- 1.30 (m, 2H). One exchangeable proton not observed. One proton under DMSO. LCMS m/z 460.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R22  3

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.3 Hz, 1H), 7.89 (br s, 1H), 7.22 (d, J = 7.7 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.89 (dd, J = 5.2, 1.5 Hz, 1H), 6.69 (s, 1H), 5.15-5.07 (m, 1H), 4.18 (s, 1H), 3.03 (s, 3H), 2.94 (t, J = 7.4 Hz, 2H), 2.81 (t, J = 7.4 Hz, 2H), 2.03 (p, J = 7.4 Hz, 2H), 1.99-1.89 (m, 2H), 1.71-1.55 (m, 4H), 1.50-1.38 (m, 2H), 1.15 (s, 3H). One exchangeable proton not observed. LCMS m/z 460.4 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R36  4

¹H NMR (DMSO-d6) δ 8.14 (d, J = 5.3 Hz, 1H), 7.87 (br s, 1H), 7.22 (d, J = 7.7 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.90 (dd, J = 5.3, 1.4 Hz, 1H), 6.69 (s, 1H), 4.99-4.89 (m, 1H), 4.15 (s, 1H), 3.03 (s, 3H), 2.94 (t, J = 7.4 Hz, 2H), 2.83 (t, J = 7.4 Hz, 2H), 2.04 (p, J = 7.5 Hz, 2H), 1.84-1.72 (m, 2H), 1.64-1.57 (m, 4H), 1.49-1.38 (m, 2H), 1.14 (s, 3H). One exchangeable proton not observed. LCMS m/z 460.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R35  5

¹H NMR (DMSO-d6) δ 8.71 (dd, J = 5.0, 0.8 Hz, 1H), 8.69-8.65 (m, 1H), 8.45- 8.40 (m, 1H), 8.38 (d, J = 1.7 Hz, 1H), 8.03 (s, 1H), 7.97 (td, J = 7.7, 1.8 Hz, 1H), 7.49-7.45 (m, 1H), 7.43 (dd, J = 5.0, 1.8 Hz, 1H), 7.29 (d, J = 7.7 Hz, 1H), 7.25 (d, J = 7.7 Hz, 1H), 3.02 (s, 3H), 2.98 (t, J = 7.5 Hz, 2H), 2.85 (t, J = 7.4 Hz, 2H), 2.07 (p, J = 7.5 Hz, 2H). One proton not observed. LCMS m/z 409.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R4  6

¹H NMR (DMSO-d6) δ 8.17 (d, J = 5.2 Hz, 1H), 7.97 (s, 1H), 7.24 (d, J = 7.7 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 6.94 (dd, J = 5.3, 1.5 Hz, 1H), 6.76 (s, 1H), 5.26-5.18 (m, 1H), 3.06 (s, 3H), 2.95 (t, J = 7.4 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H), 2.16-1.94 (m, 8H), 1.90-1.80 (m, 2H). One exchangeable proton not observed. LCMS m/z 466.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R24  7

¹H NMR (DMSO-d6) δ 8.68 (d, J = 5.1, 0.8 Hz, 1H), 8.05 (s, 1H), 7.49-7.43 (m, 2H), 7.36-7.22 (m, 6H), 3.02-2.93 (m, 5H), 2.84 (t, J = 7.4 Hz, 2H), 2.37 (s, 3H), 2.06 (p, J = 7.5 Hz, 2H). One exchangeable proton not observed. LCMS m/z 422.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R7  8

¹H NMR (DMSO-d6) δ 8.12 (d, J = 5.3 Hz, 1H), 7.59 (s, 1H), 7.17 (d, J = 7.7 Hz, 1H), 7.10 (d, J = 7.6 Hz, 1H), 6.94 (dd, J = 5.3, 1.4 Hz, 1H), 6.73 (s, 1H), 5.22-5.12 (m, 1H), 3.96-3.89 (m, 1H), 3.57-3.43 (m, 2H), 2.93 (t, J = 7.4 Hz, 2H), 2.87 (s, 3H), 2.82 (t, J = 7.4 Hz, 2H), 2.17-2.10 (m, 1H), 2.07-1.97 (m, 3H), 1.57-1.47 (m, 1H), 1.24 (m, 1H), 1.14 (d, J = 6.2 Hz, 3H). One exchangeable proton not observed. LCMS m/z 446.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R18  9

¹H NMR (DMSO-d6) δ 8.11 (d, J = 5.3 Hz, 1H), 7.65 (s, 1H), 7.18 (d, J = 7.7 Hz, 1H), 7.10 (d, J = 7.6 Hz, 1H), 6.94 (dd, J = 5.3, 1.5 Hz, 1H), 6.72 (s, 1H), 5.00 (p, J = 7.1 Hz, 1H), 4.64 (s, 2H), 4.54 (s, 2H), 2.98- 2.87 (m, 5H), 2.82 (t, J = 7.4 Hz, 2H), 2.79-2.72 (m, 2H), 2.29-2.20 (m, 2H), 2.02 (p, J = 7.5 Hz, 2H). One exchangeable proton not observed. LCMS m/z 444.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R12 10

¹H NMR (DMSO-d6) δ 8.08 (d, J = 5.3 Hz, 1H), 7.09-7.02 (m, 3H), 6.96 (dd, J = 5.3, 1.5 Hz, 1H), 6.75 (m, 1H), 5.36-5.28 (m, 1H), 3.78-3.71 (m, 1H), 3.70-3.63 (m, 1H), 2.90 (t, J = 7.4 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 2.62 (s, 3H), 2.06-1.96 (m, 4H), 1.54-1.46 (m, 1H), 1.46-1.40 (m, 1H), 1.21 (s, 3H), 1.20 (s, 3H). One exchangeable proton not observed. LCMS m/z 460.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R21 11

¹H NMR (DMSO-d6) δ 8.12 (d, J = 5.3 Hz, 1H), 7.80 (s, 1H), 7.20 (d, J = 7.6 Hz, 1H), 7.12 (d, J = 7.6 Hz, 1H), 6.94 (dd, J = 5.3, 1.4 Hz, 1H), 6.74 (d, J = 1.4 Hz, 1H), 4.92- 4.83 (m, 1H), 2.97 (s, 3H), 2.93 (t, J = 7.5 Hz, 2H), 2.81 (t, J = 7.4 Hz, 2H), 2.70- 2.59 (m, 3H), 2.21 (s, 6H), 2.02 (p, J = 7.5 Hz, 2H), 1.97-1.88 (m, 2H). One exchangeable proton not observed. LCMS m/z 445.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R14 12

¹H NMR (DMSO-d6) δ 8.59 (d, J = 5.1 Hz, 1H), 7.89 (s, 1H), 7.72-7.58 (m, 3H), 7.50- 7.31 (m, 4H), 7.26-7.18 (m, 2H), 2.98- 2.90 (m, 5H), 2.84 (t, J = 7.4 Hz, 2H), 2.09-2.00 (m, 2H). One exchangeable proton not observed. LCMS m/z 432.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R8 13

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.2 Hz, 1H), 7.90 (s, 1H), 7.23 (d, J = 7.7 Hz, 1H), 7.15 (d, J = 7.7 Hz, 1H), 6.94 (dd, J = 5.3, 1.5 Hz, 1H), 6.75 (s, 1H), 4.14 (d, J = 6.6 Hz, 2H), 3.90-3.83 (m, 2H), 3.03 (s, 3H), 2.94 (t, J = 7.5 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H), 2.08-1.97 (m, 3H), 1.72-1.63 (m, 2H), 1.41-1.27 (m, 2H). One exchangeable proton not observed. Two protons under H₂O. LCMS m/z 446.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R17 14

¹H NMR (DMSO-d6) δ 8.52 (d, J = 5.0 Hz, 1H), 7.96 (s, 1H), 7.27-7.21 (m, 2H), 7.20- 7.14 (m, 2H), 3.99-3.91 (m, 2H), 3.49- 3.40 (m, 2H), 3.05 (s, 3H), 2.98-2.90 (m, 3H), 2.82 (t, J = 7.4 Hz, 2H), 2.04 (p, J = 7.5 Hz, 2H), 1.84-1.73 (m, 4H). One exchangeable proton not observed. LCMS m/z 416.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R6 15

¹H NMR (DMSO-d6) δ 7.96 (d, J = 5.1 Hz, 1H), 7.41 (s, 1H), 7.16 (d, J = 7.6 Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 6.68 (d, J = 5.2 Hz, 1H), 5.17-5.05 (m, 1H), 2.95-2.89 (m, 5H), 2.90-2.83 (m, 1H), 2.82-2.72 (m, 3H), 2.34 (s, 3H), 2.06-1.98 (m, 4H), 1.91 (s, 3H), 1.82-1.73 (m, 2H). One exchangeable proton not observed. Two protons under DMSO. LCMS m/z 459-1 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R55 16

¹H NMR (DMSO-d6) δ 8.67 (d, J = 5.0 Hz, 1H), 8.14-8.09 (m, 2H), 7.92 (s, 1H), 7.75 (s, 1H), 7.51-7.46 (m, 2H), 7.46-7.42 (m, 1H), 7.34 (dd, J = 5.1, 1.6 Hz, 1H), 7.25- 7.21 (m, 2H), 2.96 (t, J = 7.4 Hz, 2H), 2.88- 2.82 (m, 5H), 2.04 (p, J = 7.5 Hz, 2H). One exchangeable proton not observed. LCMS m/z 408.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R5 17

¹H NMR (DMSO-d6) δ 10.30 (br s, 1H), 8.19 (d, J = 5.3 Hz, 1H), 8.11 (dd, J = 4.9, 2.0 Hz, 1H), 8.04 (s, 1H), 7.53 (m, 1H), 7.25 (d, J = 7.7 Hz, 1H), 7.17 (d, J = 7.7 Hz, 1H), 6.93 (d, J = 5.3 Hz, 1H), 6.87 (d, J = 8.6 Hz, 1H), 6.74 (s, 1H), 6.62 (m, 1H), 5.31-5.22 (m, 1H), 4.07-3.99 (m, 2H), 3.32-3.26 (m, 2H), 3.10 (s, 3H), 2.95 (t, J = 7.5 Hz, 2H), 2.81 (t, J = 7.4 Hz, 2H), 2.10-2.00 (m, 4H), 1.71-1.61 (m, 2H). LCMS m/z 508.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R30 18

¹H NMR (DMSO-d6) δ 8.38 (d, J = 5.3 Hz, 1H), 8.07 (s, 1H), 7.87 (d, J = 7.6 Hz, 2H), 7.63 (d, J = 7.5 Hz, 2H), 7.46 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.4 Hz, 2H), 7.25 (m, 2H), 7.20 (d, J = 7.7 Hz, 1H), 7.13-7.07 (m, 1H), 6.85 (s, 1H), 3.04 (s, 3H), 2.95 (t, J = 7.4 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H), 2.04 (p, J = 7.5 Hz, 2H). One exchangeable proton not observed. LCMS m/z 512.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R33 19

¹H NMR (DMSO-d6) δ 8.14 (d, J = 5.3 Hz, 1H), 7.91 (s, 1H), 7.34-7.31 (m, 4H), 7.28- 7.20 (m, 2H), 7.14 (d, J = 7.6 Hz, 1H), 6.90 (dd, J = 5.3, 1.5 Hz, 1H), 6.72-6.69 (m, 1H), 5.06-5.00 (m, 1H), 3.53 (s, 2H), 3.04 (s, 3H), 2.94 (t, J = 7.4 Hz, 2H), 2.81 (t, J = 7.4 Hz, 2H), 2.77-2.70 (m, 2H), 2.32-2.22 (m, 2H), 2.08-1.95 (m, 4H), 1.73-1.64 (m, 2H). One exchangeable proton not observed. LCMS m/z 521.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R31 20

¹H NMR (DMSO-d6) δ 8.06 (dd, J = 5.1, 0.9 Hz, 1H), 7.51-7.45 (m, 5H), 7.38- 7.29 (m, 5H), 7.27-7.22 (m, 2H), 7.20 (s, 1H), 7.14 (d, J = 7.7 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.98-6.94 (m, 2H), 2.92 (t, J = 7.5 Hz, 2H), 2.85-2.80 (m, 2H), 2.75 (s, 3H), 2.01 (p, J = 7.4 Hz, 2H). LCMS m/z 512.3 (M − H)⁻ (ES⁻). Intermediate L1 + Intermediate R32 21

¹H NMR (DMSO-d6) δ 7.52 (br s, 1H), 7.31 (t, J = 6.9 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 6.98-6.86 (m, 3H), 4.51-4.43 (m, 1H), 3.00 (s, 3H), 2.92 (t, J = 7.4 Hz, 2H), 2.86-2.76 (m, 4H), 2.58-2.52 (m, 2H), 2.35 (s, 3H), 2.07-1.92 (m, 4H), 1.78-1.66 (m, 2H). One exchangeable proton not observed. LCMS m/z 444.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R54 22

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.3 Hz, 1H), 7.90 (s, 1H), 7.22 (d, J = 7.7 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.91 (dd, J = 5.3, 1.5 Hz, 1H), 6.71 (d, J = 1.4 Hz, 1H), 5.02 (tt, J = 8.6, 4.0 Hz, 1H), 3.03 (s, 3H), 2.94 (t, J = 7.4 Hz, 2H), 2.89-2.77 (m, 4H), 2.42 (t, J = 10.5 Hz, 2H), 2.04 (p, J = 7.5 Hz, 2H), 1.99-1.91 (m, 2H), 1.68-1.55 (m, 3H), 0.47-0.38 (m, 2H), 0.36-0.25 (m, 2H). One exchangeable proton not observed. LCMS m/z 471.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R25 23

¹H NMR (DMSO-d6) δ 8.14 (d, J = 5.3 Hz, 1H), 7.64 (s, 1H), 7.35-7.28 (m, 4H), 7.25- 7.20 (m, 1H), 7.18 (d, J = 7.6 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H), 6.95 (dd, J = 5.3, 1.5 Hz, 1H), 6.75 (d, J = 1.4 Hz, 1H), 4.48 (t, J = 6.9 Hz, 2H), 3.04 (t, J = 6.9 Hz, 2H), 2.93 (t, J = 7.4 Hz, 2H), 2.88 (s, 3H), 2.82 (t, J = 7.4 Hz, 2H), 2.02 (p, J = 7.5 Hz, 2H). One exchangeable proton not observed. LCMS m/z 452.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R23 24

¹H NMR (DMSO-d6) δ 8.13 (d, J = 5.3 Hz, 1H), 7.50 (s, 1H), 7.24-7.18 (m, 2H), 7.15 (d, J = 7.7 Hz, 1H), 7.10 (d, J = 7.6 Hz, 1H), 7.00-6.93 (m, 3H), 6.80-6.74 (m, 2H), 5.18 (tt, J = 8.5, 4.0 Hz, 1H), 3.60- 3.52 (m, 2H), 3.08-3.00 (m, 2H), 2.92 (t, J = 7.4 Hz, 2H), 2.86-2.77 (m, 5H), 2.15- 2.07 (m, 2H), 2.01 (p, J = 7.5 Hz, 2H), 1.81- 1.72 (m, 2H). One exchangeable proton not observed. LCMS m/z 507.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R29 25

¹H NMR (DMSO-d6) δ 8.46 (d, J = 5.1 Hz, 1H), 7.41 (s, 1H), 7.25 (dd, J = 5.1, 1.7 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 3.62-3.55 (m, 6H), 2.92 (t, J = 7.5 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 2.75 (s, 3H), 2.44 (d, J = 5.6 Hz, 4H), 2.01 (p, J = 7.4 Hz, 2H). Two exchangeable protons not observed. LCMS m/z 431.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R41 26

¹H NMR (DMSO-d6) δ 8.58-8.52 (m, 2H), 8.12 (d, J = 5.3 Hz, 1H), 7.48 (s, 1H), 7.44-7.42 (m, 2H), 7.15 (d, J = 7.7 Hz, 1H), 7.12 (d, J = 7.6 Hz, 1H), 7.02 (dd, J = 5.3, 1.5 Hz, 1H), 6.95-6.91 (m, 1H), 5.45 (s, 2H), 2.93 (t, J = 7.4 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 2.77 (s, 3H), 2.02 (p, J = 7.5 Hz, 2H). One exchangeable proton not observed. LCMS m/z 439.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R13 27

¹H NMR (DMSO-d6) δ 8.12 (d, J = 5.3 Hz, 1H), 7.52 (s, 1H), 7.16 (d, J = 7.7 Hz, 1H), 7.10 (d, J = 7.6 Hz, 1H), 6.96 (dd, J = 5.3, 1.4 Hz, 1H), 6.79 (s, 1H), 4.16 (d, J = 6.0 Hz, 2H), 3.05 (d, J = 11.5 Hz, 2H), 2.92 (t, J = 7.4 Hz, 2H), 2.86-2.79 (m, 5H), 2.42 (s, 3H), 2.39-2.31 (m, 2H), 2.02 (p, J = 7.5 Hz, 2H), 1.88-1.75 (m, 3H), 1.48- 1.36 (m, 2H). One exchangeable proton not observed. LCMS m/z 459.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R20 28

¹H NMR (DMSO-d6) δ 7.95 (d, J = 5.2 Hz, 1H), 7.42 (s, 1H), 7.14 (d, J = 7.7 Hz, 1H), 7.03 (d, J = 7.6 Hz, 1H), 6.48-6.43 (m, 2H), 6.40 (d, J = 7.4 Hz, 1H), 3.81-3.72 (m, 1H), 2.99-2.88 (m, 7H), 2.82 (t, J = 7.4 Hz, 2H), 2.46-2.40 (m, 2H), 2.38 (s, 3H), 2.05-1.98 (m, 2H), 1.98-1.91 (m, 2H), 1.59-1.48 (m, 2H). One exchangeable proton not observed. LCMS m/z 444.2 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R42 29

¹H NMR (DMSO-d6) δ 8.11 (d, J = 5.3 Hz, 1H), 7.52 (s, 1H), 7.16 (d, J = 7.7 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.94 (dd, J = 5.3, 1.5 Hz, 1H), 6.72 (d, J = 1.4 Hz, 1H), 4.98- 4.87 (m, 1H), 2.92 (t, J = 7.4 Hz, 2H), 2.87- 2.77 (m, 5H), 2.74-2.67 (m, 1H), 2.47 (s, 6H), 2.22-2.13 (m, 2H), 2.02 (p, J = 7.5 Hz, 2H), 1.98-1.88 (m, 2H), 1.56-1.34 (m, 4H). One exchangeable proton not observed. LCMS m/z 473.4 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R27 30

¹H NMR (DMSO-d6) δ 8.16 (d, J = 5.3 Hz, 1H), 7.93 (s, 1H), 7.42-7.29 (m, 5H), 7.23 (d, J = 7.7 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 6.93 (dd, J = 5.3, 1.5 Hz, 1H), 6.74 (d, J = 1.4 Hz, 1H), 5.25-5.17 (m, 1H), 5.10 (s, 2H), 3.83-3.74 (m, 2H), 3.04 (s, 3H), 2.94 (t, J = 7.4 Hz, 2H), 2.81 (t, J = 7.4 Hz, 2H), 2.08-1.95 (m, 4H), 1.67-1.53 (m, 2H). One exchangeable proton not observed. Two aliphatic protons obscured by solvent. LCMS m/z 565.0 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R34 31

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.2 Hz, 1H), 7.85 (s, 1H), 7.22 (d, J = 7.7 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.94 (d, J = 5.3 Hz, 1H), 6.73 (s, 1H), 5.11 (d, J = 5.8 Hz, 1H), 3.05-2.87 (m, 6H), 2.82 (t, J = 7.5 Hz, 2H), 2.64 (s, 1H), 2.37-2.14 (m, 5H), 2.08-1.99 (m, 2H), 1.99-1.81 (m, 1H), 1.81-1.73 (m, 1H), 1.63-1.52 (m, 1H), 1.52-1.41 (m, 1H). One exchangeable proton not observed. LCMS m/z 445.4 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R15 32

¹H NMR (DMSO-d6) δ 8.16 (d, J = 5.3 Hz, 1H), 7.91 (s, 1H), 7.23 (d, J = 7.7 Hz, 1H), 7.15 (d, J = 7.7 Hz, 1H), 6.94 (dd, J = 5.3, 1.5 Hz, 1H), 6.74 (s, 1H), 5.26-5.19 (m, 1H), 3.95-3.89 (m, 1H), 3.70 (m, 1H), 3.21 (t, J = 9.7 Hz, 1H), 3.04 (s, 3H), 2.95 (t, J = 7.5 Hz, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.08-1.99 (m, 6H), 1.98-1.91 (m, 1H), 1.69-1.60 (m, 1H), 1.57-1.48 (m, 1H). One exchangeable proton not observed. One proton under DMSO. LCMS m/z 473.4 (M + H)+ (ES+). Intermediate L1 + Intermediate R26 33

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.2 Hz, 1H), 7.91 (s, 1H), 7.22 (d, J = 7.7 Hz, 1H), 7.14 (d, J = 7.5 Hz, 1H), 6.92 (d, J = 5.3 Hz, 1H), 6.73 (s, 1H), 5.23-5.15 (m, 1H), 3.90-3.82 (m, 2H), 3.53-3.45 (m, 2H), 3.03 (s, 3H), 2.94 (t, J = 7.5 Hz, 2H), 2.81 (t, J = 7.3 Hz, 2H), 2.08-1.97 (m, 4H), 1.69-1.58 (m, 2H). One exchangeable proton not observed. LCMS m/z 432.4 (M + H)+ (ES+). Intermediate L1 + Intermediate R9 34

¹H NMR (DMSO-d6) δ 8.20-8.17 (m, 1H), 7.89 (s, 1H), 7.50-7.45 (m, 2H), 7.41- 7.36 (m, 2H), 7.35-7.31 (m, 1H), 7.23 (d, J = 7.7 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 6.98 (dd, J = 5.3, 1.5 Hz, 1H), 6.84 (d, J = 1.4 Hz, 1H), 5.38 (s, 2H), 2.98 (s, 3H), 2.94 (t, J = 7.4 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H), 2.04 (p, J = 7.5 Hz, 2H). One exchangeable proton not observed. LCMS m/z 438.2 (M + H)+ (ES+). Intermediate L1 + Intermediate R19 35

¹H NMR (DMSO-d6) δ 8.13 (d, J = 5.3 Hz, 1H), 7.63 (s, 1H), 7.18 (d, J = 7.7 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H), 6.94 (dd, J = 5.3, 1.5 Hz, 1H), 6.75 (d, J = 1.5 Hz, 1H), 5.09- 5.00 (m, 1H), 2.97-2.88 (m, 5H), 2.82 (t, J = 7.5 Hz, 4H), 2.47-2.38 (m, 2H), 2.34 (s, 3H), 2.02 (p, J = 7.3 Hz, 4H), 1.79- 1.69 (m, 2H). One exchangeable proton not observed. LCMS m/z 445.2 (M + H)+ (ES+). Intermediate L1 + Intermediate R16 36

¹H NMR (DMSO-d6) δ 8.08 (d, J = 5.2 Hz, 1H), 7.44-7.38 (m, 2H), 7.21-7.12 (m, 5H), 7.09 (s, 2H), 7.02 (s, 1H), 2.91 (t, J = 7.4 Hz, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.60 (s, 3H), 2.00 (p, J = 7.5 Hz, 2H). One exchangeable proton not observed. LCMS m/z 424.3 (M + H)+ (ES+). Intermediate L1 + Intermediate R11 37

¹H NMR (DMSO-d6) δ 8.07 (d, J = 5.3 Hz, 1H), 7.10-7.02 (m, 3H), 6.97 (dd, J = 5.3, 1.5 Hz, 1H), 6.78 (s, 1H), 5.03-4.97 (m, 1H), 3.91-3.85 (m, 1H), 3.67-3.61 (m, 1H), 3.53-3.45 (m, 2H), 2.90 (t, J = 7.3 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 2.60 (s, 3H), 2.10-2.03 (m, 1H), 1.99 (p, J = 7.5 Hz, 2H), 1.84-1.70 (m, 2H), 1.60-1.50 (m, 1H). One exchangeable proton not observed. LCMS m/z 432.2 (M + H)+ (ES+). Intermediate L1 + Intermediate R10 38

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.3 Hz, 1H), 7.78 (s, 1H), 7.33 (dd, J = 8.8, 3.0 Hz, 1H), 7.22 (dd, J = 9.2, 3.0 Hz, 1H), 7.04- 6.97 (m, 1H), 6.84 (s, 1H), 5.12-5.02 (m, 1H), 2.94-2.85 (m, 2H), 2.81 (s, 3H), 2.40 (s, 3H), 2.09 (s, 3H), 2.07-1.97 (m, 2H), 1.82-1.71 (m, 2H). Two protons masked by DMSO and one exchangeable proton not observed. LCMS m/z 461.3 (M + H)+ (ES+). Intermediate L1 + Intermediate R43 39

¹H NMR (DMSO-d6) δ 8.20-8.08 (m, 1H), 7.78-7.62 (m, 1H), 7.23-7.12 (m, 1H), 7.09-6.90 (m, 2H), 6.90-6.73 (m, 1H), 5.12-4.98 (m, 1H), 5.65-3.54 (m, 2H), 2.92-2.69 (m, 5H), 2.41-2.29 (m, 3H), 2.10-1.95 (m, 2H), 1.83-1.55 (m, 8H), 1.39-1.18 (m, 5H). One exchangeable proton not observed. LCMS m/z 505.3 (M + H)+ (ES+). Intermediate L1 + Intermediate R51 40

¹H NMR (DMSO-d6) δ 8.14 (d, J = 5.3 Hz, 1H), 7.69 (s, 1H), 7.17-7.11 (m, 1H), 7.11- 7.04 (m, 1H), 7.04-6.96 (m, 1H), 6.83 (s, 1H), 5.11-5.02 (m, 1H), 2.93-2.80 (m, 5H), 2.48-2.44 (m, 2H), 2.39 (s, 3H), 2.07-1.98 (m, 2H), 1.93-1.83 (m, 1H), 1.82-1.70 (m, 2H), 0.88 (d, J = 6.6 Hz, 6H). Two protons behind DMSO peak and one exchangeable proton not observed. LCMS m/z 479.0 (M + H)+ (ES+). Intermediate L1 + Intermediate R44 41

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.3 Hz, 1H), 7.68 (br s, 1H), 7.20 (m, 1H), 7.10- 6.92 (m, 2H), 6.82 (s, 1H), 5.11-5.02 (m, 1H), 3.26-3.10 (m, 2H), 2.94-2.79 (m, 4H), 2.67-2.52 (m, 2H), 2.41 (s, 3H), 2.11- 1.90 (m, 4H), 1.86-1.68 (m, 4H), 1.67- 1.57 (m, 2H), 1.55-1.45 (m, 2H). One exchangeable proton not observed. LCMS m/z 491.3 (M + H)+ (ES+). Intermediate L1 + Intermediate R50 42

¹H NMR (DMSO-d6) δ 8.17 (d, J = 5.2 Hz, 1H), 7.69 (s, 1H), 7.56-7.31 (m, 5H), 7.26 (m, 2H), 7.05 (d, J = 5.4 Hz, 1H), 6.91 (s, 1H), 5.12-5.01 (m, 1H), 2.95-2.82 (m, 2H), 2.67-2.51 (m, 5H), 2.39 (s, 3H), 2.08-1.98 (m, 2H), 1.82-1.71 (m, 2H). One exchangeable proton not observed. LCMS m/z 499.3 (M + H)+ (ES+). Intermediate L1 + Intermediate R52 43

¹H NMR (DMSO-d6) δ 8.14 (d, J = 5.2 Hz, 1H), 7.71-7.51 (m, 1H), 7.20 (d, J = 9.8 Hz, 1H), 7.07-6.93 (m, 2H), 6.82 (s, 1H), 5.14-4.93 (m, 1H), 3.26-3.09 (m, 1H), 2.94-2.70 (m, 3H), 2.41-2.24 (m, 2H), 2.12-1.87 (m, 2H), 1.82-1.60 (m, 2H), 1.16 (d, J = 6.8 Hz, 6H). 5H under DMSO. One exchangeable proton not observed. LCMS m/z 465.3 (M + H)+ (ES+). Intermediate L1 + Intermediate R45 44

¹H NMR (DMSO-d6) δ 8.24 (d, J = 5.1 Hz, 1H), 7.46 (s, 1H), 7.10 (s, 1H), 6.79 (dd, J = 5.2, 1.4 Hz, 1H), 6.63 (d, J = 1.2 Hz, 1H), 4.21 (tt, J = 6.3, 3.1 Hz, 1H), 3.02 (s, 3H), 2.90 (t, J = 7.5 Hz, 2H), 2.78-2.71 (m, 2H), 2.05-1.95 (m, 5H), 0.80-0.64 (m, 4H). One exchangeable proton not observed. LCMS m/z 402.3 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R57 45

¹H NMR (DMSO-d6) δ 8.17 (t, J = 5.7 Hz, 1H), 7.35 (s, 1H), 7.08 (d, J = 5.1 Hz, 1H), 6.72 (td, J = 5.1, 2.6 Hz, 1H), 6.54 (d, J = 5.1 Hz, 1H), 5.03 (s, 1H), 3.00-2.94 (m, 3H), 2.92-2.87 (m, 2H), 2.84-2.78 (m, 2H), 2.75 (s, 2H), 2.38 (s, 2H), 2.34-2.28 (m, 3H), 2.08-1.93 (m, 7H), 1.74 (s, 2H). One exchangeable proton not observed. LCMS m/z 459.4 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R60 46

¹H NMR (DMSO-d6) δ 8.16 (d, J = 5.2 Hz, 1H), 7.17 (bs, 1H), 7.04 (s, 1H), 6.71 (dd, J = 5.2, 1.4 Hz, 1H), 6.51 (s, 1H), 4.97-4.88 (m, 1H), 2.95-2.82 (m, 5H), 2.79-2.72 (m, 2H), 2.66-2.59 (m, 1H), 2.42 (s, 6H), 2.21- 2.15 (m, 2H), 2.04-1.87 (m, 7H), 1.53-1.38 (m, 4H). One exchangeable proton not observed. LCMS m/z 487.4 (M + H)+ (ES⁺); m/z 485.3 (M − H)⁻ (ES⁻). Intermediate L1 + Intermediate R64 47

¹H NMR (DMSO-d6) δ 8.17 (d, J = 5.1 Hz, 1H), 7.25 (s, 1H), 7.07 (s, 1H), 6.75 (d, J = 5.2 Hz, 1H), 6.59 (s, 1H), 4.33-4.01 (m, 2H), 3.08-2.97 (m, 1H), 2.95-2.82 (m, 6H), 2.76 (t, J = 7.6 Hz, 2H), 2.42-2.30 (m, 3H), 2.26-2.04 (m, 2H), 2.04-1.93 (m, 6H), 1.78-1.66 (m, 2H), 1.63-1.50 (m, 1H), 1.16-1.04 (m, 1H). One exchangeable proton not observed. LCMS m/z 473.0 (M+H)⁺ (ES⁺); m/z 471.2 (M − H)⁻ (ES⁻). Intermediate L1 + Intermediate R62 48

¹H NMR (DMSO-d6) δ 8.14 (d, J = 5.2 Hz, 1H), 7.14 (s, 1H), 7.05 (s, 1H), 6.74-6.68 (m, 1H), 6.52 (s, 1H), 5.05 (tt, J = 7.1, 3.4 Hz, 1H), 4.47 (d, J = 3.9 Hz, 1H), 3.68- 3.60 (m, 1H), 3.17 (d, J = 3.3 Hz, 1H), 2.92- 2.84 (m, 4H), 2.76 (s, 1H), 2.03-1.94 (m, 5H), 1.92-1.83 (m, 2H), 1.72-1.64 (m, 3H), 1.60 (dd, J = 7.7, 4.1 Hz, 4H). One exchangeable proton not observed. LCMS m/z 460.4 (M+H)⁺ (ES⁺). Intermediate L1 + Intermediate R61 49

¹H NMR (DMSO-d6) δ 8.18 (d, J = 5.2 Hz, 1H), 7.38 (s, 1H), 7.09 (s, 1H), 6.73 (dd, J = 5.2, 1.4 Hz, 1H), 6.56 (d, J = 1.4 Hz, 1H), 5.25-5.16 (m, 1H), 3.93-3.83 (m, 2H), 3.54-3.46 (m, 2H), 2.97 (s, 3H), 2.90 (t, J = 7.4 Hz, 2H), 2.81-2.68 (m, 2H), 2.09- 1.96 (m, 7H), 1.72-1.59 (m, 2H). One exchangeable proton not observed. LCMS m/z 446.2 (M+H)⁺ (ES⁺); m/z 444.2 (M − H)⁻ (ES⁻). Intermediate L1 + Intermediate R59 50

¹H NMR (DMSO-d6) δ 8.19 (d, J = 5.2 Hz, 1H), 7.46 (bs, 1H), 7.10 (s, 1H), 6.72 (dd, J = 5.2, 1.4 Hz, 1H), 6.52 (s, 1H), 5.04-4.95 (m, 1H), 2.90 (t, J = 7.4 Hz, 2H), 2.77- 2.69 (m, 4H), 2.64 (s, 6H), 2.28-2.16 (m, 5H), 2.09-1.94 (m, 7H), 1.73-1.64 (m, 2H). One exchangeable proton not observed. LCMS m/z 488.4 (M+H)⁺ (ES⁺); m/z 486.3 (M − H)⁻ (ES⁻). Intermediate L3 + Intermediate R60 51

¹H NMR (DMSO-d6) δ 9-94 (s, 1H), 8.18 (d, J = 5.2 Hz, 1H), 7.46 (s, 1H), 7.09 (s, 1H), 6.73 (dd, J = 5.2, 1.4 Hz, 1H), 6.54 (s, 1H), 5.02 (tt, J = 8.7, 4.1 Hz, 1H), 2.90 (t, J = 7.4 Hz, 2H), 2.83-2.69 (m, 5H), 2.37- 2.24 (m, 5H), 2.07-1.97 (m, 7H), 1.77- 1.66 (m, 2H), 0.97-0.86 (m, 4H). LCMS m/z 485.1 (M + H)⁺ (ES⁺). Intermediate L2 + Intermediate R60 52

¹H NMR (DMSO-d6) δ 8.00 (d, J = 5.0 Hz, 1H), 7.07 (s, 2H), 6.59 (d, J = 5.2 Hz, 1H), 5.15-5.06 (m, 1H), 2.95-2.88 (m, 5H), 2.82-2.68 (m, 4H), 2.45-2.37 (m, 2H), 2.30 (s, 3H), 2.05-1.96 (m, 4H), 1.88 (s, 3H), 1.80-1.71 (m, 5H). One exchangeable proton not observed. LCMS m/z 473.4 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R63 53

¹H NMR (DMSO-d6) δ 8.18 (d, J = 5.2 Hz, 1H), 7.37 (s, 1H), 7.08 (s, 1H), 6.75 (dd, J = 5.2, 1.4 Hz, 1H), 6.58 (s, 1H), 5.56-5.49 (m, 1H), 3.96-3.89 (m, 1H), 3.89-3.83 (m, 1H), 3.83-3.73 (m, 2H), 2.96 (s, 3H), 2.90 (t, J = 7.4 Hz, 2H), 2.80-2.70 (m, 2H), 2.29-2.20 (m, 1H), 2.07-1.95 (m, 6H). One exchangeable proton not observed. LCMS m/z 432.2 (M + H)⁺ (ES⁺); m/z 430.1 (M − H)⁻ (ES⁻). Intermediate L1 + Intermediate R58 54

¹H NMR (DMSO-d6) δ 8.14 (dd, J = 5.1, 1.8 Hz, 1H), 7.02 (s, 1H), 6.70 (dd, J = 5.2, 1.4 Hz, 1H), 6.52 (d, J = 1.4 Hz, 1H), 5.06 (s, 1H), 3.24 (s, 3H), 2.88 (t, J = 7.4 Hz, 2H), 2.84-2.72 (m, 5H), 2.03-1.94 (m, 5H), 1.83-1.69 (m, 5H), 1.67-1.59 (m, 2H). Two protons masked by water, two exchangeable protons not observed. LCMS m/z 474.4 (M + H)⁺ (ES⁺). Intermediate L1 + Intermediate R66 55

¹H NMR (DMSO-d6) δ 8.30-8.04 (m, 1H), 6.97 (d, J = 7.8 Hz, 2H), 6.70 (dd, J = 5.2, 1.4 Hz, 1H), 6.54-6.49 (m, 1H), 5.02- 4.95 (m, 1H), 3.25 (s, 3H), 2.86 (t, J = 7.5 Hz, 2H), 2.80-2.73 (m, 2H), 2.72-2.62 (m, 3H), 2.11-2.03 (m, 2H), 2.02-1.92 (m, 7H), 1.82-1.69 (m, 1H), 1.63 (s, 1H), 1.52-1.43 (m, 2H), 1.39-1.31 (m, 1H). One exchangeable proton not observed. LCMS m/z 474.3 (M+H)⁺ (ES⁺). Intermediate L1 + Intermediate R66 56

¹H NMR (DMSO-d6) δ 8.10 (d, J = 5.2 Hz, 1H), 7.74-7.69 (m, 2H), 7.55-7.50 (m, 1H), 7.48 (dd, J = 8.2, 6.5 Hz, 2H), 7.26- 7.17 (m, 1H), 7.00 (s, 1H), 6.61 (dd, J = 5.2, 1.4 Hz, 1H), 6.51 (s, 1H), 5.12 (dq, J = 8.5, 4.2 Hz, 1H), 3.08-3.00 (m, 2H), 2.83 (t, J = 7.5 Hz, 2H), 2.78-2.67 (m, 2H), 2.14-2.04 (m, 2H), 1.96 (s, 3H), 1.94- 1.87 (m, 2H), 1.87-1.80 (m, 2H). Five protons under DMSO. One exchangeable proton not observed. LCMS m/z 521.2 (M+H)⁺ (ES⁺). Intermediate L4 + Intermediate R60 57

¹H NMR (DMSO-d6) δ 8.16 (d, J = 5.2 Hz, 1H), 7.31 (s, 1H), 7.07 (s, 1H), 6.70 (dd, J = 5.2, 1.4 Hz, 1H), 6.50 (s, 1H), 5.05-4.96 (m, 1H), 2.96 (s, 3H), 2.89 (t, J = 7.5 Hz, 2H), 2.79-2.72 (m, 2H), 2.05-1.96 (m, 7H), 1.78-1.71 (m, 2H), 1.60-1.53 (m, 1H), 1.51-1.32 (m, 4H), 1.31-1.20 (m, 1H). One exchangeable proton not observed. LCMS m/z 444.3 (M+H)⁺ (ES⁺). Intermediate L1 + Intermediate R65 58

¹H NMR (DMSO-d6) δ 8.16 (d, J = 5.2 Hz, 1H), 7.71 (s, 1H), 7.09 (s, 1H), 6.70 (dd, J = 5.2, 1.4 Hz, 1H), 6.51 (d, J = 1.2 Hz, 1H), 5.01 (tt, J = 8.8, 4.1 Hz, 1H), 2.89 (t, J = 7.5 Hz, 2H), 2.80-2.68 (m, 4H), 2.36- 2.20 (m, 5H), 2.07-1.88 (m, 7H), 1.76- 1.65 (m, 2H), 1.17 (s, 9H). One exchangeable proton not observed. LCMS m/z 501.3 (M+H)⁺ (ES⁺). Intermediate L5 + Intermediate R60

Example 59: N-((5-(2-((1-Allylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)prop-2-ene-1-sulfonamide

Prop-2-ene-1-sulfonamide (0.09 g, 0.542 mmol) was dissolved in THF (2 mL), and 2M sodium tert-butoxide in THF (0.298 mL, 0.596 mmol) was added. After 30 minutes, 2-((1-allylpiperidin-4-yl)oxy)-4-(4-isocyanato-2,3-dihydro-1H-inden-5-yl)pyridine (Intermediate R³⁹) (0.30 g, 0.559 mmol) in THF (3 mL) was added. The reaction mixture was stirred at room temperature for 18 hours, concentrated to dryness and purified by basic prep HPLC (20-50% MeCN in water) to afford the title compound (85 mg, 31%) as a white solid.

¹H NMR (DMSO-d6) δ 10.17 (br s, 1H), 8.14 (d, J=5.3 Hz, 1H), 7.84 (br s, 1H), 7.22 (d, J=7.7 Hz, 1H), 7.12 (d, J=7.7 Hz, 1H), 6.90 (dd, J=5.2, 1.5 Hz, 1H), 6.71 (s, 1H), 5.84 (ddt, J=16.8, 10.1, 6.5 Hz, 1H), 5.72 (ddt, J=17.3, 10.1, 7.3 Hz, 1H), 5.39-5.13 (m, 4H), 5.10-4.99 (m, 1H), 3.97 (d, J=7.3 Hz, 2H), 3.15-3.01 (m, 2H), 2.94 (t, J=7.5 Hz, 2H), 2.80 (t, J=7.5 Hz, 4H), 2.43-2.27 (m, 2H), 2.11-1.94 (m, 4H), 1.77-1.64 (m, 2H).

LCMS m/z 497.3 (M+H)⁺ (ES⁺).

The following examples were prepared according to the general procedure of Example 59:

Ex. Structure and name Characterisation and procedure 60

¹H NMR (DMSO-d6) δ 9.69 (bs, 1H), 8.15 (d, J = 5.2 Hz, 1H), 7.44 (s, 1H), 7.14-6.99 (m, 1H), 6.98 (s, 1H), 6.72 (d, J = 5.1 Hz, 1H), 6.67-6.55 (m, 2H), 5.22-5.12 (m, 1H), 4.95 (s, 1H), 3.22 (s, 2H), 3.11-2.94 (m, 2H), 2.85 (t, J = 7.5 Hz, 2H), 2.72-2.61 (m, 5H), 2.17-2.07 (m, 2H), 2.00-1.88 (m, 7H), 1.37 (s, 6H). LCMS m/z 569.3 (M + H)⁺ (ES⁺). Intermediate R40 + known sulfonamide 61

¹H NMR (DMSO-d6) δ 8.15 (d, J = 5.1 Hz, 1H), 7.37-7.22 (m, 1H), 7.06 (s, 1H), 6.74- 6.67 (m, 1H), 6.52 (s, 1H), 5.07-4.95 (m, 1H), 3.22-3.17 (m, 1H), 3.08-2.98 (m, 2H), 2.89 (t, J = 7.5 Hz, 2H), 2.82-2.70 (m, 4H), 2.26 (s, 5H), 2.07-1.94 (m, 9H), 1.85-1.66 (m, 5H), 1.62-1.52 (m, 2H), 1.04 (t, J = 7.1 Hz, 3H). One exchangeable proton not observed, one proton under DMSO. LCMS m/z 556.3 (M + H)⁺ (ES⁺). Intermediate R40 + known sulfonamide 62

¹H NMR (DMSO-d6) δ 8.16-8.10 (m, 1H), 7.86-7.80 (m, 1H), 7.30 (s, 1H), 7.02 (s, 1H), 6.67 (dd, J = 5.2, 1.6 Hz, 1H), 6.53 (s, 1H), 6.46 (d, J = 2.3 Hz, 1H), 5.11-5.04 (m, 1H), 4.59-4.50 (m, 1H), 3.00-2.89 (m, 2H), 2.85 (t, J = 7.5 Hz, 2H), 2.59-2.53 (m, 4H), 2.42 (s, 3H), 2.11-2.03 (m, 2H), 1.97 (s, 3H), 1.91 (p, J = 7.7 Hz, 2H), 1.86-1.75 (m, 2H), 1.42 (d, J = 6.6 Hz, 6H). One exchangeable proton not observed. LCMS m/z 553.3 (M + H)⁺ (ES⁺). Intermediate R40 + known sulfonamide 63

¹H NMR (DMSO-d6) δ 8.13 (d, J = 5.3 Hz, 1H), 7.79 (s, 1H), 7.25 (s, 1H), 7.02 (s, 1H), 6.67 (d, J = 5.3 Hz, 1H), 6.53 (s, 1H), 6.47- 6.40 (m, 1H), 5.13-5.04 (m, 1H), 4.23 (t, J = 6.6 Hz, 2H), 2.96-2.89 (m, 2H), 2.85 (t, J = 7.4 Hz, 2H), 2.66 (t, J = 6.6 Hz, 2H), 2.62-2.56 (m, 4H), 2.41 (s, 3H), 2.19 (s, 6H), 2.10-2.03 (m, 2H), 1.98 (s, 3H), 1.96- 1.90 (m, 2H), 1.87-1.73 (m, 2H). One exchangeable proton not observed. LCMS m/z 582.3 (M + H)⁺ (ES⁺). Intermediate R40 + known sulfonamide

Example 64: N-((5-(2-Cyclopropoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-yl)carbamoyl)-1-(1-(dimethylamino)-2-methylpropan-2-yl)-1H-pyrazole-3-sulfonamide, sodium salt

5-(2-Cyclopropoxypyridin-4-yl)-2,3-dihydrobenzofuran-4-amine (Intermediate R⁵³) (150 mg, 0.447 mmol) was dissolved in DCM (3 mL). Saturated aq NaHCO₃ (2 mL) was added, followed by a solution of triphosgene (55 mg, 0.185 mmol) in DCM (1 mL). The mixture was stirred for 1 hour at room temperature. The organic phase was separated by passing through a hydrophobic frit and concentrated in vacuo to give 2-cyclopropoxy-4-(4-isocyanato-2,3-dihydrobenzofuran-5-yl)pyridine as a colourless oil. 1-(1-(Dimethylamino)-2-methylpropan-2-yl)-1H-pyrazole-3-sulfonamide (110 mg, 0.447 mmol) was dissolved in dry THF (2 mL). Sodium tert-butoxide (2M in THF) (250 μL, 0.500 mmol) was added and the mixture was stirred for 30 minutes. A solution of the previously prepared isocyanate in THF (2 mL) was added via syringe and the mixture was stirred at room temperature overnight. The THF was removed in vacuo and the residue was dissolved in DMSO (2 mL) and purified by basic prep HPLC (10-40% MeCN in water). After concentration of product containing fractions, the free acid (75 mg) was isolated as a colourless solid. This solid was dissolved in 0.1 M aq NaOH (1.39 mL, 0.139 mmol) and the solution was freeze dried, giving the title compound (73 mg, 29%) as a colourless solid.

¹H NMR (DMSO-d6) δ 8.12-8.06 (m, 1H), 7.72-7.65 (m, 1H), 7.47-7.37 (m, 1H), 7.02 (d, J=8.2 Hz, 1H), 6.96-6.93 (m, 1H), 6.83 (s, 1H), 6.61 (d, J=8.4, 3.4 Hz, 1H), 6.35-6.30 (m, 1H), 4.49 (t, J=8.8 Hz, 2H), 4.22-4.17 (m, 1H), 3.04 (t, J=8.8 Hz, 2H), 1.92 (s, 6H), 1.48 (s, 6H), 0.81-0.64 (m, 4H). One CH₂ signal obscured by DMSO peak.

LCMS m/z 541.2 (M+H)⁺ (ES⁺).

The following examples were prepared according to the general procedure of Example 64:

Ex. Structure and name Characterisation and procedure 65

¹H NMR (DMSO-d6) δ 8.09 (d, J = 5.2 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.38 (s, 1H), 7.07 (d, J = 7.7 Hz, 1H), 7.04 (d, J = 7.7 Hz, 1H), 6.97 (dd, J = 5.3, 1.4 Hz, 1H), 6.86 (s, 1H), 6.30 (d, J = 2.3 Hz, 1H), 4.20 (tt, J = 6.3, 3.1 Hz, 1H), 2.95 (t, J = 7.0 Hz, 4H), 2.87 (t, J = 7.4 Hz, 2H), 2.71 (t, J = 7.5 Hz, 2H), 2.65 (s, 2H), 1.93 (p, J = 7.5 Hz, 2H), 1.82 (p, J = 7.0 Hz, 2H), 1.45 (s, 6H), 0.80-0.73 (m, 2H), 0.72-0.65 (m, 2H). LCMS m/z 551.1 (M + H)⁺ (ES⁺). Intermediate R48 + known sulfonamide 66

¹H NMR (DMSO-d6) δ 8.09 (d, J = 5.3 Hz, 1H), 7.70 (d, J = 2.4 Hz, 1H), 7.37 (s, 1H), 7.08 (d, J = 7.7 Hz, 1H), 7.04 (d, J = 7.6 Hz, 1H), 6.97 (dd, J = 5.2, 1.4 Hz, 1H), 6.86 (d, J = 1.4 Hz, 1H), 6.32 (d, J = 2.3 Hz, 1H), 4.20 (tt, J = 6.2, 3.1 Hz, 1H), 2.87 (t, J = 7.4 Hz, 2H), 2.71 (t, J = 7.4 Hz, 2H), 2.53 (s, 2H), 1.94 (s, 8H), 1.49 (s, 6H), 0.81-0.74 (m, 2H), 0.70-0.64 (m, 2H). LCMS m/z 539.1 (M + H)⁺ (ES⁺). Intermediate R48 + known sulfonamide 67

¹H NMR (DMSO-d6) δ 8.06 (d, J = 5.2 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.42 (s, 1H), 7.02 (d, J = 8.2 Hz, 1H), 6.92 (dd, J = 5.2, 1.5 Hz, 1H), 6.81 (s, 1H), 6.60 (d, J = 8.2 Hz, 1H), 6.33 (d, J = 2.3 Hz, 1H), 4.89- 4.75 (m, 1H), 4.49 (t, J = 8.8 Hz, 2H), 4.26-4.09 (m, 1H), 3.04 (t, J = 8.8 Hz, 2H), 2.48-2.40 (m, 2H), 2.38-2.28 (m, 2H), 1.83-1.69 (m, 2H), 0.78-0.71 (m, 2H), 0.71-0.63 (m, 2H). LCMS m/z 496.1 (M + H)⁺ (ES⁺). Intermediate R53 + known sulfonamide

Example 68: i-Isopropyl-N-((5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl) carbamoyl)-1H-pyrazole-3-sulfonamide, Sodium Salt

5-(2-((1-Methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-amine (Intermediate R¹⁶) (60 mg, 0.186 mmol) and (4-(dimethylamino)pyridin-1-ium-1-carbonyl)((1-isopropyl-1H-pyrazol-3-yl)sulfonyl)amide (60 mg, 0.178 mmol) were suspended in MeCN (2 mL) and stirred at 50° C. for 1 hour. The reaction mixture was purified directly by basic prep HPLC (10-40% MeCN in water). After concentration of product containing fractions, the free acid (55 mg) was isolated as a colourless solid. This solid was dissolved in 0.1 M aq NaOH (1.02 mL, 1 eq). The mixture was freeze dried overnight to give the title compound (50 mg, 50%) as a colourless solid.

¹H NMR (DMSO-d6) δ 7.99 (d, J=5.3 Hz, 1H), 7.69 (s, 1H), 7.37 (s, 1H), 7.06 (d, J=7.7 Hz, 1H), 7.02 (d, J=7.6 Hz, 1H), 6.87 (d, J=5.2 Hz, 1H), 6.69 (s, 1H), 6.31 (s, 1H), 5.03-4.93 (m, 1H), 4.49 (sept, J=6.8 Hz, 1H), 2.87 (t, J=7.5 Hz, 2H), 2.75-2.61 (m, 4H), 2.19 (s, 3H), 2.14 (t, J=10.8 Hz, 2H), 2.03-1.97 (m, 2H), 1.93 (p, J=7.5 Hz, 2H), 1.73-1.64 (m, 2H), 1.40 (d, J=6.7 Hz, 6H).

LCMS m/z 539.2 (M+H)⁺ (ES⁺); 537.3 (M−H)⁻ (ES⁻).

The following examples were prepared according to the general procedure of Example 68:

Ex. Structure and name Characterisation and procedure 69

¹H NMR (DMSO-d6) δ 8.24 (d, J = 5.1 Hz, 1H), 7.72 (d, J = 2.3 Hz, 1H), 7.37 (s, 1H), 7.21 (dd, J = 1.7, 0.8 Hz, 1H), 7.09 (d, J = 7.7 Hz, 1H), 7.04 (d, J = 7.7 Hz, 1H), 7.02 (dd, J = 5.1, 1.7 Hz, 1H), 6.32 (d, J = 2.3 Hz, 1H), 4.50 (sept, J = 6.6 Hz, 1H), 2.88 (t, J = 7.5 Hz, 2H), 2.73 (t, J = 7.5 Hz, 2H), 2.06-1.88 (m, 3H), 1.40 (d, J = 6.7 Hz, 6H), 0.96-0.87 (m, 4H). LCMS m/z 466.0 (M + H)⁺ (ES⁺). Intermediate R49 + known sulfonamide 70

¹H NMR (DMSO-d6) δ 8.02 (d, J = 5.3 Hz, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.44 (s, 1H), 7.08 (d, J = 7.7 Hz, 1H), 7.04 (d, J = 7.6 Hz, 1H), 6.90 (dd, J = 5.3, 1.5 Hz, 1H), 6.77- 6.70 (m, 1H), 6.34 (s, 1H), 5.54-5.48 (m, 1H), 4.51 (sept, J = 6.8 Hz, 1H), 3.94 (dd, J = 10.2, 4.8 Hz, 1H), 3.90-3.83 (m, 1H), 3.82- 3.73 (m, 2H), 2.88 (t, J = 7.4 Hz, 2H), 2.69 (t, J = 7.5 Hz, 2H), 2.29-2.20 (m, 1H), 2.07- 1.99 (m, 1H), 1.94 (p, J = 7.5 Hz, 2H), 1.40 (d, J = 6.7 Hz, 6H). LCMS m/z 512.1 (M + H)⁺ (ES⁺). Intermediate R46 + known sulfonamide 71

¹H NMR (DMSO-d6) δ 8.07 (d, J = 5.3 Hz, 1H), 7.68 (d, J = 2.3 Hz, 1H), 7.40 (s, 1H), 7.02 (d, J = 8.2 Hz, 1H), 6.93 (dd, J = 5.3, 1.4 Hz, 1H), 6.81 (d, J = 1.3 Hz, 1H), 6.60 (d, J = 8.2 Hz, 1H), 6.30 (d, J = 2.3 Hz, 1H), 4.50 (t, J = 8.8 Hz, 2H), 4.22-4.12 (m, 1H), 3.78- 3.65 (m, 1H), 3.06 (t, J = 8.8 Hz, 2H), 1.06- 0.98 (m, 2H), 0.98-0.91 (m, 2H), 0.78- 0.71 (m, 2H), 0.71-0.64 (m, 2H). LCMS m/z 482.1 (M + H)⁺ (ES⁺). Intermediate R53 + known sulfonamide 72

¹H NMR (DMSO-d6) δ 8.07 (d, J = 5.2 Hz, 1H), 7.70 (d, J = 2.3 Hz, 1H), 7.37 (s, 1H), 7.08 (d, J = 7.7 Hz, 1H), 7.04 (d, J = 7.6 Hz, 1H), 6.95 (dd, J = 5.3, 1.4 Hz, 1H), 6.84 (d, J = 1.3 Hz, 1H), 6.29 (d, J = 2.3 Hz, 1H), 4.18 (tt, J = 6.3, 3.0 Hz, 1H), 3.72 (tt, J = 7.4, 3.9 Hz, 1H), 2.88 (t, J = 7.4 Hz, 2H), 2.73 (t, J = 7.5 Hz, 2H), 1.95 (p, J = 7.5 Hz, 2H), 1.09- 1.01 (m, 2H), 0.95 (td, J = 7.4, 4.9 Hz, 2H), 0.79-0.72 (m, 2H), 0.69-0.64 (m, 2H). LCMS m/z 480.1 (M + H)⁺ (ES⁺). Intermediate R48 + known sulfonamide 73

¹H NMR (DMSO-d6) δ 7.99 (d, J = 5.0 Hz, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.42 (s, 1H), 7.07 (d, J = 7.7 Hz, 1H), 7.03 (d, J = 7.6 Hz, 1H), 6.88 (dd, J = 5.3, 1.5 Hz, 1H), 6.74- 6.70 (m, 1H), 6.34 (d, J = 2.3 Hz, 1H), 5.20 (tt, J = 8.9, 4.1 Hz, 1H), 4.51 (sept, J = 6.7 Hz, 1H), 3.88 (dt, J = 11.7, 4.2 Hz, 2H), 3.56- 3.46 (m, 2H), 2.87 (t, J = 7.4 Hz, 2H), 2.69 (t, J = 7.5 Hz, 2H), 2.07-2.00 (m, 2H), 1.93 (p, J = 7.5 Hz, 2H), 1.71-1.59 (m, 2H), 1.40 (d, J = 6.7 Hz, 6H). LCMS m/z 526.1 (M + H)⁺ (ES⁺). Intermediate R9 + known sulfonamide 74

¹H NMR (DMSO-d6) δ 8.00 (d, J = 5.3 Hz, 1H), 7.74 (s, 1H), 7.44 (s, 1H), 7.08 (d, J = 8.2 Hz, 1H), 7.04 (d, J = 7.4 Hz, 1H), 6.88 (d, J = 5.3 Hz, 1H), 6.71 (d, J = 1.3 Hz, 1H), 6.35 (s, 1H), 5.05-4.99 (m, 1H), 4.51 (p, J = 6.4 Hz, 1H), 3.90 (dd, J = 11.2, 2.3 Hz, 1H), 3.69- 3.63 (m, 1H), 3.56-3.46 (m, 2H), 2.87 (t, J = 7.4 Hz, 2H), 2.69 (t, J = 7.5 Hz, 2H), 2.11- 2.03 (m, 1H), 1.93 (p, J = 7.5 Hz, 2H), 1.84- 1.71 (m, 2H), 1.61-1.52 (m, 1H), 1.40 (d, J = 6.6 Hz, 6H). LCMS m/z 526.1 (M + H)⁺ (ES⁺). Intermediate R10 + known sulfonamide 75

¹H NMR (DMSO-d6) δ 7.99 (d, J = 5.3 Hz, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.43 (s, 1H), 7.08 (d, J = 7.7 Hz, 1H), 7.03 (d, J = 7.6 Hz, 1H), 6.87 (dd, J = 5.3, 1.5 Hz, 1H), 6.70 (d, J = 1.3 Hz, 1H), 6.35 (s, 1H), 5.19-5.10 (m, 1H), 4.51 (sept, J = 6.6 Hz, 1H), 2.87 (t, J = 7.4 Hz, 2H), 2.69 (t, J = 7.5 Hz, 2H), 2.45- 2.38 (m, 2H), 2.12-2.03 (m, 2H), 1.93 (p, J = 7.5 Hz, 2H), 1.83-1.75 (m, 1H), 1.70-1.60 (m, 1H), 1.40 (d, J = 6.7 Hz, 6H). LCMS m/z 496.2 (M + H)⁺ (ES⁺). Intermediate R47 + known sulfonamide 76

¹H NMR (DMSO-d6) δ 8.01 (d, J = 5.3 Hz, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.44 (s, 1H), 7.08 (d, J = 7.6 Hz, 1H), 7.03 (d, J = 7.6 Hz, 1H), 6.88 (dd, J = 5.3, 1.5 Hz, 1H), 6.71 (d, J = 1.4 Hz, 1H), 6.34 (d, J = 2.3 Hz, 1H), 5.41- 5.35 (m, 1H), 4.51 (sept, J = 6.6 Hz, 1H), 2.91- 2.84 (m, 3H), 2.77-2.67 (m, 4H), 2.43 (q, J = 7.6 Hz, 1H), 2.34-2.26 (m, 4H), 1.93 (p, J = 7.5 Hz, 2H), 1.89-1.81 (m, 1H), 1.40 (d, J = 6.7 Hz, 6H). LCMS m/z 525.2 (M + H)⁺ (ES⁺). Intermediate R37 + known sulfonamide 77

¹H NMR (DMSO-d6) δ 8.03-7.97 (m, 1H), 7.69-7.64 (m, 1H), 7.51-7.39 (m, 3H), 7.20 (t, J = 7.4 Hz, 1H), 7.16 (d, J = 7.5 Hz, 2H), 7.11-7.03 (m, 3H), 6.98 (s, 1H), 6.40-6.24 (m, 1H), 4.47 (sept, J = 6.6 Hz, 1H), 2.89 (t, J = 7.4 Hz, 2H), 2.73 (t, J = 7.4 Hz, 2H), 1.95 (p, J = 7.5 Hz, 2H), 1.39 (d, J = 6.7 Hz, 6H). m/z 518.1 (M + H)⁺ (ES⁺); 516.4 (M − H)⁻ (ES⁻). Intermediate R11 + known sulfonamide

Example 78: N′-((5-(2-((1-Methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl) carbamoyl)benzenesulfonimidamide

NaOtBu (2M in THF, 0.051 mL, 0.102 mmol) was added to a stirred suspension of N′-(tert-butyldimethylsilyl)benzenesulfonimidamide (Intermediate L6) (25 mg, 0.092 mmol) in THF:DMF (4:1, 1 mL). The reaction mixture was stirred for 30 minutes at room temperature. Then phenyl (5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamate (Intermediate R³⁸) (41 mg, 0.092 mmol) was added and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with EtOAc (30 mL), washed with water (30 mL), dried using a phase separator, and concentrated in vacuo to afford the TBS protected product. This was cooled to 0° C., taken up in HCl (4M in dioxane) (2 mL, 8.00 mmol) and stirred at this temperature for 1 hour. Then the reaction mixture was concentrated in vacuo and the resulting residue was purified by basic prep HPLC (20-50% MeCN in water) to afford the title compound (15 mg, 32%) as a white powder.

¹H NMR (DMSO-d6) δ 8.31 (br s, 1H), 8.08 (d, J=5.3 Hz, 1H), 7.87-7.67 (m, 2H), 7.65-7.48 (m, 3H), 7.44-7.27 (m, 2H), 7.15 (d, J=7.7 Hz, 1H), 7.07 (d, J=7.7 Hz, 1H), 6.89-6.80 (m, 1H), 6.75-6.63 (m, 1H), 5.08-4.98 (m, 1H). 2.90 (t, J=7.5 Hz, 2H), 2.83-2.62 (m, 4H), 2.38-2.13 (m, 5H), 2.09-1.90 (m, 4H), 1.79-1.65 (m, 2H).

LCMS m/z 506.4 (M+H)⁺ (ES⁺); 504.2 (M−H)⁻ (ES⁻).

Example 79: N-((6-Methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)benzenesulfonimidamide Step A N-((6-Methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)benzenesulfinamide

To a solution of benzenesulfinamide (Intermediate L7) (50 mg, 354.13 μmol, 1 eq) in THF (1 mL) was added with t-BuONa (102 mg, 1.06 mmol, 3 eq) at 25° C. The reaction mixture was stirred at 25° C. for 30 minutes. Then phenyl (6-methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamate (Intermediate R⁶⁷) (202 mg, 354.13 μmol, 1 eq, TFA salt) was added. The resulting mixture was stirred at 25° C. for 5 hours. Then the reaction mixture was concentrated in vacuo. The residue was purified by reversed phase flash chromatography (0.1% NH₃.H₂O-MeCN) to give the title compound (120 mg, 59% yield, 88% purity on LCMS) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 9.57-9.27 (m, 1H), 8.31-8.17 (m, 1H), 7.71-7.42 (m, 5H), 7.24-7.07 (m, 1H), 6.82-6.65 (m, 1H), 6.51 (s, 1H), 5.11-4.93 (m, 1H), 3.48-3.41 (m, 2H), 2.99-2.68 (m, 5H), 2.24-1.96 (m, 11H) and 1.89-1.61 (m, 2H). 1×NH was missing.

LCMS: m/z 505.3 (M+H)⁺ (ES⁺).

Step B N-((6-Methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)benzenesulfonimidamide

To a solution of N-((6-methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)benzenesulfinamide (0.1 g, 198.16 μmol, 1 eq) in THF (1 mL) was added 1-chloro-H-benzo[d][1,2,3]triazole (27 mg, 178.34 μmol, 0.9 eq). The reaction mixture was stirred at 25° C. for 30 minutes. Then the reaction mixture was added into a solution of NH₃/THF (5 mL) at −70° C.; NH₃ was bubbled into THF for 5 minutes to afford the NH₃/THF solution. After addition, the mixture was stirred at −70° C. for 30 minutes. Then the reaction mixture was concentrated in vacuo. The residue was purified by prep-TLC (SiO₂, DCM:methanol, 10:1) and then further purified by prep HPLC (column: Phenomenex luna C18, 150 mm×25 mm×10 μm; mobile phase [A: water (0.1% TFA); B: MeCN]; B %: 22%-42%, 10 minutes) to give the title compound (21.45 mg, 17% yield, 100% purity on LCMS, TFA salt) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 8.22-8.10 (m, 1H), 8.02-7.80 (m, 2H), 7.68-7.46 (m, 3H), 7.10 (d, 1H), 6.83-6.62 (m, 2H), 5.45-5.21 (m, 1H), 3.93-3.40 (m, 2H), 3.38-301 (m, 2H), 3.00-2.71 (m, 7H), 2.49-2.19 (m, 4H) and 2.17-1.96 (m, 5H). 3×NHs were missing.

LCMS: m/z 520.1 (M+H)⁺ (ES⁺).

Example 80: N-((6-Methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)methanesulfonimidamide Step A: N-((6-Methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)methanesulfinamide

Sodium tert-butoxide (134 mg, 1.40 mmol, 1.6 eq) was added into a mixture of methanesulfinamide (Intermediate L8) (103 mg, 1.31 mmol, 1.5 eq) in THF (2 mL) at 20° C. The reaction mixture was stirred at 20° C. for 30 minutes. Then phenyl (6-methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamate (Intermediate R⁶⁷) (400 mg, 874.20 μmol, 1 eq) was added at 20° C. and the resulting mixture was stirred at 20° C. for 30 minutes. The reaction mixture was poured into ice-water (30 mL). The aqueous phase was extracted with ethyl acetate (3×20 mL). The combined organic phases were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by reversed phase flash chromatography (0.1% NH₃.H₂O-MeCN) to afford the title compound (150 mg, 26% yield, 68% purity on LCMS) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, 1H), 7.14 (d, 1H), 6.71-6.65 (m, 1H), 6.54 (d, 1H), 5.08-5.04 (m, 1H), 2.97 (t, 2H), 2.87 (t, 2H), 2.75-2.73 (m, 2H), 2.64 (s, 3H), 2.33-2.27 (m, 5H), 2.15-2.07 (m, 7H) and 1.86-1.73 (m, 2H). 2×NHs were missing.

LCMS: m/z 443.4 (M+H)⁺ (ES⁺).

Step B: N-((6-Methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)methanesulfonimidamide

To a solution of N-((6-methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)methanesulfinamide (250 mg, 564.88 μmol, 1 eq) in THF (5 mL) was added 1-chloro-1H-benzo[d][1,2,3]triazole (78 mg, 508.39 μmol, 0.9 eq) at 20° C. The reaction mixture was stirred for 30 minutes at 20° C. Then the reaction mixture was added into a solution of NH₃/THF at −78° C.; NH₃ gas (15 psi) was bubbled into THF (5 mL) for 5 minutes to afford the NH₃/THF solution. The resulting mixture was stirred at −78° C. for 20 minutes, and then warmed to 20° C. and stirred for 2 hours. Then the reaction mixture was concentrated in vacuo. The residue was purified by prep HPLC (column: Xtimate C18, 150 mm×40 mm×10 μm; mobile phase [A: water (0.05% ammonium hydroxide v/v); B: MeCN]; B %: 19%-49%, 10 minutes) to afford the title compound (2.19 mg, 1% yield, 99.8% purity on LCMS) as a yellow solid.

¹H NMR (400 MHz, CD₃OD) δ 8.12 (d, 1H), 7.09 (s, 1H), 6.82 (d, 1H), 6.69 (s, 1H), 5.14-5.12 (m, 1H), 3.21 (s, 3H), 3.03-3.01 (m, 2H), 2.95 (t, 2H), 2.88 (t, 2H), 2.83-2.57 (m, 2H), 2.55 (s, 3H) and 2.14-1.92 (m, 9H). 3×NHs were missing.

LCMS: m/z 458.3 (M+H)⁺ (ES⁺).

Example 81: 1-(N-Cyano-S-methyl-sulfonimidoyl)-3-(6-methyl-5-(2-((1-methyl-4-piperidyl)oxy)-4-pyridyl)indan-4-yl)urea

To a mixture of N-((6-methyl-5-(2-((1-methylpiperidin-4-yl)oxy)pyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)methanesulfonimidamide (Example 80) (30 mg, 65.56 μmol, 1 eq) and triethylamine (27 mg, 262.24 μmol, 4 eq) in DMF (1 mL) was added cyanic bromide (14 mg, 131.12 μmol, 2 eq) at 25° C. The reaction mixture was stirred at 25° C. for 12 hours, and then quenched with water (0.5 mL) and concentrated in vacuo. The residue was purified by prep HPLC (column: Phenomenex Gemini-NX C18, 75 mm×30 mm×3 m; mobile phase [A: water (0.1% TFA), B: MeCN]; B %: 20%-30%, 7 minutes) to afford the title compound (21.8 mg, 54% yield, 97.6% purity on HPLC, TFA salt) as yellow oil.

¹H NMR (400 MHz, DMSO-d6+D₂O) δ 8.16 (t, 1H), 7.09 (s, 1H), 6.79 (t, 1H), 6.63 (d, 1H), 5.27-5.13 (m, 1H), 3.48-3.45 (m, 1H), 3.35-3.32 (m, 1H), 3.27-3.12 (m, 5H), 2.88 (t, 2H), 2.81-2.75 (m, 5H), 2.34-2.30 (m, 1H), 2.18-2.13 (m, 1H), 3.05-1.96 (m, 6H) and 1.83-1.75 (m, 1H). 2 X NHs were missing.

LCMS: m/z 483.2 (M+H)⁺ (ES⁺).

EXAMPLES—BIOLOGICAL STUDIES NLRP and Pyroptosis

It is well established that the activation of NLRP3 leads to cell pyroptosis and this feature plays an important part in the manifestation of clinical disease (Yan-gang Liu et al., Cell Death & Disease, 2017, 8(2), e2579; Alexander Wree et al., Hepatology, 2014, 59(3), 898-910; Alex Baldwin et al., Journal of Medicinal Chemistry, 2016, 59(5), 1691-1710; Ema Ozaki et al., Journal of Inflammation Research, 2015, 8, 15-27; Zhen Xie & Gang Zhao, Neuroimmunology Neuroinflammation, 2014, 1(2), 60-65; Mattia Cocco et al., Journal of Medicinal Chemistry, 2014, 57(24), 10366-10382; T. Satoh et al., Cell Death & Disease, 2013, 4, e644). Therefore, it is anticipated that inhibitors of NLRP3 will block pyroptosis, as well as the release of pro-inflammatory cytokines (e.g. IL-1β) from the cell.

THP-1 Cells: Culture and Preparation

THP-1 cells (ATCC #TIB-202) were grown in RPMI containing L-glutamine (Gibco #11835) supplemented with 1 mM sodium pyruvate (Sigma #S8636) and penicillin (100 units/ml)/streptomycin (0.1 mg/ml) (Sigma #P4333) in 10% Fetal Bovine Serum (FBS) (Sigma #F0804). The cells were routinely passaged and grown to confluency (˜10⁶ cells/ml). On the day of the experiment, THP-1 cells were harvested and resuspended into RPMI medium (without FBS). The cells were then counted and viability (>90%) checked by Trypan blue (Sigma #T8154). Appropriate dilutions were made to give a concentration of 625,000 cells/ml. To this diluted cell solution was added LPS (Sigma #L4524) to give a 1 μg/ml Final Assay Concentration (FAC). 40 μl of the final preparation was aliquoted into each well of a 96-well plate. The plate thus prepared was used for compound screening.

THP-1 Cells Pyroptosis Assay

The following method step-by-step assay was followed for compound screening.

-   1. Seed THP-1 cells (25,000 cells/well) containing 1.0 μg/ml LPS in     40 μl of RPMI medium (without FBS) in 96-well, black walled, clear     bottom cell culture plates coated with poly-D-lysine (VWR #734-0317) -   2. Add 5p compound (8 points half-log dilution, with 100M top dose)     or vehicle (DMSO 0.1% FAC) to the appropriate wells -   3. Incubate for 3 hrs at 37° C., 5% CO₂ -   4. Add 5 μl nigericin (Sigma #N7143) (FAC 5 μM) to all wells -   5. Incubate for 1 hr at 37° C., 5% CO₂ -   6. At the end of the incubation period, spin plates at 300×g for 3     mins and remove supernatant -   7. Then add 50 μl of resazurin (Sigma #R7017) (FAC 100 μM resazurin     in RPMI medium without FBS) and incubate plates for a further 1-2     hrs at 37° C. and 5% CO₂ -   8. Plates were read in an Envision reader at Ex 560 nm and Em 590 nm -   9. IC₅₀ data is fitted to a non-linear regression equation (log     inhibitor vs response-variable slope 4-parameters)

96-Well Plate Map

1 2 3 4 5 6 7 8 9 10 11 12 A High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low B High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low C High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low D High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low E High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low F High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low G High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low H High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low High MCC950 (10 uM) Compound 8-point half-log dilution Low Drug free control

The results of the pyroptosis assay are summarised in Table 1 below as THP IC₅₀.

Human Whole Blood IL-1μ Release Assay

For systemic delivery, the ability to inhibit NLRP3 when the compounds are present within the bloodstream is of great importance. For this reason, the NLRP3 inhibitory activity of a number of compounds in human whole blood was investigated in accordance with the following protocol.

Human whole blood in Li-heparin tubes was obtained from healthy donors from a volunteer donor panel.

-   1. Plate out 8 μl of whole blood containing 1 μg/ml of LPS in     96-well, clear bottom cell culture plate (Corning #3585) -   2. Add 1 μl compound (8 points half-log dilution with 10 M top dose)     or vehicle (DMSO 0.1% FAC) to the appropriate wells -   3. Incubate for 3 hrs at 37° C., 5% CO₂ -   4. Add 1 μl nigericin (Sigma #N7143) (10M FAC) to all wells -   5. Incubate for 1 hr at 37° C., 5% CO₂ -   6. At the end of the incubation period, spin plates at 300×g for 5     mins to pellet cells and remove 20 μl of supernatant and add to     96-well v-bottom plates for IL-1β analysis (note: these plates     containing the supernatants can be stored at −80° C. to be analysed     at a later date) -   7. IL-1β was measured according to the manufacturer protocol (Perkin     Elmer-AlphaLisa IL-1 Kit AL220F-5000) -   8. IC₅₀ data is fitted to a non-linear regression equation (log     inhibitor vs response-variable slope 4-parameters)

The results of the human whole blood assay are summarised in Table 1 below as HWB IC₅₀.

For comparison, three compounds outside the scope of the claims are included in Table 1:

TABLE 1

Exam- ple No THP IC₅₀ HWB IC₅₀  1 ++++++ +++  4 ++++++ +++++  8 +++++ +++ 15 +++++ +++++ 19 ++++++ +++ 22 ++++++ ++ 27 +++ ++++ 29 ++++++ ++++++ 33 +++++ +++ 35 ++++++ ++++++ 39 ++++++ +++ 41 ++++++ +++ 42 +++ +++ 43 ++++ ++++++ 44 ++++++ +++++ 45 ++++++ ++++++ 46 ++++++ ++++++ 47 ++++++ ++++++ 48 ++++++ ++++++ 49 ++++++ ++++++ 50 ++++++ ++++++ 51 ++++++ ++++++ 52 +++++ +++++ 53 ++++++ +++++ 54 ++++++ ++++ 55 ++++++ ++++ 56 ++++++ ++++ 57 ++++++ +++ 58 ++++++ ++ 59 ++++++ +++ 60 ++++++ ++++ 62 ++++++ +++++ 64 ++++++ +++++ 65 ++++++ +++++ 66 ++++++ +++++ 67 ++++++ ++++ 68 ++++++ +++++ 69 ++++++ ++++ 70 ++++++ ++++ 71 ++++++ ++++ 72 ++++++ +++ 73 ++++++ ++++ 74 ++++++ +++ 75 ++++++ +++ 76 ++++ ND 77 ++++++ + 78 ++++++ ++ 79 ++++++ +++ 80 ++++++ ++++ comp ex 1 +++ inactive comp ex 2 ++ ND comp ex 3 ++ ND NLRP₃ inhibitory activity (≤0.25 μM = ‘++++++’, ≤0.5 μM = ‘+++++’, ≤1 μM = ‘++++’, ≤2 μM = ‘+++’, ≤5 μM = ‘++’, ≤10 μM = ‘+’, >10 μM = ‘inactive’, not determined = ‘ND’).

As is evident from the results presented in Table 1, surprisingly in spite of the structural differences versus the prior art compounds, the compounds of the invention show high levels of NLRP3 inhibitory activity in the pyroptosis assay and in particular in the human whole blood assay.

It will be understood that the present invention has been described above by way of example only. The examples are not intended to limit the scope of the invention. Various modifications and embodiments can be made without departing from the scope and spirit of the invention, which is defined by the following claims only. 

1. A compound of formula (I):

or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein: A is a phenyl or 5- or 6-membered heteroaryl group, wherein A is substituted in the α position with B and in the α′ position with R⁴, and wherein A is optionally further substituted; B is a phenyl, 5- or 6-membered heteroaryl, or 4- to 6-membered saturated heterocyclic group, wherein B is substituted with -L-R², and wherein B is optionally further substituted; X is O, NH or N(CN); Y is O or S; R¹ is a C₁-C₄ alkyl, C₂-C₄ alkenyl, —NH(C₁-C₄ alkyl), —N(C₁-C₄ alkyl)₂, or —R²⁰-R²¹ group, all optionally halo-substituted; L is a bond, —O—, —OC(R¹²)₂—, —OC(Ph)(R¹²)—, —OC(R¹²)₂C(R¹²)₂—, —C(R¹²)₂—, —C≡C— or —NR¹³—; R² is a C₃-C₆ cycloalkyl, phenyl, 4- to 6-membered saturated heterocyclic, or 5- or 6-membered heteroaryl group, all optionally halo-substituted and/or optionally substituted with one, two or three substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, phenyl, benzyl, 4- to 6-membered saturated heterocyclyl, —CO(C₁-C₄ alkyl), —CO(C₁-C₄ haloalkyl), —CO₂(C₁-C₄ alkyl), —CO₂(C₁-C₄ haloalkyl), —CO₂(benzyl), —OH, —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —NH₂, —NH(C₁-C₄ alkyl), —NH(C₁-C₄ haloalkyl), —N(C₁-C₄ alkyl)₂, —N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl) and —N(C₁-C₄ haloalkyl)₂; either R⁴ is monovalent, and attached to A in the α′ position, and selected from C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl and phenyl, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from oxo, —OH, —O(C₁-C₄ alkyl) and —O(C₁-C₄ haloalkyl); or R⁴ is divalent, and attached to A in the α′ and β′ positions, and selected from —CH₂CH₂CH₂—, —CH═CHCH₂—, —CH₂CH═CH—, —CH₂CH₂O—, —OCH₂CH₂—, —CH₂CH₂CH₂CH₂— and —CH═CH—CH═CH—, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from oxo, —OH, —O(C₁-C₄ alkyl) and —O(C₁-C₄ haloalkyl); each R¹² is independently selected from hydrogen, halogen, methyl and halomethyl; R¹³ is hydrogen or methyl; R²⁰ is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene; R²¹ is a C₃-C₆ cycloalkyl, phenyl, 4- to 6-membered saturated heterocyclic, or 5- or 6-membered heteroaryl group, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, —R²²—OH, —R²²—O(C₁-C₄ alkyl), —R²²—O(C₁-C₄ haloalkyl), —R²²—NH₂, —R²²—NH(C₁-C₄ alkyl), —R²²—NH(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄ alkyl)₂, —R²²—N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄ haloalkyl)₂ and —R²²-R²³; R²² is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene; and R²³ is a C₃-C₆ cycloalkyl or 4- to 6-membered saturated heterocyclic group, all optionally halo-substituted.
 2. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, wherein A is a phenyl group, substituted in the α position with B, substituted in the α′ position with R⁴, and optionally further substituted.
 3. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, wherein B is a pyridinyl group, substituted with -L-R², and optionally further substituted.
 4. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, wherein Y is O.
 5. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, wherein: either R⁴ is monovalent, and attached to A in the α′ position, and selected from isopropyl, cyclopentyl, cyclohexyl and phenyl; or R⁴ is divalent, and attached to A in the α′ and β′ positions, and selected from —CH₂CH₂CH₂—, —CH₂CH₂O— and —OCH₂CH₂—.
 6. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, wherein the compound is of formula (II):

wherein: X is O, NH or N(CN); R¹ is a C₁-C₄ alkyl, C₂-C₄ alkenyl, —NH(C₁-C₄ alkyl), —N(C₁-C₄ alkyl)₂, or —R²⁰-R²¹ group, all optionally halo-substituted; L is a bond, —O—, —OC(R¹²)₂— or —NR¹³—; R² is a C₃-C₆ cycloalkyl or 4- to 6-membered saturated heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally halo-substituted and/or optionally substituted with one, two or three substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, phenyl, benzyl, —OH, —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —NH₂, —NH(C₁-C₄ alkyl), —NH(C₁-C₄ haloalkyl), —N(C₁-C₄ alkyl)₂, —N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl) and —N(C₁-C₄ haloalkyl)₂; R³ is hydrogen or methyl; R^(4a) is C₁-C₄ alkyl, C₃-C₆ cycloalkyl or phenyl, all optionally halo-substituted; R⁵ is hydrogen; or R^(4a) and R⁵ together form —CH₂CH₂CH₂—, —CH═CHCH₂—, —CH₂CH═CH—, —CH₂CH₂O—, —OCH₂CH₂—, —CH₂CH₂CH₂CH₂— or —CH═CH—CH═CH—, all optionally halo-substituted; R⁶ is hydrogen, halogen or cyano; R⁷ is hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl or halogen; each R¹² is independently selected from hydrogen, halogen, methyl and halomethyl; R¹³ is hydrogen or methyl; R²⁰ is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene; R²¹ is a C₃-C₆ cycloalkyl, phenyl, 4- to 6-membered saturated heterocyclic, or 5- or 6-membered heteroaryl group, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkenyl, C₂-C₄ haloalkenyl, —R²²—OH, —R²²—O(C₁-C₄ alkyl), —R²²—O(C₁-C₄ haloalkyl), —R²²—NH₂, —R²²—NH(C₁-C₄ alkyl), —R²²—NH(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄ alkyl)₂, —R²²—N(C₁-C₄ alkyl)(C₁-C₄ haloalkyl), —R²²—N(C₁-C₄ haloalkyl)₂ and —R²²-R²³; R²² is a bond, C₁-C₄ alkylene or C₁-C₄ haloalkylene; and R²³ is a C₃-C₆ cycloalkyl or 4- to 6-membered saturated heterocyclic group, all optionally halo-substituted.
 7. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 6, wherein: either R⁵ is hydrogen and R^(4a) is isopropyl, cyclopentyl, cyclohexyl or phenyl; or R^(4a) and R⁵ together form —CH₂CH₂CH₂—, —CH₂CH₂O— or —OCH₂CH₂—.
 8. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 6, wherein R⁶ is hydrogen or fluoro.
 9. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 6, wherein R⁷ is hydrogen, methyl, cyclopropyl or fluoro.
 10. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, wherein X is O.
 11. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, wherein R¹ is C₁-C₄ alkyl, C₂-C₄ alkenyl, —NHMe, —NMe₂, —NHEt, —NEt₂ or —NMeEt, all optionally halo-substituted; or R¹ is a C₃-C₆ cycloalkyl, phenyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, furanyl, thiophenyl, pyrazolyl or imidazolyl group, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from C₁-C₃ alkyl, —R²²—OH, —R²²—O(C₁-C₃ alkyl), —R²²—NH(C₁-C₃ alkyl), —R²²—N(C₁-C₃ alkyl)₂ and —R²²-R²³; wherein R²² is a bond or C₁-C₄ alkylene; and R²³ is a C₃-C₆ cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group.
 12. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, wherein L is a bond, —O— or —OCH₂—.
 13. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, wherein R² is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl or tetrahydropyranyl group, all optionally substituted with one or two substituents independently selected from fluoro, C₁-C₃ alkyl, C₂-C₃ alkenyl, phenyl, benzyl, —OH, —O(C₁-C₃ alkyl), —NH₂, —NH(C₁-C₃ alkyl) and —N(C₁-C₃ alkyl)₂.
 14. The compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, selected from the group consisting of:


15. (canceled)
 16. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, and a pharmaceutically acceptable excipient.
 17. A pharmaceutical composition as claimed in claim 16, wherein the pharmaceutical composition is an oral or topical pharmaceutical composition.
 18. (canceled)
 19. A method of treating or preventing a disease, disorder or condition in a subject, the method comprising the step of administering an effective amount of the compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1 to the subject, thereby treating or preventing the disease, disorder or condition, optionally wherein the disease, disorder or condition is responsive to NLRP3 inhibition.
 20. The method as claimed in claim 19, wherein the disease, disorder or condition is selected from: (i) inflammation; (ii) an auto-immune disease; (iii) cancer; (iv) an infection; (v) a central nervous system disease; (vi) a metabolic disease; (vii) a cardiovascular disease; (viii) a respiratory disease; (ix) a liver disease; (x) a renal disease; (xi) an ocular disease; (xii) a skin disease; (xiii) a lymphatic condition; (xiv) a psychological disorder; (xv) graft versus host disease; (xvi) allodynia; and (xvii) any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.
 21. The method as claimed in claim 19, wherein the disease, disorder or condition is selected from: (i) cryopyrin-associated periodic syndromes (CAPS); (ii) Muckle-Wells syndrome (MWS); (iii) familial cold autoinflammatory syndrome (FCAS); (iv) neonatal onset multisystem inflammatory disease (NOMID); (v) familial Mediterranean fever (FMF); (vi) pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA); (vii) hyperimmunoglobulinemia D and periodic fever syndrome (HIDS); (viii) Tumour Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS); (ix) systemic juvenile idiopathic arthritis; (x) adult-onset Still's disease (AOSD); (xi) relapsing polychondritis; (xii) Schnitzler's syndrome; (xiii) Sweet's syndrome; (xiv) Behcet's disease; (xv) anti-synthetase syndrome; (xvi) deficiency of interleukin 1 receptor antagonist (DIRA); and (xvii) haploinsufficiency of A20 (HA20).
 22. (canceled)
 23. The method as claimed in claim 19, wherein the compound is administered as a pharmaceutical composition further comprising a pharmaceutically acceptable excipient.
 24. A method of inhibiting NLRP3 in a subject, comprising administering the compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1 to the subject thereby inhibiting NLRP3.
 25. A method of analysing inhibition of NLRP3 or an effect of inhibition of NLRP3 by a compound, comprising contacting a cell or non-human animal with the compound or a pharmaceutically acceptable salt, solvate or prodrug thereof as claimed in claim 1, and analysing inhibition of NLRP3 or an effect of inhibition of NLRP3 in the cell or non-human animal by the compound. 